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 i 
ABSTRACT 
 
Over the past several years, both government and the profession of pharmacy have 
acknowledged that pharmacists are not being used to their full potential in our health care 
system.  In order to advance the profession of pharmacy in this area, guidance on how 
pharmacists can be integrated need to be investigated. 
The purpose of this study was to identify how to integrate a pharmacist into an already 
established primary health care team, at the Student Health Centre at the University of 
Saskatchewan.  The project was divided into three phases: defining the role of the 
pharmacist, implementing the proposed role and then evaluating and prioritizing the role.  
Using action research, an expert panel consisting of established primary health/ambulatory 
care pharmacists from across Canada helped to identify possible clinical activities for a 
Student Health Centre pharmacist.  The results were presented to the primary health care 
team, who then collaborated with the pharmacist and researchers to define the role of the 
pharmacist.  Once an agreement was reached, a pharmacist provided eight weeks of full-
time clinical services.    Upon completion, focus groups with the primary health care team 
members were used to evaluate the pharmacist’s clinical services. 
The role of the pharmacist was tailored specifically for the student health care centre 
selected for the study.  However, the process of integrating and evaluating the role of the 
pharmacist, will serve as a template for other pharmacists desiring to be involved in any 
primary health care team interested in expanding their multidisciplinary service. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
It has been approximately five years since Commissioner Fyke and Commissioner 
Romanow released their reports regarding the provincial and federal status, respectively, of 
our health care system.  Both documents acknowledged that pharmacists were not used to 
their full potential in our health care system and recommended the role of pharmacists on 
primary health teams be enhanced.1, 2  Since then, some literature has surfaced which 
explored possible activities and responsibilities of pharmacists in this field, such as 
Saskatchewan’s Pharmacy Coalition on Primacy Care position statement, Role of the 
Pharmacist in Primary Health care.3  However, there were no published articles discussing the 
actual implementation process of a pharmacist into a primary health care site. 
The profession of pharmacy places a high value on evidence-based medicine, and 
encourages both pharmacists and pharmacy students to incorporate this systematic 
approach into their practice.   Due to the demand for evidence-based medicine, not only in 
pharmacy but our entire health care system, research into how pharmacists can be 
integrated into primary health care centres is essential.  To advance the profession of 
pharmacy, guidance on how this integration can be achieved is needed.  Several studies 
using quantitative research methods suggest pharmacists can have a positive effect on 
patient care; however qualitative inquiry has not been implemented to investigate the 
conditions that contributed to this positive effect. 
 
1.2 Research Question 
How can a pharmacist be integrated into an already established primary health care 
team?   More specifically: 
1) Can action research be used to assist with this integration process? 
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2) How do the primary health care team members feel about having a clinical 
pharmacist join their team? 
3) What recommendations can be provided to support the integration of pharmacists 
onto primary health care teams? 
 
1.3 Objectives 
The study objective was divided into three phases: 
 
Phase I: Define the role of the pharmacist. 
Lack of a defined role has been identified as an obstacle for pharmacists desiring to 
join primary health care teams.4  Successful interdisciplinary teams are able to dialogue on 
their differences about roles, responsibilities and timing of integrated care.  Role ambiguity, 
due to difficulties in defining roles, can lead to dissatisfaction within the team.5  Therefore, it 
is essential that the role of the pharmacist be defined and agreed upon prior to providing any 
clinical services.  Both the primary health care team and established primary health and 
ambulatory care pharmacists were consulted to help shape the pharmacist’s role. 
 
Phase II: Implementing the purposed role.  
Once the role of the pharmacist was defined, I provided two months of clinical 
pharmacy services for the Student Health Centre at the University of Saskatchewan.  All 
clinical activities and interactions were documented.  After one month, a team meeting was 
held to discuss how the role of the pharmacist had been received by the staff to date.  The 
pharmacist’s role would be modified if needed, based on the recommendations that surface 
from the meeting. 
 
Phase III: Evaluate and prioritize the role of a clinical pharmacist. 
At the end of two months of clinical services, focus groups were organized with 
Student Health Centre staff.  Participants were asked to reflect on their experience of having 
a clinical pharmacist on the primary health care team.  The purpose of the focus groups was 
to identify what went well, what did not and areas for improvement from all stakeholders’ 
perspectives.   
 2 
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1.4 Significance 
The role of the pharmacist was defined, implemented, evaluated and prioritized to 
meet the specific needs of the primary health care centre chosen for this project.  However, 
the intent was to develop a process that could be generically applied to any primary health 
care team.  This study will provide guidance on how to integrate a pharmacist into a 
primary health care team and serve as a stepping stone toward other investigations. 
 
1.5 Important Terms 
Action Research: an inquiry that is conducted by or with the insiders of an organization or 
community, but never to or on them.  It is a reflective process oriented to some action or 
cycle of actions that organizational or community members take to address a particular 
problematic situation.  This approach is based on the theory that changes occur either 
within the setting and/or within the researchers themselves.6 
 
Clinical Pharmacist: a pharmacist who contributes to health care teams by optimizing drug 
therapy.  They improve patient outcomes by educating patients, optimizing medication use, 
and monitoring medication endpoints.  Activities are tailored to the needs of the patient 
population and seldom include dispensing medications.4 
 
Primary Care: a level of care, which is accessible to patients when they seek services offered 
at the first level of contact with the health care system.  It is the element within primary 
health care that focuses on health care services, including health promotion, illness and 
injury prevention, and the diagnosis and treatment of illness and injury.7 
 
Primary Health care: refers to an approach to health and a spectrum of services beyond the 
traditional health care system. It includes all services that play a part in health, such as 
income, housing, education, and environment.7 
 
 
 
 
CHAPTER 2: LITERATURE REVIEW 
 
2.1 Primary Health care 
2.1.1 Background 
Primary care is a level of care, which is accessible to patients when they seek services 
offered at the first level of contact with the health care system.  It is coordinated care 
provided to individuals to address a particular problem of basic everyday health need – 
focusing on both treatment and prevention.   Primary care is an element within primary 
health care that centres on health promotion, illness and injury prevention, and the 
diagnosis and treatment of illness and injury.   Primary health care encompasses primary 
care, as well as the other determinants of health – like social and economic influences.  
These primary health care services are delivered by a group of health care professionals, and 
the interdisciplinary team offers a holistic approach to patient care.8, 9   
To provide optimal care, primary health care teams assess and evaluate the health 
needs of their patient population, and subsequently customize their services based on these 
needs.4  A diverse group of health care professionals offers a broader range and higher 
quality of services to address the health needs of a population.  Ultimately, this 
multidisciplinary collaborative approach can result in a more sustainable system of primary 
health care services.1 
 
2.1.2 Primary Health care in Saskatchewan 
In 2001, Commissioner Kenneth Fyke released his Commission on Medicare report, 
which recommended an action plan to enhance the sustainability of Saskatchewan’s health 
care system.   His report focused on the development of an integrated approach for the 
delivery of primary health services.  The document also recognized that pharmacists were 
not utilized to their full potential in the health care system.  One of Fyke’s recommendations 
was to enhance the role of the pharmacist on primary health teams and to allow the 
profession to apply their knowledge as full participants in prescribing decisions.1   
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Commissioner Fyke’s document served as a valuable resource for Commissioner Roy 
Romanow, who used the information when preparing his report, Building on Values: The 
Future of Health care in Canada.  His recommendations echoed those of Commissioner Fyke, 
regarding the under utilization of pharmacists.  This widely reviewed federal initiative, 
acknowledged the potential for pharmacists to have a progressively important role on 
primary health care teams.2   
Soon after the release of the reports of Commissioners Fyke and Romanow, the 
Saskatchewan’s Pharmacy Coalition on Primary Care circulated their position statement, 
the Role of the Pharmacist in Primary Health care.   The paper highlighted the fact that 
pharmacists throughout the province were eager to become members on primary health care 
teams.  The potential role of the pharmacist was investigated, and the Coalition stated that 
the clinical pharmacy activities should be site specific.  As such, the team should consider 
the patient population needs; the professional diversity and strengths of team members; 
cross-training requirements; and the pharmacist’s experience, interest areas, and availability.   
At the end of the consultation process, the Coalition concluded the weaknesses of the 
profession were limited experience with team establishment and no clear understanding of 
its role on primary care teams.3  
 
2.1.3 The Value of Primary Health care Pharmacists10 
Current evidence supports the addition of clinical pharmacy services in primary health 
care.  Randomized trials have demonstrated a positive effect from clinical pharmacy 
services on patient outcomes, particularly in the areas of chronic disease management.  
More specifically, involving pharmacists in the provision of health care can result in greater 
patient safety, enhanced disease and drug therapy management, as well as improved 
compliance and quality of life.  In addition, clinical pharmacy services can improve health 
care spending, resulting in an overall savings to the health care system.  
 
2.1.4 Bridging the Gap 
In addition to the Pharmacy Coalition on Primary Care position statement; there are a 
number of examples cited in the literature discussing the role of a clinical pharmacist in 
primary health care.11-15  The provincial government is encouraging pharmacists to become 
involved in primary health care.1  Saskatchewan pharmacists have expressed interested in 
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this unique approach.3  The value of adding a clinical pharmacist to health care teams has 
been demonstrated;10 yet, pharmacists have not been incorporated into primary health care 
to the degree that the profession is able to make a substantial impact on patient care.   
In the current health care system, health care professionals strive to incorporate 
evidence-based medicine into their daily practice, and the evolution of health care relies on 
this emergence of clinical evidence and expertise.   As stated earlier, limited experience with 
team establishment and lack of a defined role have been identified as barriers for 
pharmacists desiring to be part of a primary health care team.3  To date, there are no 
published articles discussing the actual implementation process of a pharmacist into a 
primary health care team.  Until literature is available highlighting solutions to these 
concerns, as well as guidance on how to successfully integrate a pharmacist into a primary 
health care team, the profession of pharmacy may be unable to exploit this opportunity. 
 
2.2 Defining the Role of a Pharmacist 
To aid with successful integration into a health care team, the new team member’s 
role, responsibilities, and timing of the care need to be clearly defined prior to joining the 
team.  This process should be a collaborative effort put forth by all of the members of the 
team.16, 17  Role conflict, role overload, and variable acceptance for the new team member 
can result when there is a lack of role clarity and inconsistent expectations.  In addition, 
dissatisfaction within the team can occur when uncertainty with a job description (i.e. role 
ambiguity) exists.18   
As mentioned, the primary health care team should assess and evaluate the needs of 
the patient population.  To tailor the clinical pharmacy activities based on these patient 
needs it would seem logical to initiate discussion with those who know the population best - 
that is, the primary health care team. However, this can be very difficult and frustrating 
when the team has no clear understanding of the spectrum of activities that can be offered 
by a clinical pharmacist.   
An example of when this problem can occur is found with the Seniors Medication 
Assessment Research Trial (SMART).19  The study evaluated the collaboration between 
specially trained expanded role pharmacists and family physicians.  A major drawback for 
the pharmacists involved was the physicians did not recognize their full potential.  The 
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physicians expected the pharmacists to stick specifically with investigations involving over-
the-counter medications.  In addition, the pharmacists could not discuss possible 
alternatives with patients as the physicians felt this would be a criticism on their 
performance.  This inhibited the pharmacists from having significant impact on patients’ 
drug therapy.  In addition, the pharmacists were not aware of occasions when physicians 
had unsuccessfully tried a particular therapy or plan because they were restricted from 
discussing therapeutic alternatives with patients.19  
Another study, conducted in California, investigated physician expectations of 
pharmacists.  A questionnaire was used to capture medical residents’ and physicians’ (office 
and hospital based) current and future expectations, as well as their current experiences with 
pharmacists.  A total of 463 physicians (19.3% response rate) participated in the study.  The 
authors concluded the physicians did not know what to expect of pharmacists.  In addition, 
there was no correlation between the responses and practice setting.20 
If health care professionals do not realize the range of clinical activities that can be 
implemented or do not know what to expect from pharmacists, integration is jeopardized. 
Interdisciplinary teams report an increased awareness of each member’s role, however 
difficulties in defining the roles of professional groups may still exist.4  Another approach for 
defining the role of a pharmacist involves discussion with those who hold a similar role 
within another organization.  These colleagues can offer their expertise on how to establish 
activities based on the needs of the patient population.  In addition, establishing 
relationships with these key players can lead to greater peer support in the future.21 
 
2.2.1 Nursing Practitioners 
Pharmacy is not the first profession to investigate role expansion in the area of primary 
health care.   In the 1990s, nurse practitioners began to extend their role in health care.22  
However, their success was not without the same obstacles that pharmacists are currently 
facing.14  Nurse practitioners credit clearly defined roles as an integration strategy for 
incorporating themselves in primary health care.14, 23-25   
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2.3 Implementing the Purposed Role 
Several published articles are available which highlight the roles pharmacists’ have 
developed in family medicine, ambulatory care and primary health care settings.  Review of 
this literature sheds light on the diverse range of services that pharmacists have successfully 
implemented in these practice areas.  Examples include: 7, 9, 13, 26-44 
 
Patient Care 
• Advise on medication use in pregnancy. 
• Respond to medication related telephone calls from patients. 
• Provide patient education and counselling on medications and disease states. 
• Identify actual or potential drug therapy problems. 
• Identify barriers to patient compliance and provide strategies to improve adherence. 
• Obtain medication histories: past and present prescription and over-the-counter 
medications, drug allergies, and vaccinations. 
• Review of current medications for drug-drug interactions, drug-disease interactions, 
and adverse drug reactions. 
• Ensure drug choice and dosage regimen is appropriate. 
• Confirm that no duplicate therapy exists and medications are having the desired 
effect. 
• Provide health promotion services (for example, smoking cessation). 
• Advise on sexual health (for example, supply emergency contraception). 
• Maintain medication profiles. 
• Calculate appropriate dosages. 
• Demonstrate proper use of a medical device. 
• Counsel patients on financial reimbursement for drug costs. 
• Provide information concerning cost and availability of drugs. 
• Participate in multidisciplinary reviews of patients’ progress. 
 
Monitoring Drug Therapy 
• Ensure safe and efficacious drug use. 
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• Assess objective lab values (for example: blood glucose, blood pressure). 
• Perform clinical pharmacokinetic interpretation: reviewing drug blood levels and 
providing recommendations. 
• Follow-up on culture and sensitivity reports (for example, throat cultures). 
 
Drug Information & Guidelines 
• Organize & maintain drug information services. 
• Prepare and distribute medication newsletters. 
• Create and present educational sessions to the staff.  
• Develop disease treatment protocols.  
• Develop formulary guidelines. 
• Meet with representatives of pharmaceutical companies and dispense samples to the 
patients. 
• Perform drug utilization reviews: chart or prescription review. 
• Participate in clinical drug trials. 
• Provide academic detailing to physicians. 
 
2.4 Evaluation of the Integration Process 
2.4.1 Qualitative Analysis 
Qualitative inquiry seeks to find the quality or meaning of experience.  These 
approaches are exploratory in nature and can identify outcomes, including unforeseen 
problems and benefits, from several perspectives.45  Qualitative analysis has been employed 
in health care research to evaluate interdisciplinary teams,17 collaborations between 
community pharmacists and family physicians,15 the integration of nurse practitioners into 
primary health care,21 and defining roles for health care professionals4.   
 
2.4.2 Action Research 
Action research is a qualitative methodology which is a cyclical, dynamic, and 
collaborative process where researchers strive to improve their practices.  In action research, 
the object under study is human or social action versus behaviour.  In other words, the 
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researcher does not simply observe the participants in his/her environment.  Change is 
instituted, and it is how the participants respond to this modification which is evaluated. It 
is purposive, intentional, and goal directed versus a physical response to stimuli.  There are 
two main aims within action research – improvement and involvement.  The first aim, 
improvement, refers to the desire to change the situation in which the practice occurs, to 
enhance practitioners understanding of their practice, and/or to remake the practice itself.  
As for involvement, action research is a collaborative process and stakeholders are 
encouraged to participate in all phases of planning, acting, observing, and reflecting.42   
Ernest Stringer developed an action research model, which cycles through three stages: 
Look-Think-Act. During the “Look” stage, researchers gather relevant information and data 
to define and describe the situation.  The “Think” stage requires the participants to explore, 
analyze, interpret and explain.  In other words, reflect on what is occurring.  Then for the 
“Act” stage, researchers plan, report, implement or evaluate.42 
Recently action research, as a qualitative method of inquiry, has gained popularity in 
the health care field with health care professionals desiring to improve their daily 
practices.46, 47  More specifically, nurses have used action research for investigating and 
implementing changes within primary health care teams,21, 48 patients have been involved in 
this form of research to enhance an integrative approach to their cancer therapy,49 and 
action research has been used to develop the role of a pharmacist specializing in 
menopause.50 
 
2.4.2.1 Positionality in Action Research 
Qualitative researchers are encouraged to identify their positionality – i.e. the position 
they take towards the setting and participants under study.  For example, this may include 
their gender, race, and socioeconomic background.  Action research adds another 
dimension to positionality, as researchers should define their relationship with the group or 
team involved in the initiative.   The terms ‘insider’ and ‘outsider’ are used to describe these 
connections.  An insider is an action researcher who is already part of the team, whereas an 
outsider is not part of the group under study but uses relevant skills and resources to assist 
with conducting the research.1 
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Although positionality should be acknowledged, it is also important to note that it 
does not always fall into clearly defined categories.  For example, some outside researchers 
may have extensive knowledge of the setting they are investigating, while other may not.  In 
addition, these relationships can shift throughout a study and at times, a researcher may 
simultaneously be an insider and outsider in various dimensions.1 2 
 
2.4.3 Focus Groups 
There are several different methods of collecting data for qualitative inquiry.51  Focus 
groups are an option, which allow researchers to obtain a richer understanding of 
participants’ experiences with an intervention and provide immediate and vivid feedback.52  
The interaction that occurs amongst individuals during a focus group provides a stimulus 
for discussion and the generation of ideas, resulting in a wider range of ideas than would 
result from individual interviews.53  The topic under debate is discussed in great depth and 
allows researchers to assess if group consensus exists on major themes.  Focus groups allow 
participants to be involved and provide them with a forum to meet and develop 
recommendations for the project under consideration.45 
Focus groups have become increasingly prominent in health care research over the 
past several years .49  Nursing groups have incorporated focus groups as a means of 
qualitative inquiry to evaluate the role and development of clinical nurse specialists, the 
relationship between nurse/patient and doctor/patient, and client satisfaction.19, 20, 54  Focus 
groups have also been employed to evaluate the collaboration between pharmacists and 
medical practitioners.41 
 
2.4.3.1 On-line Focus Groups 
On-line focus groups have been used as a data collection tool in qualitative health 
services research.49, 55, 56  As with in-person focus groups, on-line focus groups have the 
advantages of obtaining a broader range of responses and elicitation of details that are not 
captured during individual interviews.57  Despite not having the participants physically in 
the same location, on-line focus groups are still able to create active engagement and group 
interaction.51  In addition, studies show when face-to-face focus groups are compared to on-
line focus groups, similar themes emerge from both methods.58, 59  Due to the confidential 
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nature of on-line focus groups, these trials have also revealed participants feel more 
comfortable and offer more input via on-line focus groups, versus face-to-face focus groups, 
when the focal point of discussion is of a sensitive or health related issue.54, 55  Compared to 
in-person focus groups, on-line focus groups offer several advantages, such as: 51, 52, 60 
• No stringent time limits; 
• Quick to assemble and disassemble; 
• Less expensive than in-person focus groups; 
• More convenient for subjects as they can participate without leaving their home or 
office; 
• Anonymity can be protected for subjects concerned about the nature and sensitivity 
of the discussion topic; 
• Potential for better quality of data as comfort level is increased; 
• Participants from geographically distant locations can be easily incorporated into the 
group; 
• Data entry and analysis are faster and cost less; and 
• Group size is not an issue therefore more participants can be included. 
Disadvantages may include:51, 52, 56 
• Limited participant access to computers; 
• Can be more time consuming for the moderator; 
• Lack of nonverbal and vocal cues; 
• Individuals may feel too free to express themselves resulting in less discretion and 
tact; 
• A few participants may engage in their own exclusive dialogue and alienate the rest 
of the group; 
• Technological problems may arise; and  
• Participants may not be comfortable with using an electronic medium.  
There are two main types of on-line focus groups – synchronous and asynchronous.  
Synchronous focus groups use chat rooms or focus group software packages to allow real 
time interactions between the moderator and participants.  Disadvantages of synchronous 
focus groups include inconvenience for participants in different time zones; most software 
 12 
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packages do not save transcripts and have a limited scrolling function, and therefore it may 
not be possible to view all that has been discussed.  Asynchronous groups use discussion or 
message boards, listservs, or mailing lists, which allow participants to log in and reply to 
discussion questions on their own time.  Benefits include producing more in-depth and 
richer responses versus synchronous environments; transcription is already completed which 
saves time and money, and increases the accuracy of the transcripts; global time differences 
are not an issue; more time is allotted for participants with variable typing skills; and 
participants have longer to focus and reflect on responses. 56 
 
2.5 Study Objective 
The purpose of this study was to identify how to integrate a pharmacist into an already 
established primary health care team.  Action research was the methodology employed to 
answer this question.  The project was divided into three phases: defining the role of the 
pharmacist, implementing the purposed role, and evaluating and prioritizing the 
implemented role.   The role of the pharmacist was tailored specifically for the primary 
health care centre selected for this study.  However, the process will serve as a template for 
other pharmacists desiring to be integrated into primary health care teams. 
 
 
 
 
CHAPTER 3: METHODOLOGY 
3.1 Researcher’s Story 
In qualitative research, researchers are encouraged to share their position, values and 
judgments on the study subject, due to the interpretive nature of the research. 
I received my Bachelor of Science in Pharmacy degree, from the University of 
Saskatchewan, in 2003.  While I was working towards this degree, I volunteered with a peer 
health education group – the Student Health Initiatives Program (SHIP), through the 
Student Health Centre.  My involvement as a volunteer lead to a summer student position 
as assistant to the Health Education Coordinator.  This opportunity was extended into the 
school year, and I was fortunate to hold the position for approximately one and one-half 
years.  During my employment, I worked closely with several of the Student Health Centre 
employees while developing pamphlets, presentations, and displays. I was always impressed 
with their dedication to patient care and the team approach they used to deliver health 
services. 
This exposure to a health care team influenced my decision to practice as a hospital 
pharmacist.  I had witnessed the benefits of working in a collaborative fashion, and was 
eager to transfer this experience into a hospital setting.  Once I had completed my pharmacy 
degree, I moved to Winnipeg, Manitoba to work in a community hospital.   During my 
eighteen months in Winnipeg, I had the opportunity to specialize in pain and palliative care.  
A hospital setting was the perfect environment to foster my interest in a team-based 
approach to direct patient care.  However, the clinical pharmacy services at the hospital 
were inconsistent due to the pharmacist storage.  As such, it was difficult to establish 
relationships and roles with the other health care professionals on the wards. 
After working for a year and a half in Winnipeg, I relocated to Regina, Saskatchewan 
and worked at the Regina General Hospital.  I practiced in the therapeutic areas of 
cardiology and psychiatry, where clinical pharmacy services were well established.  I really 
enjoyed working with the health care teams dedicated to these wards.  However, with my 
increased direct patient care interactions and level of participation on the teams, I soon  
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became frustrated with the lack of preventive measures in the community which led to some 
of the hospital admissions.  This sparked a new found appreciation for primary health care.  
As I am sure is true for most pharmacists, I often reflect on where the profession of 
pharmacy stands within our health care system.  As a hospital pharmacist, I feel very 
fortunate to have had the clinical pharmacy opportunities to which I have been exposed. 
Yet, I also realize that barriers exist which may inhibit some pharmacists from expanding 
their role to include clinical functions.  These concerns led me to wonder whether providing 
guidance on how to deal with obstacles would assist the profession in further establishing 
clinical roles. 
My background as a single, educated, Caucasian female focused on career 
advancement, brought opinions and values to this study, as I was the research instrument.  
Bias and subjectivity are natural and acceptable in action research, providing they are 
identified rather than ignored.6 Reflexivity is built into the research process when the 
researcher acknowledges the perspectives they have acquired via their unique experiences.6  
Keeping a reflexive diary throughout the study is another measure, which can articulate 
evolving perspectives.  In addition, my interpretation of the study findings have to meet the 
approval of my committee members – which increases the trustworthiness of the research.6  
I really did enjoy the two months that I spent with the Student Health Centre staff as 
their clinical pharmacist.  It was great to reconnect with the team members I had previously 
worked with and meet the new staff who had joined the team since I had left my position in 
Health Education.  In addition, I was able to interact with patients and practice as a clinical 
pharmacist – which was something I really missed, as I no longer worked full-time due to 
graduate studies.  However, there were times that I felt frustrated with my perceived lack of 
progress to establish a clinical role for a pharmacist at the Centre.  I was eager to create 
clinical opportunities, similar to the services I was used to providing as a hospital 
pharmacist, yet I sometimes failed to pause and remind myself that a clinical pharmacy role 
was novel to the Student Health Centre staff.  I did experience obstacles, but I was there for 
the team and not myself.  Therefore, I was willing to be patient and compromise, as to not 
jeopardize my integration into the team.  By the end of the two months, I was pleased with 
how much we were able to accomplish.  I do wish that I would have been able to establish a 
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stronger/larger direct patient care role; however I accept only so much could be achieved in 
the study timeframe. 
  
3.2 Qualitative Inquiry 
There are numerous quantitative studies in the literature which portray the positive 
impact pharmacists have on patient care,22, 23, 27-29, 31, 40, 61 the favourable impressions that 
physicians and nurses have towards clinical pharmacist’s interventions,22, 27, 31, 32, 62 and the 
satisfaction patients express regarding their interactions with clinical pharmacists.22, 63  
However, to date, there are no studies that tried to capture the social aspect of how this 
positive impact on patient care is created or how relationships are formed.  Therefore, a 
qualitative approach was selected as the research methodology for this project; it not only 
informed us of what went well and what did not, but also provided us with rich detail that 
gave us a sense of why things were successful or not, from several stakeholders’ perspectives. 
Action research was the qualitative method employed for the project.  The 
improvement or change sought was the integration of a pharmacist into a primary health 
care team.  To ensure a truly collaborative process, primary health and ambulatory care 
pharmacists, the primary health care team members, and patients were encouraged to 
participate in various phases of the research project.   
Stringer’s action research model of Look-Think-Act was applied throughout the three 
phases of the project: defining, implementing, evaluating and prioritizing the role of a 
pharmacist (see Appendix I).  This unique research methodology allows the researcher to 
become more knowledgeable with each Look-Think-Act cycle, ultimately leading to a 
solution for the research question.2   
For our study, the results we obtained from Phase I helped form Phase  II, and Phase 
II results shaped Phase III.  Our research questions, however, were not answered until 
Phase III.  Therefore, some of the results from the first two phases are presented and 
discussed under the methodology section to ensure continuity and flow for the reader.  The 
results and discussion sections of the report focus on the data collected in Phase III and 
answering the research questions. 
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3.3 Primary Health care Centre Chosen for this Project 
The Student Health Centre at the University of Saskatchewan was selected as the 
primary health care centre for this project.  The centre received its primary care designation 
in March 2000 and is one of eight primary care sites within the Saskatoon Health Region.6   
The centre provides comprehensive health care services to students registered at the 
university and their families.  The team includes a variety of health care professions 
including physicians, a nurse practitioner, psychiatrists, dietitian, nurses, massage therapist, 
chiropractor, social worker, orthopedic surgeon, internal medicine specialist, 
obstetrician/gynecologist resident, and health education coordinator, along with a manager 
and front office staff.  Prior to our study, a pharmacist had never been incorporated into this 
mix. 64  There is no pharmacy or dispensary located in the Student Health Centre; therefore 
the role of the pharmacist was solely clinical. 
 
3.4 Ethics Approval 
Our project received ethics approval from the Behavioural Research Ethics Committee 
of the University of Saskatchewan on July 28th, 2006.   
 
3.5 Phase I: Defining the Role of the Pharmacist 
The first step using the action research model was to “Look” by gathering all relevant 
information and data through observation, interaction and discussion with stakeholders.  
The goal was to create a picture of the situation and identify who will be involved.42 
Information on the Student Health Centre and literature view helped form the research 
project. 
 
3.5.1 Look: Gather information from the Student Health Centre 
The Student Health Centre served as a valuable resource for identifying the needs and 
patient population for this project.  More specifically, these resources included the staff, 
program evaluations and administrative documents.  The following paragraphs take a closer 
look into each of these sources, which helped set the stage for developing clinical pharmacy 
activities. 
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3.5.1.1 Student Health Centre Staff 
As mentioned in the literature review, the primary health care team knows the patient 
population best and therefore should be consulted when developing the clinical pharmacy 
activities.  The manager at the Student Health Centre informally presented the project to the 
team during a staff meeting.  The team welcomed the idea, however because they had never 
worked with a clinical pharmacist, they were unsure of what the role of this new team 
member would be. As such, the staff could not identify any specific activities or role for a 
pharmacist.   
 
3.5.1.2 Program Evaluations 
In 1997, the Centre conducted their first needs assessment survey on student health 
behaviour and knowledge.65   A second needs assessment was subsequently conducted in 
2003 to update their original findings, obtain more in-depth demographic data, and evaluate 
the existing services offered by the centre.66  The survey participants were selected amongst 
all university students, not just those who received services from the Student Health Centre. 
Both of these documents offered insight into the demographics and health needs of students 
enrolled at the University of Saskatchewan. 61, 66   
 
3.5.1.3 Administrative Documents 
Administrative documents that contain data on demographics and billing codes 
revealed the type of students and their medical reasons for accessing the services.  
 
3.5.1.4 Shadowing Team Members 
Observation is another method for collecting information.  On Thursday, February 
23rd, 2006, I spent an entire day shadowing staff members at the Student Health Centre to 
gain a deeper appreciation of the day-to-day medical concerns that students present with to 
the staff.  The morning was spent shadowing a registered nurse while the afternoon was set 
aside to observe a physician.  There was also an opportunity to witness an interaction 
between the nurse practitioner and a female student regarding contraception. 
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3.5.2 Look: Gather information by conducting a literature review 
A literature review of how other health care professionals, such as nurse practitioners, 
expanded their role into primary health care provide guidance for the profession of 
pharmacy.   Additional articles were retrieved and reviewed to aid with the project.  For 
example, information on the importance of having a clearly defined role before joining a 
team; possible clinical pharmacy activities; and methodology that had been previously 
employed in health services research – such as action research and focus groups. 
 
3.5.3 Think: Explore & analyze collected information 
The information collected from the Student Health Centre helped to define the patient 
population and identify the health needs of this group, which were in turn used to explore 
possible roles for the pharmacist.  Reflecting on how other health care professionals have 
integrated themselves into primary health care also assisted with defining the role.    
 
3.5.4 Act: Develop a plan for enacting the investigation 
3.5.4.1 On-line Focus Group with Pharmacists 
Since the Student Health Centre staff was unsure of what would be the role a clinical 
pharmacist, pharmacists already established on primary health care teams were consulted to 
help tailor clinical pharmacy activities for the Centre.  Ambulatory care pharmacists 
function in a similar capacity to primary health care pharmacists on health care teams, 
therefore we felt that ambulatory care pharmacists could also help shape the role of the 
pharmacist.  Bringing experts together in this manner has previously been used by nurse 
practitioners for establishing their role in primary health care.19, 20  To establish consensus 
amongst these specialists, focus groups can be used.49 
Primary health and ambulatory care pharmacists are relatively new to the Canadian 
health care system.  As such, there are a limited number of pharmacists specializing in these 
areas throughout the country; therefore, both provincial and national pharmacists were 
invited to participate in this stage of the study.  An asynchronous on-line focus group was 
an economical method of extracting information and formulating ideas from the 
geographically dispersed panel of pharmacists.  In addition, an asynchronous web-based 
data collection method allowed the pharmacists to tailor their participation around their 
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hectic schedules.  Focus groups allowed the pharmacists to draw on their own experiences 
and discuss with colleagues a range of possible clinical activities that could be implemented 
at the Student Health Centre.   
The focus group pharmacists were selected by using purposeful sampling, in other 
words selecting participants based on their characteristics.47  The list of potential participants 
was developed by Dr. Shannan Neubauer, Dr. Alfred Rémillard, and myself; however the 
bulk of the names were provided from Dr. Neubauer, who specializes in both primary 
health and ambulatory care.   The inclusion criteria were pharmacists who:  
1) had established themselves on Canadian primary health or ambulatory care teams;  
2) were the first pharmacist to join their primary health or ambulatory care team;  
3) were willing to share their experiences with primary health or ambulatory care teams 
using an on-line focus group; and 
4) were willing to complete a survey regarding the use of an on-line focus group 
Dr. Neubauer contacted the potential participants via e-mail in June, 2006, to introduce 
the study and invite them to be a member of the panel (see Appendix II).  A letter was also 
sent in the mail to follow-up with the potential participants.  In the event there was not 
enough interest generated in the on-line focus group, we planned to use the snowball 
technique to recruit additional pharmacists.  As such, the pharmacists who agreed to 
participate would be asked for the names of other potential people to recruit.67   
Ten of the twelve pharmacists contacted agreed to participate in the study, and this 
was a sufficient number to proceed with the focus group without additional recruitment.67  
Over half of the pharmacists (n=7) practiced in primary health/ambulatory care settings 
within Saskatchewan – one from Fort Qu’Appelle, one from Leader, two from Regina, one 
from Saskatoon, and two from Wynyard.  Two of the participants were from Ontario – one 
from Toronto and the other from Hamilton.  The remaining participant was from Halifax, 
Nova Scotia.  The majority of the pharmacists (n=8) specialized in general medicine.  As for 
the other two, one pharmacist specialized in a lipid clinic and the other in a chronic renal 
insufficiency clinic.  
WebCT® has previously been used by nurses for on-line focus groups in Australia.51  
We worked closely with the Information Technology Services department at the University 
of Saskatchewan to create an on-line focus group website through WebCT® for the study.  
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In addition, I completed a WebCT® orientation workshop offered by the Information 
Technology Services department to gain a better understanding of the software – 
particularly designing a website and moderating an on-line discussion.  The WebCT® 
website for the study was designed to be an asynchronous, closed site, multithreaded 
discussion board.  Participants required University of Saskatchewan network services 
identification (NSID) numbers and passwords to log into the website. Some of the 
participants, as alumni, already had NSID and passwords, however, those who did not were 
provided with a user account for the project.   
The on-line focus group questions, instructions for using WebCT® and the WebCT® 
website were pre-tested for one week in July, 2006.  Eight were asked to participate in the 
pre-testing, which included two of the researchers, two committee members with qualitative 
backgrounds, a College of Pharmacy & Nutrition faculty member who specializes in survey 
and questionnaire design, a primary health care pharmacist and two graduate students.  A 
friendly e-mail reminder was sent mid-week to the eight pre-testers.  Unfortunately, the two 
graduate students did not assist with the pre-testing (one had technical difficulties and the 
other had no time), but valuable feedback for the wording of the focus group questions was 
obtained from the rest of the participants.  
Prior to executing the on-line focus group with the pharmacist experts, each 
participant received an information package.  The contents of the package included the 
consent form; background information on the Student Health Centre – such as team 
structure, patient demographics, the types of services offered and their utilization, and the 
needs of the patient population; instructions for using the on-line focus group website; the 
focus group questions for discussion; and background information on the research project 
(see Appendix III). The purpose of providing participants with this information was to 
enable them to contribute to the focus group from an assumed baseline knowledge.68   
The on-line focus group with the pharmacists ran for the first three weeks in 
September, 2006.  I initially posted a few questions for discussion, and posted additional 
questions at the beginning of the second week to encourage further dialogue.  For the final 
week, a summary of the focus group discussion was posted, and the participants were asked 
to verify the summary was accurate and complete.  Refer to Appendix IV for a list of the 
focus group questions and posting schedule.  All focus group questions for the study were 
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formulated using the question categories recommended by Richard Krueger.69  Participants 
were asked to log onto the website at least once a week.  Discussions between the 
participants were automatically saved and were available to view throughout the entire 
focus group duration.  Subjects were also informed that an activity log was kept to assess 
how many times each participant logged onto the website, which could also serve as a 
means of identifying passive members and to encourage them to participate to a greater 
extent.51, 52, 54, 56 
To facilitate the discussion, I served as the moderator and logged onto the website at 
least once a day.  During this time, I strived to maintain the discussion and keep it focused.  
As such, I posted additional questions or comments to clarify participant responses or probe 
deeper into a subject.  Participants were asked to refrain from composing their own separate 
messages; however, some of the pharmacists asked specific individuals questions pertaining 
to their primary health or ambulatory care practice.  As moderator, I felt that the questions 
were relevant and allowed them, with the hopes that the participants would not only 
contribute to the process, but also learn from each other as well.    
  Friendly reminder e-mails were sent to the participants once a week to encourage 
them to continue reading responses and posting replies.   Each participant contributed to the 
discussion at least once a week.  Some logged on more than one weekly, to either finish 
posting their responses or to comment on/add to other participants’ statements.  Overall the 
pharmacists were motivated to assist with this stage of our study.  In fact, two participants 
emailed me after the on-line focus group was completed to provide me with further 
guidance on our project. 
Participants had all three of the researchers’ e-mail addresses and office phone 
numbers, in case of they had any questions.  In addition, each were provided with the 
University of Saskatchewan’s computer help-line contact information, in case of technical 
problems with the on-line software.51, 52, 56 Upon completion of the focus group, the 
participants received a $50 honorarium to partially compensate them for their time. 
Thematic coding occurs when researchers abstract general ideas or common threads 
from data.47  This was the method of analysis that was implemented to evaluate the data 
collected from the on-line focus groups.  Analysis began as soon as data were generated by 
the participants, and continued throughout the three week period.47 Themes and ideas that 
 22 
surfaced during the focus group were used to create a list of possible clinical pharmacy 
activities to be implemented at the Student Health Centre.  Both Dr. Neubauer and I 
conducted the thematic coding - first independently and then together we discussed the 
findings, to ensure we were in agreement.  Computer word documents were used to sort, 
categorize and rearrange statements. 
3.5.5 Look: Use the on-line focus group data to define and describe the situation 
Approximately halfway through September, 2006, a meeting with the Student Health 
Centre staff was organized to formally introduce the project. An overview of the study was 
provided via a PowerPoint presentation and each staff member was given a copy of the 
PowerPoint presentation slides, as well as the project plan (see Appendix V).  The staff was 
made aware I would be one of the researchers involved in the study, while also serving as 
their clinical pharmacist.  The inclusion criteria to participate in the study were discussed 
with the staff, and were as follows: 
1) willing to participate in a discussion with other staff members and the researchers to 
define and tailor the role of a clinical pharmacist for the Student Health Centre; 
2) willing to participate in a staff meeting at the end of November, 2006, to discuss how 
the role of the pharmacist had been implemented to date and provide 
recommendations for the remaining month; 
3) willing to participate in a focus group after the clinical pharmacist had provided two 
months of service to discuss their experience; and 
4) employed at the Student Health Centre between September, 2006 to January, 2007 
Ideally, staff members would participate in all three sessions – all meetings and the focus 
group discussion.  Consent forms were distributed to those in attendance.  Copies of the 
signed consent forms were returned to the staff members the same day.  For staff members 
who could not attend the meeting, copies of the PowerPoint presentation, project plan and 
consent form, were left in their mailboxes at the Student Health Centre, along with a cover 
letter (see Appendix VI). 
Once we had completed the data analysis of the on-line focus group discussion with 
the primary health and ambulatory care pharmacists, a second meeting was held with the 
Student Health Centre staff.  During this time, a list of possible clinical pharmacy activities, 
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generated by the expert panel was presented to the primary health care team (see Appendix 
VII). 
 
3.5.6 Think: Explore, analyze and interpret on-line focus group findings 
Together, we reflected with the staff on possible clinical pharmacy activities.  The staff 
had the opportunity to comment on the pharmacist focus group findings and explore how 
the activities could complement the Centre’s current services.  Preliminary discussion 
regarding a process of referring patients to me, their pharmacist, also took place.   
Prior to the second meeting with the staff, we decided to schedule an additional 
meeting with the team.  It was our belief that since a clinical pharmacist had never been 
integrated into the team before, it would be beneficial for the team members to have a 
longer reflection period on the list of possible clinical pharmacy activities.   During this 
reflection time, the staff was encouraged to mentally fuse the focus group findings with their 
patient interactions to identify areas where a pharmacist’s expertise would be valuable.   
This additional meeting took place at the end of October, which provided us and the 
staff with an opportunity to finalize my role as clinical pharmacist and further discuss the 
logistics of adding me to their team.  It was agreed upon that I would initially focus on three 
therapeutic areas: mental health, asthma, and contraception; however I would also assist in 
the care of any patient at the request of individual team members.  Answering drug 
information questions and providing patient medication histories were also identified as part 
of my role.  Project ideas included expanding and updating the Contraception Counselling 
program information for the staff; investigating last minute travel concerns, medication use 
in athletes, appropriate antibiotic use, herbal therapy as well as concurrent medication and 
alcohol consumption.  In terms of logistics, we decided that patients could be referred to me 
on a walk-in and appointment basis.  It was also determined that an appointment book 
would be kept with the receptionists in the front office to block off one-hour time slots with 
the referred patients.  
After the meeting, I sent a memo out to the entire staff, summarizing what we resolved 
during the discussion (see Appendix VIII).  I created a Pharmacist Referral form (see 
Appendix IX), which was also delivered to the staff that afternoon as they were encouraged 
to start referring patients to me at their earliest convenience.  The form was to be filled out 
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by a staff member and then given to the patient, who would subsequently take it to the 
receptionists to book the appointment.  I also developed a Patient Documentation form to 
record pertinent patient information for my own files (see Appendix X). 
 
3.6 Phase II: Implementing the Proposed Role of the Clinical Pharmacist 
 
3.6.1 Act: Implementation  
I provided two months of full-time clinical pharmacy services at the Student Health 
Centre for the months of November and December, 2006.  During this “Act” stage of the 
action research cycle, the first month of clinical services was conducted.  It is important to 
note that the amount of time I invested into the Student Health Centre, as their clinical 
pharmacist, was approximately forty hours per week.  We wanted to ensure the hours 
devoted to the Centre reflected a full-time position to help assess whether full-time or part-
time pharmacy services were required for and desired by the primary health care team.  In 
addition, controlling the time I spent working with/for the team decreased the risk of me 
dedicating additional hours to the project since I was the researcher and pharmacist.   
 
3.6.2 Look: Gather information to define and describe the situation 
During the first month of providing clinical services, I documented all clinical activities 
and interactions with staff members and patients.  The time required to complete each task 
was also tracked.  In addition, I kept a reflexive diary to fully capture my experiences.   
 
3.6.2.1 Projects 
Knowing that it would take time for the staff to adapt to having a clinical pharmacist 
on site and start referring patients, I immediately began working on projects to make the 
best use of my time. I wanted to start establishing credibility with the staff, and felt that the 
projects would help with this transition.  My goal was to use a team approach, and I 
therefore consulted with several team members with each initiative I undertook.  
For each activity, I would start by gathering input from individual team members who 
had a vested interest in the project at hand.  During this time, I also investigated what the 
current practice was for dealing with the issue, within the Centre.  To use time efficiently, 
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both mine and the team members, I would approach only one staff member with my initial 
draft, to obtain feedback on the content, logistics and feasibility of what I developed.  This 
team member was usually the senior physician or the person who initially requested the 
specific project.  I selected the senior physician as my primary contact for most scenarios, as 
he was one of the two full-time physicians at the Centre, and was responsible for overseeing 
the clinical responsibilities of the staff.  The team members who I originally gathered input 
from were subsequently approached for their thoughts on what I had created, and revisions 
were made until a final draft was agreed upon. 
 
3.6.2.1.1 Antibiotics 
When we met with the staff during Phase I, to define my role, we had discussed the 
possibility of adding antibiotics to my list of clinical activities.  Suggestions that surfaced 
included assessing the appropriateness of prescribed agents, following up with patients to 
see if their symptoms were resolving, and developing an antibiogram.  Shortly after I started 
at the Student Health Centre, I started exploring these ideas to further investigate a potential 
role for a pharmacist. 
 
Antibiogram 
An antibiogram is a tool for guiding empiric antibiotic therapy based on the local 
sensitivity patterns of bacteria to different antibiotics.  My co-supervisors and I felt that an 
antibiogram would be a good starting place.  The project would be relatively easy and was 
something we were sure the team would find valuable, thus aiding with establishing my 
credibility.  I met with a faculty member from the College of Pharmacy & Nutrition, Dr. 
Yvonne Shevchuk, who specializes in infectious diseases.  She agreed that an antibiogram 
was a good project for me to work on, but through further discussion, it became evident that 
the project would not be as easy as we originally thought. 
The biggest barrier to creating an antibiogram was getting the local laboratory on 
board with the project.  The bulk of the work, i.e. collating the data, would fall onto the 
shoulders of the laboratory department.  Dr. Shevchuk had provided me with a name and 
phone number for a contact person, and helped generate a list of questions for me to ask.  
First off, there is more than one medical laboratory in the city of Saskatoon, and I was not 
 26 
sure if all of the isolates from the Student Health Centre went to the main department, 
located in the Royal University Hospital.  If isolates were sent to various laboratories, it 
would complicate the process, possibly making the project impractical.  Secondly, we 
needed to know whether or not the laboratory was able to extract the Student Health Centre 
data from all of the Royal University Hospital results.  One of the benefits of having an 
antibiogram is the assurance that the sensitivity rates are specific to the patient population.  
A few other questions included how many years of isolates was the laboratory able to 
provide us with, along with the number of isolates for each bacterial species.  And lastly, I 
needed to know what timeframe we were working with, as I was only going to be at the 
Student Health Centre for two months.  Unfortunately, none of my e-mails or phone calls to 
the contact person at the laboratory were returned.  As such, I could not go ahead with the 
antibiogram project. 
 
Antibiotic Management Form 
Despite not being able to create an antibiogram, I decided to continue exploring 
another potential role with antibiotics. I conducted a literature search to see if there were 
any published articles describing the role of a pharmacist in an ambulatory care setting with 
regards to antibiotic management.  Unfortunately, at the time, there were no such articles 
available.  I developed a draft form in which I would review culture and sensitivity reports 
when they arrived.  The goal was to save time for the physicians/nurse practitioner, create a 
clinical role for myself and help establish credibility with the staff.   
I met with the senior physician to brainstorm a possible protocol and discuss the draft 
form that I created.  Initially, we thought that I would review all culture and sensitivity 
reports, as that would be easiest for the front office staff and decrease the workload for the 
physicians/nurse practitioner.  We discussed several scenarios, which were dependent on 
the results of the reports, and are as follows:   
1) The culture and sensitivity report comes back stating there was no significant growth 
(i.e. not a bacterial infection).  The patient’s chart is pulled to see if a prescription 
was given when the specimen was taken.   
a. If a prescription was provided, whether or not action was needed depended 
on the duration of therapy.  If it was a short course of therapy – for example, 
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three days of sulfamethoxazole/trimethoprim for a urinary tract infection, no 
action was required as typically the patient would be finished the antibiotic 
before the laboratory results were available.  For longer courses of therapy, a 
phone call to the patient was required to inform them to discontinue the 
antibiotic. 
b. If no prescription was provided, the culture and sensitivity report was signed 
indicating that it was reviewed, and placed in the patient’s chart. 
2) The culture and sensitivity report returns showing significant growth.  Again, the 
patient’s chart is pulled to see what occurred during the appointment. 
a. If no prescription was provided, then a prescription would need to be written, 
the patient informed and the prescription faxed to the patient’s pharmacy. 
b. If a prescription was provided during the initial patient visit, and was 
appropriate based on the culture and sensitivity report, no further action was 
required other then signing the report and placing it in the patient’s chart. 
c. If a prescription was provided, but the culture and sensitivity shows that the 
bacteria were resistant to the empiric therapy, an alternative medication may 
need to be prescribed and the patient contacted.  
The senior physician agreed that I could responsible for orchestrating all of the above, 
except for the last scenario.  He acknowledged that a pharmacist was capable of 
recommending an alternative antibiotic when a bacterial species is resistant to empiric 
therapy.  However after further discussion, we both were concerned that adding a 
pharmacist to the process may complicate things and result in additional phone calls to the 
patients.  In order for me to be able to make a sound recommendation, I would need to call 
the patient to assess allergies, identify previous courses of antibiotics and investigate any 
change in symptoms.  The senior physician felt that the physicians/nurse practitioner would 
still want to contact the patients as well, to assess whether or not antibiotic therapy was even 
required, since some bacterial infections spontaneously resolve.  Therefore, we abandoned 
the idea of a protocol and the draft form. 
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3.6.2.1.2 Mental Health 
Antidepressant Counselling  
Back in 2004, the Student Health Centre developed a contraception counselling 
program based on the results of two needs assessments they conducted, as well as the high 
volume of patients they see who desire contraception.  To ensure the patients receive 
comprehensive care and to assist with the documentation between nurses and 
physicians/nurse practitioner, a Patient History Contraception form was developed.  The form 
outlines all the required information to gather from the patient, along with a list of items 
which should be discussed during the medical appointment.   
Expanding on this concept, I decided to create a similar form that I could use when 
counselling patients suffering from depression.  My primary intent was to offer a 
comprehensive outline of what a pharmacist-patient interaction could consist of.  This in 
turn would hopefully alleviate some of the staff’s concerns surrounding the unknown 
capabilities of a clinical pharmacist.  Prior to starting the project, I had preliminary 
discussions with the senior physician and a few of the nurses, and they agreed it was a good 
idea.  I then proceeded to conduct a literature review, particularly focusing on pharmacists’ 
roles when counselling depressed patients and the management of antidepressant side 
effects.  Literature was also sought to help tailor the information to the patient population – 
i.e. university students.  For example, the effects of binge drinking while on antidepressants.  
Some of this information was difficult to track down, and I therefore sought the advice of 
one of my co-supervisors, Dr. Alfred Rémillard, who specializes in mental health.  He was 
able to provide me with the required information – both in the form of articles and his 
experience as a clinical pharmacist practicing in the area.    
My initial draft consisted of two appointments, at minimum, with the patients – an 
initial visit in close proximity to when an antidepressant was prescribed or changed, 
preceded by a follow-up visit to assess compliance, presence and severity of side effects, and 
to address any questions the patient may have (see Appendix XI).   Once my first draft was 
ready, I consulted with Dr. Rémillard again to obtain his feedback on my proposed outline.  
With his approval, I felt prepared to present the Student Health Centre team with the idea. 
The senior physician was the first team member I met with to discuss this first draft.  
He liked the format and content of the template, but had very valid questions regarding the 
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logistics of me providing this care.  As such, he suggested that we discuss it with the rest of 
the staff during the next staff meeting.  In the meantime, he had given me permission to use 
the format while seeing his patients.  To help the staff prepare for the meeting, I circulated 
copies of the draft to all of the physicians, psychiatrists, nurse practitioner, nurses, social 
worker, dietitian, health education coordinator, and front office staff. 
During the meeting, one of the other physicians expressed his concern that I was 
getting into the ‘therapeutics’ of depression, and felt that I should only focus on adherence 
and side effects.  Another physician was worried about the duplication of services.  Those in 
favour of the original outline argued that I was providing supplemental care and it would be 
beneficial for the patients to hear the same message more than once.  In the end, we 
compromised and I collapsed the two pharmacist visits into one – concentrating on 
assessment of adherence and side effect management (see Appendix XII).   I had also 
developed a patient information handout on managing side effects along with the first draft 
of the counselling form, and its use was approved by the staff (see Appendix XIII). 
As for logistics, it was agreed upon that I would see referred patients approximately 
one week after they started an antidepressant.  Whether a patient was referred to me or not, 
was left to the discretion of the physician/nurse practitioner and willingness of the patient.  
After I had seen a patient, the Antidepressant Counselling form was completed and placed in 
the patient’s chart, along with additional documentation in the progress notes that I saw the 
patient.   
 
Antipsychotics and Metabolic Syndrome 
In addition to counselling patients on antidepressants, one of the psychiatrists 
suggested that I could be a resource for both the staff and patients regarding atypical 
antipsychotic medications and metabolic syndrome.  These agents have been linked to the 
metabolic risk factors that are associated with the syndrome, such as abdominal obesity, 
changes in cholesterol and the body’s response to insulin, as well as elevations in blood 
pressure.  I agreed that a pharmacist could assist with the monitoring of these changes, and 
make recommendations for the prevention and treatment of metabolic syndrome.  
Unfortunately, because of the time constraints of the study, no patients on atypical 
antipsychotics were referred to me.   
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3.6.2.1.3 Last-Minute Travel Health Information Package 
The staff had requested information on travel health, particularly for patients who seek 
medical advice in close proximity to departure of their trip.  It was clearly laid out that the 
staff did not want to replace or compete with Public Health’s International Travel Centre.  
However, they desired information that would allow them to be better prepared for seeing 
patients who could not afford, did not have time, or refused to visit the Travel Centre. 
I began by sending out an e-mail to the primary care physicians and nurse practitioner 
to gather ideas for a Last-Minute Travel Health Information Package.   In addition, I had 
conversations with the nursing staff to obtain their input on the subject.  I took into account 
all of their suggestions, and added some topics I discovered while investigating the subject 
and felt would be beneficial.  Topics included: 
• Malaria prophylaxis 
• Last-minute hepatitis vaccinations 
• Prevention and treatment of Traveler’s Diarrhea 
• Economy Class Syndrome (travel-induced thrombosis) 
• Recommended over-the-counter medications for travel 
• Traveling with medication 
• Drug-induced photosensitivity 
• High-altitude sickness 
• Reputable resources for additional travel health information 
Gathering ideas and some preliminary investigation was as far as I got during this “Look” 
stage of the action research cycle. 
 
3.6.2.1.4 Asthma 
The key areas I wanted to focus on for asthma included proper device technique; 
assessment of drug therapy in terms of efficacy, presence of side effects and patient 
compliance; and education on differences between medications (e.g. preventer versus  
reliever), signs that asthma is not controlled and alert symptoms of an asthma attack.  
I gathered several patient education tools to assist in the delivery of the above information.  
This included obtaining copies of Health Quality Council’s Asthma Action Plan; the 30 Second 
Asthma Test™; placebo devices of an inhaler, turbuhaler, and diskus; and patient 
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information sheets demonstrating proper device technique.  Because the Student Health 
Centre provides health services to many international students, I ensured that the 
information sheets on device techniques included pictures to facilitate a patient’s learning 
process. 
 
3.6.2.1.5 Pharmaceutical Information Program  
The Pharmaceutical Information Program (PIP) provides authorized health care 
professionals access to Saskatchewan patient medication records.   Prior to me joining the 
team, the Student Health Centre was not registered with PIP.  I had introduced the program 
to the staff during a meeting, and met with the manager separately to provide additional 
information.  Shortly thereafter, the Centre became a registered site.  A few of the 
physicians, along with myself, were granted approval to access the records.  This allowed us 
to view both current and previous medications histories, identify all of a patient’s 
physicians/nurse practitioners and community pharmacies, assess compliance, and check 
on exception drug status.   
 
3.6.2.2 Drug Information 
3.6.2.2.1 Contraception 
Alesse® and Triphasil® Shortage 
Approximately one week after I started at the Student Health Centre, there was a 
national supply shortage of two oral contraceptives – Alesse® and Triphasil®.  Both 
products are manufactured by the same pharmaceutical company, and problems within the 
manufacturing plant resulted in the shortage.  I contacted the drug company and a few 
community pharmacies in Saskatoon to assess the situation.  The company could not 
provide an expected date for when new stock would be available.  As such, I sent out an e-
mail to the entire staff explaining the above, as well as providing a list of alternative oral 
contraceptives which could be used in the meantime (see Appendix XIV).   Prior to sending 
the e-mail, I discussed what I had prepared with one of the physicians, to ensure all of the 
information was applicable to the Centre. 
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Evra® Transdermal Contraceptive Patch and Risk of Thrombosis 
On Thursday, November 23rd, 2006, Health Canada released a notice regarding new 
safety information for the transdermal contraceptive patch, Evra®, and the risk of 
thrombosis.  I reviewed the preliminary, but conflicting studies this new warning was based 
on, and summarized the information in an e-mail I sent to the primary health care 
physicians, nurse practitioner and nursing staff.  In addition, I included a few statements to 
keep the warning in perspective, which would hopefully assist the staff in dealing with any 
questions they may receive from patients currently on Evra® (see Appendix XV).  I had 
showed the senior physician the e-mail before I sent it out, again to guarantee that the 
information was tailored specifically for the Centre. 
 
3.6.2.3 Drug Information Questions 
I received a variety of drug information questions, ranging from patient specific 
scenarios to personal inquires from individual staff members.  Depending on the question, I 
either gave an immediate verbal answer or a written response citing evidence to support my 
reply.  Below is a list of the twenty questions I was asked, broken down into categories. 
 
Therapeutic Options: 
1) What other medications could be used to treat Clostridium difficile in a patient 
currently being treated with Flagyl® (metronidazole), but vomits after each dose? 
2) What ‘as needed’ medications can be used to treat diarrhea-predominate irritable 
bowel syndrome and the associated cramping? 
3) What kind of iron supplement should a patient take? 
 
Safety and Efficacy of Medications: 
4) Why is an allergy to gentamicin listed as a contraindication to the flu vaccine? 
5) What are the safety concerns with energy drinks, like Red Bull®? 
6) Can the hepatitis A vaccine, Vaqta®, be given to a patient with an egg allergy?  
7) Does Nexium® (esomeprazole) become inactivated if chewed, as a patient who 
cannot swallow the delayed release tablet is still suffering from gastro esophageal 
reflux symptoms? 
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8) Can ciprofloxacin be safely used to treat a urinary tract infection in a patient with an 
eating disorder and allergies to penicillin and sulfa drugs?  Will the medication be 
absorbed if she vomits the medication? 
 
Availability of Medications: 
9) Does Ovol® (simethicone) come in a pediatric formulation? 
10) Are immediate release propanolol 10mg tablets still available? 
11) What combination topical steroid and antifungal agents are currently on the market? 
 
Drug Identification/Indication: 
12) Can you tell me what two medications a patient is currently taken, but has 
mispronounced the drug name and it is unclear as to what she is on? 
13) What is metocloperamide and what is it used for? 
 
Drug Coverage/Regulation: 
14) Is Imovane® (zopiclone) included in the new prescription review program?  
15) Is Wellbutrin® (bupropion) covered by the Saskatchewan Drug Plan? 
 
General Resource: 
16) What are good references for herbal medications? 
17)  What do you think of the new Human Papillomavirus vaccine? 
 
Personal Use: 
18) Are bioidentical hormones better than conventional hormone replacement therapy? 
19) What are the goals for cholesterol levels? 
20) Is it okay to take both Advil® (ibuprofen) and Tylenol® (acetaminophen) for severe 
muscle spasms? 
 
3.6.2.4 Direct Patient Care Interactions  
I met with fourteen patients during the month of November.  Taking into account both 
the initial visits and all follow-up appointments, I had twenty-two interactions with patients.  
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Two additional patients were referred to me, but unfortunately, they did not show up for 
their appointments.  For each patient I saw, I documented the exchange in the patient’s 
chart and, whenever possible, provided the team member who referred the patient to me 
with a verbal report of what transpired.   
A summary of the patient interactions, sorted by the primary reason for the referral, are 
as follows: 
 
Over-the-Counter Product Selection 
1) Suggested a non-prescription product for a patient complaining of nasal congestion 
and a cough due to post-nasal drip. 
 
Gastrointestinal Disorders 
2) Counselled a patient suffering from an ulcerative colitis relapse on a new prescription 
for prednisone.  Discussed the benefits and side effects of prednisone, recommended 
to avoid non-steroidal anti-inflammatory agents, and discussed the importance of 
getting adequate calcium and vitamin D while on a corticosteroid.  Suggested a 
change in therapy to the physician – discontinue Cortenema® (hydrocortisone) and 
increase the dose of prednisone, which was accepted. 
3) Discussed the benefits of starting Paxil® (paroxetine) for the treatment of irritable 
bowel syndrome and comorbid social phobia, in addition to providing education on 
primary prevention for cardiovascular events. 
4) Compared antidepressants to antispasmodics as therapeutic options for the treatment 
of pain associated with irritable bowel syndrome. 
 
Travel Health  
5) Reviewed malaria prophylaxis; recommended vaccinations and over the counter 
medications for traveling; how to prevent Traveler’s Diarrhea;  reputable websites for 
travel health information; guidelines for traveling with medications and travel health 
insurance with two patients heading to Mexico – one visiting the Mayan Riviera and 
the other heading to Puerto Vallarta. 
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Depression 
6) Followed the Antidepressant Counselling form while counselling a patient on starting 
Celexa® (citalopram). 
7) Reviewed Celexa® (citalopram), using the Antidepressant Counselling form as a guide, 
with a patient who had previously been on the medication.  The patient had concerns 
regarding her history of weight gain while on antidepressants and inquired about 
using herbal weight loss drugs.  I warned her of the lack of safety and efficacy with 
these products, and encouraged her to try lifestyle changes instead (e.g. diet, 
exercise).  This patient already had a referral to the Centre’s dietitian.   
8) Received a phone call from a patient who was concerned about possible 
antidepressant side-effects.  Her complaints appeared to be a mixture of side effects 
and symptoms of depression.  The patient admitted to having suicidal thoughts, and 
I therefore transferred her onto a physician to address the urgent matter. 
 
Chronic Disease Management 
9) Met with a patient who suffers from depression, hypertension, diabetes, and asthma 
over three appointments: 1) medication review, assessment of compliance and 
education on primary prevention for cardiovascular events; 2) review of herbal 
medications and supplements the patient was previously taking; and 3) 
recommendations for treating insomnia and constipation. 
10) Demonstrated how to properly use Pulmicort® (budesonide) and Bricanyl® 
(terbutaline) inhalers to an asthmatic patient.  I also discussed with her the role of 
each inhaler, the signs of uncontrolled asthma and how to identify an asthma attack.    
 
Abnormal Laboratory Results 
11) Investigated probable drug-induced hepatotoxicity for a patient who was on Effexor 
XR® (venlafaxine) and Nexium® (esomeprazole), and had a recent course of 
Zantac® (ranitidine).  I found case reports of elevated liver enzymes that were 
suspected to be caused by Effexor XR® (venlafaxine).  I assisted in the management 
and monitoring of the patient, and submitted an Adverse Drug Reaction form to Health 
Canada. 
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12) Researched a possible herbal-laboratory interaction for a patient with an elevated 
vitamin B12 level who was taking several homeopathic medications.  Laboratory 
values returned to normal shortly after the homeopathic mixtures were discontinued.  
I sent another Adverse Drug Reaction form to Health Canada.  Overall, I met with the 
patient for a total of three visits: 1) to gather patient specific information, timelines 
and a list of the homeopathic agents; 2) to review the information I obtained 
regarding the possible herbal-laboratory interaction; and 3) to encourage her to take 
an antibiotic for a urinary tract infection. 
13) Explored another case of hepatotoxicity potentially linked to herbal products.  The 
patient was taking five different types of herbals, one of which was L-Theanine – the 
major amino acid found in green tea.  Green tea has been linked to hepatotoxicity, 
which may have caused the elevated liver enzymes alone, or in combination with the 
other products.  Again, an Adverse Drug Reaction form was submitted.  I met with this 
patient twice.  The first visit was regarding his elevated liver enzymes, and the 
second appointment was to discuss therapeutic options for essential tremor. 
 
Contraception  
14) Counselled a patient who was requesting her third dose of emergency contraception 
due to non-compliance with her oral contraceptive.  I focused on compliance, birth 
control options, continuous versus cyclical oral contraceptive regimens and the use 
of multiple emergency contraception doses. 
 
In the first month, I estimated that I spent approximately 55% of my time working on 
projects, 30% on direct patient care, and 15% answering drug information questions. 
 
 
3.6.3 Think: Explore and analyze as a team 
At the end of the first month of clinical service, another meeting was held with the 
Student Health Centre staff.  During this session, I presented a summary to the team of all 
the clinical activities that had been implemented thus far.  In addition, the staff was asked to 
provide feedback on the pharmacy services that I provided.  This allowed the staff and I to 
reflect on how the project had been received to date.    
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With action research being a collaborative process, I decided that I would personally 
obtain the staff’s opinions on what I had accomplished thus far, as all key players should be 
incorporated in the search of solutions to issues, rather than having a third party involved.  I 
had already been working with the team, receiving their comments on what I had 
developed, throughout the month of November.  I also felt that my presence would be 
needed in case further explanation was required for the summary of activities.  In addition, I 
had worked with the team each step of the way, starting from the initiation of the study.  I 
wanted to maintain that team approach, and felt that I should be involved in any discussion 
regarding my role.   As health care professionals, I felt confident that, as a team, we could 
discuss any issues in an open and professional manner.  
 
3.6.4 Act: Evaluate, plan & implement second month 
Originally, my co-supervisors and I were to evaluate the findings from the staff 
meeting and modify the clinical services based on the team’s recommendations.  However, 
the team provided positive feedback on the study and had no suggestions for change.  I, 
therefore, did not alter my role and continued with the responsibilities I had achieved thus 
far. 
 
3.6.5 Look: Gather information to define and describe the situation 
During the month of December, I documented all of the clinical activities and 
interactions in the same manner as I did throughout November.  
 
3.6.5.1 Projects 
3.6.5.1.1 Suppressive Therapy for Genital Herpes Simplex Virus 
A discussion surrounding suppressive therapy for genital herpes simplex virus and the 
recently released Canadian Guidelines on Sexually Transmitted Infections took place during 
one the staff meetings.  The guidelines stated that safety and efficacy data for two of the 
antiviral agents - acyclovir and valacyclovir, had only been established for up to one year of 
therapy, and only up to four months of administration with famciclovir.  The team 
expressed their frustration, as the duration of suppressive therapy is often beyond these 
timeframes.  In addition, they admitted to struggling with their patient’s inquiries of how 
safe extended antiviral therapy is. 
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I was asked by one of the team members if I knew what the side effects were with 
chronic antiviral treatment.  I could not provide an immediate answer, but jumped at the 
opportunity to offer another example of how a pharmacist could add value to a health care 
team.  Subsequently, I volunteered to conduct a literature review assessing the long-term 
safety of antiviral agents when used as suppressive therapy to treat genital herpes simplex 
virus.   
My review included the recommendations published in both the Canadian and 
American treatment guidelines for sexually transmitted infections, as well as safety data 
from the longest antiviral trials I could retrieve – ten years for acyclovir, and one year for 
both valacyclovir and famciclovir.  The senior physician reviewed and approved my first 
draft, which was then sent out to the remaining primary health care physicians and nurse 
practitioner for their input. 
While conducting the literature review, I noticed a discrepancy with the duration of 
one of the famciclovir trials referenced in the 2006 Canadian Guidelines on Sexually 
Transmitted Infections.  The trial was conducted over a period of 52 weeks, however as 
mentioned earlier, the guidelines stated that no safety and efficacy data was available 
beyond four months of administration.  I sent an e-mail to the Public Health Agency of 
Canada, who published the guidelines, asking for clarification.  My e-mail was returned 
stating that the duration was printed in error and an erratum would be posted on their 
website.  I forwarded the e-mail to the Student Health Centre to inform them of this change.  
The erratum appeared on the website this past spring.  Despite the fact that I was no longer 
providing services at the Centre, once the erratum was available, I updated the original 
document, printed off copies of the erratum and distributed the revised version to the 
primary health care physicians and nurse practitioner (see Appendix XVI).  
 
3.6.5.1.2 Last-Minute Travel Health Information Package 
During the month of December, I continued to search for and review literature on the 
travel health topics to be included in the Last-Minute Travel Health Information Package.  In 
addition to the documents I prepared for the staff, I added three information sheets 
specifically for patients which focused on Traveller’s Diarrhea, Economy Class Syndrome 
and recommended over-the-counter medications for travel.  I asked the senior physician to 
 39 
review the initial draft first.  After I made his suggested revisions, I then gave copies to the 
remaining primary health care physicians and nurse practitioner for their feedback.   
The final document was 24-pages, and I wanted to present the information to them in 
a manner that was practical and could be easily updated.  I therefore assembled the package 
in a thin binder, one for each physician/nurse practitioner, and placed several copies of the 
patient information sheets in clear plastic binder inserts.  A Public Health International 
Travel Centre business card was also attached to the first page of the document (see 
Appendix XVII). 
 
3.6.5.1.3 Contraception Counselling Program 
Since the Student Health Centre already had a Contraception Counselling Program in 
place, my suggested role was primarily to update and expand the information for the staff.  I 
talked to the nursing staff to obtain ideas for changing their existing resources.  They were 
able to provide me with a wealth of suggestions, however due to time constraints of being at 
the Centre for a total of only two months; I decided to focus on the topics related 
specifically to pharmacy.  I, therefore, elected to update their information sheets on drug 
interactions.  Their present documents included medications that had since been withdrawn 
from the market (e.g. clofibrate) and did not contain information on oral contraceptives that 
had been recently introduced (e.g. Yasmin®).  
I created three separate documents on oral contraceptive drug interactions.  The first 
handout included a list of medications, categorized by drug class, whose drug 
concentrations are altered by oral contraceptives, a description of the effect and 
recommendations for dealing with the interaction.  The second information sheet was 
similar in terms of content, but outlined drugs that may affect oral contraceptives drug 
concentrations.   The third, and final, section focused solely on the oral contraceptive, 
Yasmin®, due to the medication’s unique pharmacology.  The mechanisms, as well as 
recommendations for both monitoring and managing the interactions were summarized.   
Unfortunately, it was near the end of December when I had a draft ready to circulate 
to the staff.  I provided copies of the documents to the nurse practitioner and one of the 
registered nurses.  Since my time at the Student Health Centre was drawing to an end, I was 
unable to receive their feedback on the information I put together.  However, these files, 
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along with all other projects I created, were saved on a shared computer folder through their 
network.  As such, the staff could access, alter and update any of the documents I 
developed. 
 
3.6.5.1.4 Antibiotics 
 
Cross-Reactivity of Antibiotics 
Shortly after the mid-point meeting with the staff, the nurse practitioner identified an 
antibiotic project for me when she reflected back to the summary I presented.  She requested 
information on the cross-reactivity of sulfa antibiotics to assist her in providing care to 
patients with these allergies.  Based on my experience as a hospital pharmacist, I knew that 
concerns regarding the cross-reactivity between beta-lactam antibiotics are also relatively 
common, and therefore I decided to include penicillin and cephalosporin antibiotics.  
The document I created included a list of questions to help assess if a reaction is a true 
allergic reaction, the incidence of allergies to the chosen antibiotics, the types of allergic 
reactions, and recommendations for handling cross-reactivity concerns.  Once my first draft 
was approved by the nurse practitioner, I distributed copies to the rest of the primary health 
care physicians for their input and subsequently a final version was circulated (see Appendix 
XVIII). 
 
3.6.5.1.5 Sports Medicine 
Developing a role in sports medicine was suggested by a physician during one of the 
September meetings.  The physician provided me with the contact information for the 
Huskie Athletics’ head physical therapist.  Due to her busy schedule, we were not able to 
meet until December.  At that time, the majority of the athletes were focusing on final 
exams and then heading home for the holidays.  As such, she was able to provide me with 
several examples of how a pharmacist could collaborate with the sports department, but we 
were unable to implement any of the suggestions.  The following is a list of the examples she 
provided me: 
1) Provide drug information consults – e.g. can athletes take their prescribed 
medications; how much of a substance can be safely taken; how long will a 
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medication stay in their system; if a medication is prohibited, what permitted 
substance can be substituted. 
2) Hold in-services for the athletes – e.g. asthma education. 
3) Assist with the paper work for any appeals process when the use of a medication is 
declined by the Canadian Centre for Ethics in Sport – e.g. explaining why a patient 
needs Ritalin® (methylphenidate) and why using another agent is not an option. 
4) Review the doctor’s kit for sports games to see if anything else should be included. 
5) Conduct a literature review for efficacy of topical anti-inflammatory agents.  
6) Answer questions on the safety and efficacy of supplements, as well as checking 
whether a substance in question has been authorized for use. 
 
3.6.5.2 Drug Information 
 
Aerochamber Insurance Coverage  
While counselling a patient on the proper use of an aerochamber, the issue of cost 
came up.  I knew that aerochambers are costly, but was unsure if the health insurance 
through the University of Saskatchewan Students’ Union Health and Dental Plan would 
cover the expense of the device.  I called the insurance plan, but they could not provide me 
with an answer right away.  I had talked to a few of the team members, and they were 
unsure themselves.  Within a week, I had received an e-mail from the insurance plan 
informing me that the cost of an aerochamber is covered.  I forwarded the e-mail to all of 
the physicians and nurse practitioner to ensure they were aware of the available coverage. 
 
Information on Salvia (Legal Hallucinogen) 
During one of the last staff meetings I had with the staff, they discussed an article on a 
legal hallucinogen – Salvia, which made the front page of the Star Phoenix.  The team 
members were concerned about the use of this agent in their specific patient population, and 
asked if I had any information on it.  I could not answer their question immediately, but 
promised that I would look into it for them.  After gathering the information needed to 
answer their questions, I sent out an email to all of the staff, attached a link to the article for 
those who had not attended the meeting and a document summarizing what I had found.  
In addition, I posted the information and article in their staff lunch room. 
 42 
3.6.5.3 Drug Information Questions 
The staff had asked me a total of eleven drug information questions during the month 
of December.  A summary of the questions, categorized by topic, is as follows: 
 
Safety and Efficacy of Medications: 
1) Can inhaled corticosteroids be used during lactation? 
2) Can a hepatitis C positive patient take doxycycline for malaria prophylaxis? 
3) A patient who is taking lithium ran out of refills and her regular doctor is not in 
today.  All of the other physicians are booked for the day.  Does the patient need to 
be seen by a doctor today? 
4) Can Effexor XR® (venlafaxine) capsules be opened and the contents divided to aid 
with tapering in a patient who is very sensitive to the medication? 
5) Which medications interact with alcohol? 
6) Does the drug interaction between antibiotics and hormonal contraception still occur 
if you select a non-oral route, like a transdermal patch? 
 
Drug Coverage/Regulation: 
7) What are the exception drug status requirements for HP-PAC® (lansoprazole, 
amoxicillin, and clarithromycin seven day pack), and the process for getting the 
medication approved? 
 
Personal Use: 
8) What is a good muscle relaxant to take? 
9) What is the best type of calcium supplement to take? 
10) Are thyroid supplements interchangeable? 
11) What antihistamine will not make me drowsy? 
 
3.6.5.4 Direct Patient Care Interactions  
During the month of December, I had eight new patients referred to me, and only one 
of whom I met with more than once.  In addition, I saw one of the patients I originally met 
in November, for a follow-up appointment.  As such, I had a total of ten direct patient care 
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encounters.  I continued to document the patient visits and provide verbal reports to the 
referring team member whenever possible, as I did in the previous month. 
The following is a summary of the patient interactions I had, sorted by primary reason 
for referral. 
 
Depression 
1) Assessed compliance and the presence and severity of antidepressant side effects with 
three patients approximately one week after they initiated therapy, as per the 
Antidepressant Counselling form. 
2) Discussed antidepressant therapy with two patients who requested additional 
information before they were willing to begin pharmacological treatment.  One 
referral was from a physician, and the other from a clinical psychologist employed at 
Student Counselling Services.   
 
Chronic Disease Management 
3) Counselled a patient on salbutamol for exercise-induced asthma.  I educated her on 
the purpose of the medication, the signs of uncontrolled asthma, how to identify an 
asthma attack, as well as proper inhaler and aerochamber technique.  The patient 
belonged to Huskie Athletics, and I began the paperwork required for the 
prescription to be approved for therapeutic use – i.e. the Canadian Centre for Ethics 
in Sport’s Abbreviated Therapeutic Use Exemption Form. 
4) Followed up with a patient I met with in November regarding asthma, at the request 
of her physician.  I assessed the patient’s compliance and comprehension of her 
respiratory disease.  Further education was provided on topics as needed. 
 
Pain Management 
5) Reviewed the therapeutic options for migraine prophylaxis with a patient who had 
not responded to first line therapy.  At the patient’s request, I focused primarily on 
efficacy and side effects.  A second encounter with the patient was required to 
discuss additional information I had found for her. 
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6) Performed a pain management assessment on a patient suffering from uncontrolled 
pain.  In addition, I educated her on proper use of pain medication and the 
management of side effects, such as drowsiness and constipation.  The patient also 
inquired about the effects of combining alcohol with Tylenol #3® (acetaminophen 
and codeine) tablets, which I addressed. 
 
As for the proportion of time spent on the clinical services during the month of 
December, I estimated that approximately 65% of my time was dedicated to projects, 20% 
to direct patient care activities, and 15% answering drug information questions.  
 
3.7 Phase III: Evaluating & Prioritizing the Role of a Clinical Pharmacist 
 
3.7. 1 Look: Gather information to define and describe the situation 
Upon completion of the two month commitment at the Student Health Centre, focus 
groups were organized to collect information on how the staff and patients felt about their 
experiences with a clinical pharmacist.  The objectives of the focus groups were to identify 
what went well, what did not and areas for improvement, surrounding the integration of a 
pharmacist into an already established primary health care team. 
 
3.7.1.1 Focus Groups with the Primary Health care Team 
My co-supervisors and I wanted to organize face-to-face focus groups with the Student 
Health Centre staff in close proximity to the completion of Phase II.   We decided on using 
face-to-face focus groups instead of on-line focus groups primarily because the Student 
Health Center staff had approached the study as a team from the beginning.  To hide their 
identities from each other for the final evaluation would seem contrived.  With their team-
based philosophy, I was confident that they would feel comfortable discussing the project in 
an open group setting.    
 I estimated that approximately sixteen staff members would participate, and therefore 
planned to divide the staff into two groups for the focus group discussions.   
There were a total of twenty-eight staff members on the team; however several of them filled 
0.5 positions – or less.  I therefore had minimal interactions with some of the team 
members.  In fact, there were a few employees that I did not have the opportunity to meet 
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over the two month period.  Despite this, we sent invitations to participate in the focus 
groups to all of the employees, as they had received information on my project since our 
initial planning stages.  My estimate of recruiting sixteen staff members was based on the 
number of people I had interacted with while providing clinical pharmacist services. 
I met with the manager of the Student Health Centre, and she was willing to schedule 
the focus groups during times set aside for weekly meetings.  She felt that the focus groups 
would have to be conducted during business hours, as the staff had too many personal 
commitments in the evenings and on weekends.  She also could not afford to have the focus 
groups cut into clinical hours. 
I worked closely with the office manager to reserve dates for the focus groups during 
the month of January.  A number of the staff work on a part-time basis, and for that reason, 
we selected both Monday noon and Thursday morning meeting times to accommodate as 
many staff schedules as we could.  I had originally targeted for two hour long focus group 
sessions, however staff meetings at the Centre are only allotted one hour.  Therefore, the 
office manager set aside two Mondays for one focus group and two Thursdays for the other.  
I sent an e-mail to the entire staff inviting them to participate in the evaluation of my study.  
In the e-mail, I had listed the dates for the staff to choose from.  I also asked for those team 
members who were interested to reply with their preference for either the Monday or 
Thursday sessions.  I knew that some of the team members would be able to attend both 
days of the week, but wanted to create two groups with relatively the same number of 
participants and also ensure there was a mix of health care professionals per group. 
To reduce bias, an external moderator was recruited to facilitate the focus groups as I 
was both a researcher and the intervener.  The Primary Health care Director of the 
Saskatoon Health Region provided us with one of their staff members, in kind, to serve as 
the moderator.  I met with the facilitator before the focus groups began to discuss the 
logistics and confirm dates.  In addition, we reviewed the focus group questions for the staff 
and he offered valuable recommendations for modifying the format and phrasing of the 
questions.  These suggestions were discussed with my committee and revisions made until a 
final list of focus group questions were agreed upon (see Appendix XIX).  
The focus group discussions were conducted in Student Counselling Services’ 
conference room on campus, as the Student Health Centre did not have the space to 
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comfortably accommodate the sessions.  The focus group questions were written on a flip 
chart for the participants to follow along with.  Tables and chairs were arranged ahead of 
time to create a welcoming and relaxed environment, and to be conducive for a group 
discussion.  The discussions were tape recorded using two separate recorders and 
microphones.  We recruited the Student Health Centre’s office manager to attend each of 
the focus group sessions and record the order of speakers.  The purpose of keeping such a 
record is to assist with the transcription of the tapes, in case the transcriber had any 
difficulty distinguishing voices.  A $50 honorarium was given to the office manager for her 
assistance. 
A few of the focus group sessions had to be rescheduled for various reasons.  The very 
first Monday session was interrupted by a fire alarm.  The facilitator’s schedule changed mid 
January, and the original date for the second Monday focus group was no longer an option.  
Therefore, two alternative dates were arranged and a total of three focus groups were 
required to provide the staff with ample time to discuss all of the questions.  As for the 
Thursday group, the first session was scheduled for the day after a blizzard had occurred in 
the city.  Only a small number of the team members were able to make it to campus that 
morning, and therefore the focus group was postponed for a later date.  For the last focus 
group session with the Thursday group, the facilitator forgot about the appointment and did 
not show.  I knew that the facilitator would be away for half of February, and therefore the 
final session could not be rescheduled until early March.  The staff had been very patient 
with the rescheduling of so many sessions, but I was concerned about taking up too many of 
their meeting times, which they needed for other obligations as well.  As such, I gave the 
staff the option of having one of them lead the focus group or to reschedule for another date.  
The team was willing to discuss the questions on their own, and one of them volunteered to 
moderate the discussion.   
Since I had worked closely with the team for two months, there was a chance that I 
could recognize individual’s voices on the focus group tapes.  As such, we hired a 
transcriber to write out the recorded discussions for us.  The transcriber was instructed to 
leave out the names of the participants, and instead assign numbers to each of the speakers.  
Before each of the focus groups, the facilitator reminded the staff of this, and assured them 
that I would be blinded to who made each comment.  The participants were encouraged to 
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be as open and honest as possible when reflecting on their experience with having a 
pharmacist join their team. 
Once the focus groups were completed, I delivered all of the cassette tapes to the 
transcriber, along with the lists that the office manager kept to record the order of speakers.  
After the tapes were transcribed, I prepared to have the participants verify the transcripts 
which would provide them with the opportunity to add, alter or delete any of their 
statements.  As mentioned earlier, each staff member was represented as a number in the 
transcripts, to separate individual’s statements yet preserve confidentiality.  Participants may 
have had a different number for each of the focus groups they attended.  In order to send the 
appropriate transcripts to each staff member, we needed to identify which number belonged 
to whom, as well as inform each individual of their corresponding number to the quotes.  
Since I was blinded to this information, we solicited the help from someone who was not 
directly involved in the study.  This removed individual prepared a list of which transcripts 
should be delivered to each staff member.  In addition, every participant received a sealed 
envelope containing their number(s) for each focus group(s) they were involved with, which 
was also created by this third party individual.   
The focus group transcripts and sealed envelopes were sent to the participants, along 
with a letter explaining the transcript verification process (see Appendix XX).  They were 
allotted a total of four weeks to review the transcripts and make changes.  If they had any 
changes, we asked that they write the changes on the transcripts and return the documents, 
anonymously, to us.  A friendly reminder e-mail was sent to the staff two weeks into the 
transcript verification period.   
  
3.7.1.2 Collecting Data from the Patients 
Primary health care encourages patients to take more responsible for their health and 
become active members on their own health care team.6  Action research strives to include 
all relevant stakeholders.  It is therefore beneficial to obtain the opinions of patients who I 
had direct involvement with. 
Mental health concerns are the number one reason why patients seek medical services 
at the Student Health Centre.  Contraception is the second most common cause.  Due to the 
nature and sensitivity of these reasons, particularly with mental health issues, we originally 
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proposed using an on-line focus group.  The anonymity that accompanies on-line focus 
groups helps create a non-threatening environment for the participants.  University students 
also have demanding schedules, and therefore, the on-line focus group would allow the 
patients to participate when it was convenient for them.  In addition, all University of 
Saskatchewan students are provided with computer accounts and can access computers 
throughout campus.  See Appendix XXI for a list of the focus group questions. 
The same website used for the on-line focus groups with the expert panel of 
pharmacists was proposed to be used with the patients.  All University of Saskatchewan 
students are assigned Network Services Identification (NSID) numbers.  The computer 
programmer required the participants’ NSID numbers, which was used to create 
pseudonyms to ensure anonymity and confidentiality.  As researchers, my co-supervisors 
and I were to be blinded to the pseudonyms.  At the beginning of January, I provided our 
Information Technology Services department contact with a list of patients I had seen at the 
Student Health Centre.  Pseudonyms were created at that time, to assist with the short 
timeframe we were dealing with. 
As with the on-line focus group with the expert panel, the patient focus group was to 
run over a period of three weeks.  The timelines for the data collection were sensitive, as we 
wanted to minimize the time span between my interaction with the patient and their 
evaluation of the experience.  In addition, the University’s mid-term break began the week 
of February 12th, 2007 and students typically have exams prior to the holiday.  As such, we 
did not want the focus group to interfere with the patients’ academic schedules. 
We were also concerned with the number of patients we had to recruit from.  In total, 
I only saw twenty-two patients during the months of November and December, 2006.  We 
felt that a minimum of five participants would be required to conduct an on-line focus 
group.  If we could not recruit that minimum, we planned to use an on-line survey instead 
as a method of collecting data from the patients.  Due to the time constraints we were 
facing, we wanted to be proactive.  As such, I submitted a protocol amendment to 
Behavioural Research Ethics Board outlining this possible change in data collection.  The 
amendment was approved on January 8th, 2007.   
In early January, we initially planned to have the on-line focus group begin on the 
morning of Wednesday, January 17th and end midnight, Tuesday, February 6th, 2007.  Once 
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I confirmed these dates with our Information Technology Services contact, I sent an e-mail 
invitation to nineteen patients I worked with while at the Student Health Centre (see 
Appendix XXII).  One patient whom I provided care to was my cousin, and as such was 
excluded from the study to avoid any conflict of interest.  In addition, two patients - 
suffering from borderline personality disorders, were also not sent the e-mail invitation.  
When I met with these two patients to provide care, both had very negative opinions of the 
health care system as a whole and a high distrust for health care professionals.  Due to the 
nature of their illness, these patients were very opinionated and I was concerned that they 
could easily have a negative influence on the focus group discussions, and hence their 
exclusion from the evaluation.   
The e-mail invitation was sent on Tuesday, January 9th, 2007, and I requested for those 
who were interested to let me know by Monday, January 15th, 2007.  The e-mail was sent to 
the patient’s university e-mail account.  Since we could not guarantee that this was their 
primary e-mail account and therefore receiving the e-mail in a timely fashion, a letter of 
invitation was also sent to each patient via regular mail.  A friendly reminder e-mail was 
sent on Friday, January 12th, 2007.  
By the reply deadline, not one patient had contacted me.  The following day, I 
received a phone call from one of the patients, expressing interest in the study as he had just 
received his letter in the mail.   The week I mailed the invitations was the same week a 
blizzard occurred in Saskatoon.  As such, mail delivery was delayed.  We, therefore, 
decided to extend the deadline and set a new start date for the on-line focus group – 
Monday, January 22nd, 2007.  I sent an e-mail to the patients on Wednesday, January 17th 
explaining the reason for the delay in receiving the letters, as well as informing them of the 
extension and new start date. 
Despite extending these dates, only one other patient had contacted me stating he 
would participate in the study.  Since our total number of participants was less than five, we 
carried out our back-up plan of switching to an on-line survey instead.  As such, another e-
mail was sent to the patients informing them of the change and inviting them to complete 
the on-line survey (see Appendix XXIII).  The survey would only require ten-fifteen minutes 
of their time, compared to the two-three hour commitment with the on-line focus group.  
The start date for the survey was January 24th, 2007, and was available over a one-week 
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period.  Instructions on how to access the survey were included in the e-mail.  The website 
for the on-line survey was secured, and therefore a username and password were required to 
access it.  In order to maintain confidentiality, only one username and password was 
provided for the entire group.  A friendly reminder e-mail was sent mid-week to the patient 
group (see Appendix XXIV for the on-line survey questions). 
At this time, we decided to revisit the idea of inviting the two borderline personality 
disorder patients who were originally excluded from the on-line focus group.  It was an 
assumption, and unfair judgment on our part, that their comments would be negative.  If, by 
chance, they did have a negative response to the questions, the on-line survey eliminated the 
concern of their comments influencing others.  Lastly, since mental health issues are a 
predominant concern with the Student Health Centre patient population; these patients in 
particular should have the opportunity to voice their opinions on the services they receive.   
After taking all of the above into consideration, e-mail invitations to participate in the on-
line survey were sent to the two borderline personality disorder patients as well.   
Unfortunately, in the end, only one patient took the time to partially complete the on-
line survey.  Because of the poor response rate (n=1, 4.8%), the survey results could not be 
analyzed but have been included as an appendix (see Appendix XXV).  There are several 
reasons which may explain the unsuccessful attempt of obtaining patient feedback. 
For the on-line focus group with the patients, we mirrored the steps and timelines we 
had implemented for the on-line focus group with the pharmacists during Phase I - with the 
exception of providing a monetary incentive for participation, which has been shown to 
increase response rates.70 We provided the pharmacists with a $50.00 honorarium to 
partially compensate them for their time.  As for the patients, since we wanted to evaluate 
the relationship I established with them, we felt it was unethical to offer them any financial 
enticement for their feedback.   
Another difference between the pharmacists and the patients could be the motivation 
to participate in the on-line focus groups.  The pharmacists were selected to participate in 
the focus group based on their own initiatives to expand the role of pharmacists on health 
care teams.  The patients, on the other hand, would not have the same interest to see the 
profession of pharmacy evolve towards a more clinical focus.  An additional factor, which 
may have contributed to the lack of participation in the on-line focus group, was the time 
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commitment (i.e. two to three hours over a three week period). However, the on-line survey 
we opted to use only required ten to fifteen minutes of the patient’s time, yet still resulted a 
in poor response rate. 
Looking specifically at the on-line survey, the number and type of emails sent to the 
patients inviting them to participate may have impacted their interest.  To increase survey 
response rates, it is recommended that at least four separate mailings be sent to participants 
– an advance-notice letter, a cover letter with more detail and the questionnaire, follow-up 
postcard, and another letter and questionnaire to non-responders.70  The goal is to make 
repeated and well-timed contacts in an inoffensive way.70  A total of five emails were sent to 
the patients, however this included messages for both the on-line focus group and on-line 
survey.  We could not follow the recommended contact steps for the on-line survey, as our 
goal to collect the data before the mid-term back was approaching fast.  In addition, we had 
already sent three emails to the patients prior to switching to an on-line survey, and 
therefore we wanted to minimize the number of emails we sent to avoid any sense of 
harassment.   
Both the focus group discussion and the survey were Web-based, prompting an 
investigation as to whether technology had a negative impact on participation.  We had 
used a Web-based data collection method, with the established primary health and 
ambulatory care pharmacists, during the first phase of our study.  The on-line focus group 
was not a deterrent for the pharmacists to participate, as approximately 80% (n=10) of those 
invited to contribute to the study agreed to do so.   Looking specifically at university 
students and web-based technology, a study was conducted at the University of Florida to 
determine if differences existed in response rates, response times, number of items 
completed, item completion errors and number of sensitive items answered between mailed 
and web-based surveys.71  A total of 361 undergraduate students (60% response rate), with 
free computer accounts and access to computers, completed either the paper or web-based 
survey which included 99 items focusing on health risk behaviour.  The researchers found 
that there was no difference in the response rates between the two data collection methods.  
They did find that the web-based survey required fewer days to complete and return the 
questionnaire.  In addition, the web-based participants were more likely to answer sensitive 
questions than participants in the mail group.71  Therefore, based on our own experience 
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with the on-line focus group with the pharmacists and the study from the University of 
Florida, the use of technology to gather data from the patients should not have contributed 
to the low response rate.  Lastly, we had only a small sample of patients to recruit from 
which limited the potential number of participants. 
 
3.7.2 Think: Explore, analyze, interpret & explain the collected data 
I reflected on the information gathered from the focus groups & own personal 
experience.   
 
3.7.3 Act: Report 
The data has been analyzed, and the findings reported in this thesis. The results have 
also been presented to the Student Health Centre staff.  
 
3.8 Ensuring Validity with Action Research 
Because there are no objective methods to measure validity in qualitative research, 
establishing trustworthiness is recommended.  Trustworthiness is referred to as the extent in 
which we can trust the truthfulness or adequacy of a research project.  Credibility, 
transferability, dependability and confirmability all help to establish trustworthiness, and are 
attained through: 42 
• Prolonged engagement: The duration of the research process influences the 
relationship that develops between the researcher and participants.  I had only 
provided two months of full-time clinical service; however I was also previously 
employed at the Student Health Centre.  This previous position was not as a 
pharmacist, however relationships with several of the staff members had already 
been established. 
• Triangulation: Triangulation refers to the integration of several sources.  Using 
information obtained from the Student Health Centre; the literature view; and input 
from primary health and ambulatory care pharmacists, staff members and patients; 
provided a diverse collection of material. 
• Member checks: With member checks, participants are given the opportunity to 
review the data that are produced.  For the on-line focus group, the last question 
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posed for discussion included a summary of the data and the participants were asked 
to confirm that it was an accurate summation.  The transcripts for the on-line focus 
group were saved verbatim, therefore checking for the accuracy of transcription is not 
necessary.  Participants could read their responses at any time during the on-line 
focus group time period to confirm that their meaning was captured.  As for the 
focus groups with the Student Health Centre, participants were given a copy of the 
transcripts to review and an opportunity to add, alter or delete any of their 
contributions during the focus group discussions.  In addition, the focus group 
findings were presented to the Student Health Centre team members during a staff 
meeting, to ensure all of the topics which were discussed at length during the focus 
group discussions were included in the themes extracted from the transcripts. 
• Transferability: Thick, that is, rich and detailed, descriptions of the study context and 
participants were included to allow others to assess the applicability of the research 
to their own situation. 
• Participatory validity: Participation of stakeholders can increase the credibility of a 
project. Stakeholders – primary health and ambulatory care pharmacists, staff, and 
patients, were involved throughout the various phases of the study. 
• Pragmatic validity: To ensure the utility of the outcomes, the research question was 
created based on timely issues the profession of pharmacy is currently facing.  For 
this project, the role of the pharmacist was tailored specifically for the Student Health 
Centre. However, the process provides a template that can be applied to other 
primary health care teams.  
• Participant debriefing: Debriefing is used to review the appropriateness of the 
research procedures and to clarify the participants’ interpretation of events.  This 
proposal was reviewed by Dr. Jennifer Nicol, my instructor for a graduate level 
course on naturalist research methods.  In addition, the project as a whole must meet 
the approval of my committee members.  Member checks were used to ensure we 
accurately captured the participants’ viewpoints brought forth during the focus group 
discussions. 
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3.9 Ensuring Rigor with Focus Groups 
Numerous steps were proposed to help ensure rigor with using the focus groups.  Pre-
testing the focus group questions can increase the validity of the data obtained.66  All focus 
group questions, the instructions for using the on-line focus group website – WebCT®, and 
the WebCT® website were pre-tested during the summer of 2006.  This ensured the 
questions were phrased clearly and the sequence was logical, the instructions for using the 
website were clear and concise, and to identify and solve any glitches with the website.  All 
four of my committee members were asked to review the questions, two of the members 
were clinical pharmacists, and the other two have qualitative backgrounds.  A faculty 
member with the College of Pharmacy and Nutrition, who specializes in questionnaire 
design, was also consulted for his input.  In addition, another graduate student who 
previously was a primary health care pharmacist, along with two non-pharmacist graduate 
students with the College of Pharmacy & Nutrition, were asked to pre-test the process as 
well. 
An external moderator was contracted to facilitate the focus groups with the Student 
Health Centre staff.   Using the external moderator reduced bias, as I was both the clinical 
pharmacist and one of the researchers.  For the on-line focus group, the software transcribed 
the interactions verbatim and therefore increased the accuracy of the data.56  Summary 
questions were used to end the focus group to confirm the adequacy of the findings.65  
Lastly, two of the researchers – Dr. Neubauer and myself independently coded the data to 
compare and verify the results.72    
CHAPTER 4: RESULTS AND DISCUSSION 
 
4.1 Approach to Data Analysis 
To preserve confidentiality, I deleted the opening question from the focus group 
transcripts, which asked the participants to state their position at the Student Health Centre 
and the number of years they had been employed there.  The purpose of this question during 
the focus groups was to help the participants feel comfortable, as everyone could provide an 
answer.52 However, their identity may have been revealed had the question remained in the 
transcripts during analysis.  It should be noted that despite our efforts to protect the 
participants’ identity, we could not guarantee it as some self declared their professional 
backgrounds during the focus group.   For the quotes included in the results and discussion 
section, the professional designation was removed if the risk of revealing that participant’s 
identity was present. 
Since the participants may have had more than one participant number representing 
their statements within the transcripts; there were five focus group sessions in total, we 
needed to alter the transcripts in such a way that each person would have one individual 
identifier for all group discussions they participated in.  The purpose of having one 
individual identifier is to differentiate between one participant repeating a statement several 
times or more than one person expressing a similar idea.  To do this, without compromising 
confidentiality, the same third party individual who assisted in the preparation of the 
transcript verification, assigned each participant with a letter of the alphabet and then 
replaced each participant number throughout the transcripts with the appropriate letter. 
Just as was done with the data from the expert panel of pharmacists, thematic coding 
was the approach used to analyze the data from the focus groups with the staff.  Again, I 
used computer word documents to sort, categorize and rearrange statements, along with 
different font colours to highlight common themes.  While rearranging the transcripts into 
themes, I left sentences as whole statements to ensure that I would not lose the context of
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the original quote.   A theme was defined as a topic which was brought forward by two or 
more participants.  Both Dr. Neubauer and myself coded the data individually and then 
discussed the themes we extracted to ensure they were similar.   
Saturation occurs when themes are repeated during the discussions and no new ideas are 
generated.  Saturation was reached on all topics except for the action research process.  When 
saturation is not achieved, additional focus group sessions may be arranged to obtain further data 
from the participants.  However, the transcripts indicated the Student Health Centre team provided 
as much feedback as they could on the topic, and further probing would not have yielded saturation. 
The quotes selected to represent the Student Health Centre staff’s opinions are 
presented in a more polished format – i.e. where necessary the grammar has been 
corrected/modified, for ease of readability.  Only portions of the statements have been 
altered to ensure that the original meaning behind the quote was not jeopardized.72  For 
example, ‘umms’ and repetition of words with pauses in-between (e.g. “… and I think.. I 
think we all perhaps learned…” re-written as “… and I think we all perhaps learned…”) 
have been deleted. The unique identifier for each participant (i.e. a letter of the alphabet) 
begins each of the quotes, except when the transcriber was unable to match a statement to 
an individual.  A question mark has been used in place of a letter of the alphabet when the 
source was unclear.  
 
4.2 Student Health Centre Focus Group Participants 
A total of fifteen Student Health Centre staff members participated in the focus group 
discussions.  This was a fairly representative sample of health care professionals from the 
Centre, and included four physicians, three registered nurses, one nurse practitioner, one 
psychiatrist, one manager, one dietitian, one health educator, one social worker, and two 
front office staff members.  Despite our efforts to create two focus groups of equal size and 
professional background, the need to reschedule some of the focus group discussions 
interfered with this attempt.  As such, the risk of professional dominance influencing the 
focus group discussions may have been a possibility.  Professional dominance may have 
occurred had there been an overrepresentation of one of the health professions (e.g. the 
number of nurses in attendance being greater than any other group) or due to professional 
hierarchy (e.g. the physicians directing the discussion, as they worked closest with the 
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clinical pharmacist).   However, similar themes arose from both focus groups leading us to 
believe that this was not an issue.  For the Monday focus groups, the number of participants 
in attendance was as follows: January 8th, 2007 – six; January 22nd, 2007 – three; and 
February 5th, 2007 – two.  As for the Thursday focus groups, eleven staff members attended 
the January 18th, 2007 session and ten for the February 1st, 2007 gathering.   
It is recommended that a focus group be comprised of six to ten participants.67  
Unfortunately, two of the Monday focus group sessions had less than six participants.  
Because of the low participant numbers, it is important to recognize that the information 
collected during these sessions may have mirrored personal dialogues more than traditional 
focus group discussions.  
The low number of participants for the Monday group likely occurred for several 
reasons.  First, the Monday focus group discussions had to be rescheduled twice – once due 
to a fire alarm, and a second time because of a last-minute scheduling conflict with the 
facilitator.  Second, it could have been the time of day when the discussions were held.  The 
Thursday meetings were scheduled at the start of the day, between 8:30-9:30am – prior to 
the Centre opening while the Monday meetings are scheduled over lunch.  Appointments 
with patients sometimes extended into lunch breaks and this may have affected attendance. 
Although the Thursday meetings may have been more accommodating to some of the 
staff, it was not ideal for the Centre as a whole since some of the Thursday time slots had 
been booked for other reasons (e.g. presentations, joint meetings with Student Counselling, 
etc.).  From a researcher’s point of view, we wanted to schedule the focus groups soon after 
the clinical services component of the study.  Scheduling the focus groups solely on 
Thursday mornings would have drawn out the process, left long time lapses between 
discussions with each group and excluded some of the part-time staff. 
 
 
4.3 Themes and Sub-themes 
4.3.1 Major Themes 
Seven major themes emerged from the Student Health Centre focus group discussions, 
as the staff members reflected on their experience of having a pharmacist join their primary 
health care team. Within each of these seven themes are several sub-themes, which are as 
follows: 
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I. Perceptions 
a. Positive: excited, open to the idea and curious 
b. Concerns: uncertainty with role, degree of utilization and proper utilization 
 
II. Content of Role 
a. Staff 
i. Drug information resource 
ii. Support to the team 
iii. Sufficient timeframe to demonstrate support to the staff 
b. Patients 
i. Drug information resource 
 
III. Roles 
a. Role Ambiguity 
i. Researcher versus clinical pharmacist 
ii. Previous employee versus clinical pharmacist 
b. Role Overlap 
c. Role Evolution 
d. Impact on the Team Members’ Roles 
 
IV. Attributes  
 
V. Process 
a. Co-located clinical pharmacy services 
b. Full-time versus part-time clinical pharmacy services 
c. Patient referral process  
d. Action research process 
 
VI. Communication 
a. Formal and informal discussions 
b. Consultations for medication-related projects 
c. Debriefing after direct patient care interactions 
 
VII. Limitations 
a. Duration of the study 
i. Limited the impact and exploration of the role 
ii. Generation of patient referrals 
b. Patient population 
i. Narrow patient demographic 
ii. Timing of the study 
iii. Lack of patient buy-in 
c. Funding and Space 
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4.3.2 Minor Theme 
During the focus group sessions, the staff members were asked to provide 
recommendations to assist with future integrations of pharmacists into primary health care 
teams.  The staff generated several suggestions, based on their experience.  Despite having 
numerous ideas, few of the recommendations were brought forward by more than one 
individual and are therefore presented as a minor theme. 
I. Recommendations 
 
4.4 Discussion of Themes 
 
4.4.1 Major Themes 
4.4.1.1 Theme 1: Perceptions 
4.4.1.1.1 Positive: excited, open to the idea, curious 
When the staff members were asked to share how they felt about having a pharmacist 
join their primary health care team, many responded positively, stating that they felt 
privileged to have this additional resource co-located with them at the Student Health 
Centre. 
E) … it was a surprisingly rich resource that was just right there,… I felt so privileged 
to have her there, it just made the day go smoother and you felt like you were 
supporting your clients... 
 
G) Well I was pleased to have Lynette there and saw it as an opportunity to, you 
know, ask a lot of questions, get a lot of help, easily, very convenient.  
 
I) I felt almost a bit privileged to have a pharmacist in our Clinic, and I felt that it was 
a great resource. A luxurious resource… 
 
In addition to feeling privileged, the staff acknowledged that they were ‘excited’ and 
‘intrigued’ with the idea of adding a pharmacist to their team.  Their interests were 
particularly focused on whether a pharmacist was suitable for their specific primary health 
care team and how a pharmacist’s expertise would be integrated into their current mix of 
health care professionals.  
 
C) I was really excited to be able to see if the role of a pharmacist was appropriate for 
our team. 
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E) I felt very positive and excited about it. I thought too it would be very interesting to 
see what role that potentially a pharmacist could play and I found the idea intriguing 
and interesting… I was very curious to see how it would unfold and just how we could 
incorporate her skills into our team.  
 
The Centre’s team focus also helped, as one participant stated, “…at Student Health we’re 
pretty committed to kind of a team approach to care anyway, so the more the merrier…” 
when reflecting on the addition of a pharmacist to their team.   
This project needed the support of the primary health care team.   Integration would 
have been compromised had the staff not welcomed the initiative or had not been as open to 
the idea of what a pharmacist could offer.16, 19  Having a group of practitioners who are 
willing to discuss difference about roles and responsibilities is a key component for creating 
effective interdisciplinary team work.16 
 
4.4.1.1.2 Concerns: uncertainty with role, the degree of utilization and proper utilization 
 The staff was curious with what I could offer the team as their pharmacist, however, 
with this curiosity came some uncertainty concerning what my role would be and the degree 
of utilization, as the staff ‘wondered what [I] was going to be able to do for [them]’.  
Reasons for their concerns included the Centre’s unique patient population, a lack of 
understanding of what a clinical pharmacist can offer and what type of education a 
pharmacist receives.   
 
H) I was certainly very open to the idea and I could see some potential positive 
benefits. I probably had some, not misgivings, but some wonder about - especially 
particularly, you know, with the demographics of students that we’re looking after and 
the nature of concerns that they were coming forward with, etc. as to how fully 
implemented such a role could be in our setting… And just how well utilized her role 
would be. 
 
D) Initial reaction was - just wondered what she was going to be able to do for us, 
because I didn’t understand, initially … I kept asking her, what is a clinical 
pharmacist? … just never had exposure to that outside of the [pharmacists] in the 
community that you see behind the big counter.... 
 
E)  … the role of pharmacy is certainly evolving… it seems to be growing so 
dynamically and I feel like I don’t really understand yet exactly what they do anymore, 
like I feel stuck in a box where I think of a pharmacy and a pharmacist dispensing 
medications…   
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A) I think that physicians don’t really know the training that pharmacists get.  
 
The specific patient population is a limitation of the study, and will be discussed in 
more detail further on.  It is expected that the staff would not have a clear idea of what a 
clinical pharmacist could offer.  As mentioned in the introduction, a study involving 
physicians concluded that they did not know what to expect of pharmacists.20   One of the 
participants admitted to being surprised with the knowledge that a pharmacist can have, 
“She knew more than I thought she would know.”  Perhaps having an understanding of the 
training pharmacists receive would help other health care professionals gain a better 
appreciation for what we do. 
The uncertainty with my role lead to some concerns surrounding the proper utilization 
of a clinical pharmacist.  More specifically, the staff wondered if their questions were 
appropriate for a clinical pharmacist. Along these same lines, they questioned whether they 
should be asking someone to answer their drug related inquires since they could also carry 
out those responsibilities themselves.   
 
G) … there is always that sort of wondering at first, well, is this an appropriate 
question to ask, you know. Is it at the right level, is it sort of challenging enough… not 
wanting to misuse Lynette.…  Am I asking a question that she thinks is worth her 
time, or am I asking her to look up something I could look up …. 
 
H) … sometimes becomes a matter of - do you feel right asking someone to do that, 
because I mean, typically if you don’t have that resource…  
 
Another concern that the staff members had was whether or not they were keeping me 
engaged and maximizing the opportunities of having a pharmacist on staff.   
 
H) I would have had not negative feelings but anxieties I guess again about, you know, 
are we able to appropriately utilize a person in this role? … I was getting a little 
anxious at times of, you know, is she just sort of having to find work for herself or are 
we able to really keep her engaged in everything that’s going on, and are we missing 
opportunities to have some students see her that might have benefited from it…. 
  
Inexperience with an expanded role for a health care professional can lead to 
misinterpretation, as well as under utilization and inconsistent use of the role.18  As direct 
contact with a clinical pharmacist increases, physicians’ awareness of our scope of clinical 
services enhances.73  In the interim, delegating tasks within a health care team enhances the 
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utilization of each team member’s skills and training.73  Had I provided services for a longer 
period, over time I would expect that the team would have a better idea of what a clinical 
pharmacist can offer.  Consequently, my responsibilities may change to better suit my 
expertise and thus increase the utilization of my role on the team. 
 
4.4.1.2 Theme 2: Content of Role 
 
When analyzing the content of the pharmacist’s role, the role branched into two 
sections – the role with the staff and the role with the patients.   
 
4.4.1.2.1 Content of Role with the Student Health Centre Staff 
4.4.1.2.1.1 Drug Information Resource 
 
My primary role on the team was as a drug information resource.  The staff felt that I 
was a ‘great resource’ and ‘helped [them] untangle some differences in areas with 
medications’.   Their questions included inquiries pertaining to ‘drug interactions’ and ‘side 
effects of medications’ – which were both general and obscure in nature.   
 
D) … The effect for my practice again was that I had this added value resource of 
someone who could answer all of the obscure questions that I end up having… 
 
G) … I found when patients had questions about the medication and it was something 
a little unusual, I wasn’t sure of the answer, I could ask Lynette and she got back to me 
very quickly and I could get back to the patient. 
 
The team valued the drug information services.  One physician went as far as saying 
that ‘having a pharmacist in our team was – for me, it was vital’.  Providing the staff with 
this information allowed them to ‘learn more about the medications’ and feel ‘more 
prepared’ when carrying out their daily functions.  In addition, they appreciated my updates 
on relevant and current medication related issues. 
 
 B) … there was good communication by e-mail from Lynette about changes in 
drugs… I think we were probably more on the ball with that kind of stuff than we 
perhaps normally would be. 
 
One staff member was also pleased that I introduced him/her to several reliable drug 
information resources. 
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D) I often have questions about medications and interactions and she just set me up 
with some just wonderful web sites and information… I know it is good sound 
scientific information that I’m looking at. 
 
The team members were impressed with the quality of the drug information services I 
provided. Several of the staff made encouraging comments, stating that “the depth of what 
[I] provided was really excellent clinically”, and that the information was ‘very detailed’ and 
delivered in a ‘very timely manner’.  Others described the service as being efficient and 
effective, and one staff member stated that it ‘really did meet [his/her] needs’.   
 
A) I think the research piece that she did for us, I mean if we had questions about some 
medication… she would take that piece and go and research it and provide all that 
information to us, and that was very efficient and effective. 
 
 Another feature of the drug information service that the team valued was receiving 
objective information.  This was particularly important for them, as they recognize the 
limitations of receiving information from pharmaceutical companies as ‘[drug reps] have a 
huge bias’ in terms of the literature they provide the Centre with.  The team felt that I ‘knew 
where to go for unbiased information’, and felt that I was ‘an objective source’ for 
answering their questions related to medications. The team also appreciated that I provided 
them with literature to support the answers. 
 
E) … if you were to ask Lynette a question, you know, in a very short timeframe, she 
came back with all sorts of information that was printed out… And for every single 
question we always got a bounty of information. 
 
?) … not only would she be able to give you information right away but she would 
back it up and she would immediately go and research it and then provide you with 
that information as well. 
 
 By using a thorough approach to investigating their inquiries, I was able to start 
establishing credibility with the team. 
 
G) … a positive experience I had was the thoroughness with which she researched the 
question I had… so that when I answered the patient’s question I had, you know, I 
was very certain that yes, this was a sound answer. 
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The focus group participants also noted that ‘a pharmacist is the expert in drug therapy’.  
Having access to a health care professional with this ‘expertise’ provided them with a sense 
of assurance when dealing with medication related issues. 
 
?) ... she was an expert resource, which we could have confidence in what she was 
advising or in information that she was presenting. 
 
G) … Lynette look into it thoroughly and me feel safer in what I was doing… 
 
 The staff identified that there was an increase in the efficiency of the team when a 
pharmacist researched drug information questions.  The health care professionals on the 
team acknowledged that they were capable of answering the same questions.  However, this 
enhanced efficiency occurred when a pharmacist provided the drug information services.   
 
B) So there is a degree of efficiency maybe as well in utilizing the right person for the 
job… in looking at side effects, looking at drugs… I think that there is efficiency in 
utilizing a pharmacist. 
 
D) … about the research aspect, having her do some of that legwork for me was very 
efficient… 
 
H) … she might be a little more directed based on her experience in terms of knowing 
how to hone in on the valuable information. 
 
J) It was like a lot of the research that, you know, you’d normally do yourself you 
could just ask her and then she would be able to do the research or answer your 
question directly. 
 
As a pharmacist, it was not surprising that a considerable portion of my responsibilities 
was to provide drug information.  I felt that it was a logical starting point to establishing 
credibility with the staff.  I hoped that if I could gain their confidence when answering their 
questions, eventually they would feel comfortable with entrusting their patients to me.  
Other pharmacists have also found that becoming a drug information resource for 
physicians was a means of establishing credibility.26 
Holding a professional license to practice in health care is not indicative of what that 
person can offer the team.16  The team appraises the knowledge, skill, experience, 
performance, reliability, credibility and ability of the new member to apply these attributes 
to a new clinical setting.16 The majority of physicians expect pharmacists to be drug therapy 
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experts.20  Meeting and/or exceeding the team’s expectations can help establish 
competence, which is the most important determinant of success when joining an already 
established team.16  
 
4.4.1.2.1.2 Support to the Primary Health care Team 
By having a pharmacist provide drug information services to the team, the staff felt like 
they had additional support while caring for their patients.  It was noted that my presence 
was a support for both the team and patients, but the impact was greater with the former. 
 
M) … support for me and support for the client.   
 
C) But I think she really did provide some valuable support to staff… and probably less 
so directly with the patients. 
 
My role complemented what the other health care professionals offered, and one staff 
member stated, “I found that she was a great ally for what I do.”  Another participant added 
that having a pharmacist available to them gave him/her “an overall sense of having 
backup”.   
The staff also felt that having a pharmacist on their team was a means for them to offer 
enhanced care to their patients, as it was “added support to the entire service [they] were 
able to offer”.  One participant commented that adding a pharmacist to their primary health 
care clinic allowed them to offer ‘Cadillac care’ and that ‘it’s better care for the patient’.  
Along those lines, a physician shared with the group that a pharmacist is an ‘added 
resource’ – both directly and indirectly, for patients. 
 
H) … whether it’s the resources by the patient actually having direct contact with the 
pharmacist or by me as a physician going to the pharmacist and using that person as a 
resource so that I’m better educated, even if I’m the one who’d been, you know, 
providing that information, by face-to-face with the patient, either way it’s a resource 
overall to for the care that’s being given. 
 
Creating a supportive work environment should not be overlooked when trying to 
integrate a new team member into a health care team.  Physicians tend to be more receptive 
to a wide range of clinical pharmacy opportunities when the services are provided in a 
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consultative and supportive role.20  An effective interdisciplinary health care team has the 
patients’ best interest in mind, and being a support to the team helped foster this 
philosophy.16 
 
4.4.1.2.1.3 Sufficient Timeframe to Demonstrate Value as a Support to the Team 
 In spite of the short study duration, one staff member noted that two months was an 
adequate period for me to make an impact as a support to them, “… the help for staff… she 
was there enough and did enough that proved itself”.   Some of the other staff members 
were impressed with how much I was able to accomplish during my time with them. One 
participant said, “I think that she did lots for us actually, more than I initially thought that 
she would”.  
 By the end of the two months, a few of the team members commented that my ‘role 
was almost leveled when [I] left, in comparison to the time [I] started’.  In other words, the 
staff had started to become familiar and knowledgeable with what I could offer.  Another 
participant reinforced this by adding, “… it was just kind of catching on to what she was 
doing and what she could offer, and then it was done”.  Their increased understanding of 
what a clinical pharmacist could do was also portrayed by their ability to generate 
additional drug information activities to broaden the role of their pharmacist. 
 
B)  Because if you think about the issues we have with Chinese medicine, that would 
be just a great area to look into. I don’t know how many internationals are taking some 
medicine, Chinese medicine.  That would be a great area to really do some big 
education on…  
 
D)  … she was such a good resource for us that it would have been interesting to see 
her work with the health education outreach people, and be able to supply them with 
some more detailed knowledge and accurate information to go out to the general 
public.  
 
L)  I think a value that we could have used her for but probably just didn’t have 
enough time is doing some in-services, you know, on new drugs or new areas… in-
services for the peer health educators , they also just, you know, to offer to students 
workshops on different things.   
 
Despite the ability to make some headway with the staff in terms of my role over a two 
month period, there were several drawbacks with the short timeframe.  These will be further 
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discussed under the limitation theme.    To my knowledge, no other action research study 
investigating the integration of an expanded health care professional role has been 
conducted over a comparable duration – as similar trials cite one to three years as a study 
timeframe.25, 50  Our study showed that a two month period is an adequate timeframe for a 
clinical pharmacist to demonstrate added value, as a support to the staff, when added to a 
primary health care team.  This benefit was in the form of non-direct patient care activities, 
as there was insufficient time to develop a direct patient care role.   
 
4.4.1.2.2 Content of Role with the Patients 
4.4.1.2.2.1 Drug Information Resource 
The Student Health care staff also defined my role with the patients as being a drug 
information resource, as I provided education and counselled on medication side effects and 
compliance.   
 
D)  I certainly used Lynette as a resource and I did refer a number of people to her 
which I think really impacted the education that they needed at that time and feel it 
was positive. 
 
?)  I used Lynette for people who were having problems with side effects of birth 
control pills and compliance, and emergency contraception; she did great work with 
those girls. 
 
The patient population at the Student Health Centre is unique and made up of a narrow 
demographic.  The bulk of the patients are university students, who are – in general, very 
keen to find out about their medications but often seek information from unreliable sources. 
 
J)  … the students here tended to want to know a lot more about their medications 
than what a lot of patients in a lot of other situations would want to know…  
 
Part of my role with the drug information service was to provide objective information 
and correct patient’s inaccurate perceptions about their medications. 
 
A) I think one thing it adds is that, I think maybe especially in this population group, 
it’s a resource that students can come and I think would say okay, I can go to this 
pharmacist and get an objective assessment of what’s with this medication that I’m on.  
 
D) … the students come in quite well educated but often misinformed… 
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E)  Lynette’s role in sort of our well population, she was really helpful in reassuring 
patients about other medications and sort of the fallacies and the misinformation that 
sometimes patients get stuck on.  
 
O)  Patients want to know everything - especially when you start them on psychiatric 
medication… and they get wrong information from wrong resources. That was a very 
important part of having a pharmacist on your team.  
 
Another component to the drug information services I imparted to the students was to 
reinforce what other team members had told the patients.  This also strengthened our team 
approach for providing patient care. 
 
D)  … Lynette was able to kind of straighten that out and reinforcement of those 
messages from all three of us I think was very helpful for the patient in the long run.  
 
J)  … to have her just to reinforce kind of a lot of the things that I said…  
 
The team noted that when I discussed drug therapy with the patients, it assisted the patients 
with their decision making around medications.  One physician reflected on my 
involvement with counselling patients on antidepressants, and how the information I 
presented either empowered a patient to make a decision regarding initiating therapy or 
reassurance that it was appropriate. 
 
H) I don’t mean she scared them off or anything, but that they had enough 
information then that they had some reservations and then felt that perhaps it wasn’t 
absolutely essential for them. I saw that as a positive thing... and then there were other 
situations where her information to the patient was reassurance to them, when they 
had serious misgivings about being on the antidepressant, she was able to reassure 
them to the point that by the time they saw me again they were more comfortable with 
it, so I would say it definitely affects for patients even in terms of their own decision 
making about whether this was appropriate for them or not, so that was neat. 
 
Clinical pharmacists have previously provided medication consultations to patients in 
primary care settings.17, 19, 37  One advantage of providing counselling in this manner is that 
patients can receive medication advice in an unhurried environment.37 This can be 
particularly important when patients have several questions or misperceptions surrounding 
medications.  In addition, when patients have the opportunity to discuss their medications 
with a primary health care pharmacist, there is a greater opportunity to achieve medication 
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concordance – i.e. the health care professionals and patient have established a shared 
agreement for therapeutic goals.37   
 
4.4.1.3 Theme 3: Roles 
Because of my dual role as researcher and clinical pharmacist, some role ambiguity 
surfaced during the study.  This was also confounded by the fact that I was previously 
employed at the Student Health Centre as a Health Education Coordinator Assistant.  In 
addition to some overlap in the roles I took on, the staff also questioned how their roles 
would be impacted, in the long-term, when a pharmacist is added to their team. 
 
4.4.1.3.1 Role Ambiguity 
4.4.1.3.1.1 Researcher versus Clinical Pharmacist 
For our research project, I wore two hats – one as a researcher and another as the 
clinical pharmacist.  One staff member noted that during the meetings to discuss the project, 
my role as researcher dominated over my role as their pharmacist. 
 
B)  … her role at meetings was the [graduate] student… it was more about her research 
and not of her as pharmacist on the team, so when we had meetings it was more about 
the research than the pharmacist coming. 
 
Originally, I intended to only be the researcher and the plan was to hire another pharmacist 
to fulfill the clinical role for the team.  However, the staff had requested that I work with 
them as their clinical pharmacist because of my previous history with the Student Health 
Centre.   
The term ‘double-act’ has been used to describe scenarios where one person acts as the 
researcher and another in a clinical role.  However, the literature only provides examples of 
having an ‘outsider’ – i.e. someone not part of the health care team, taking on the role as 
researcher and an ‘insider’ – i.e. someone already part of the team, acting as the 
intervention.74 Galvin et al. (1999) conducted a study using action research to implement 
change within a primary health care nursing team.  They used a ‘double-act’ approach, but 
found that the research project manager – as an outsider, had a difficult time with the role.  
Group boundaries and responsibilities were unclear; therefore maintaining a collaborative 
approach was sometimes complicated.  They recommended that a joint clinical/research 
role be used to offset these issues.25  Our project was unique in the sense that I was an 
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outsider who took on both roles.  Seeing that a pharmacist had never been part of the 
Student Health Centre team, it was inevitable that an outsider would have to fill that role.   
 
4.4.1.3.1.2 Previous Employee versus Clinical Pharmacist  
As mentioned earlier, I had previously worked at the Student Health Centre as an 
undergraduate student in health education.  The team identified both positive and negative 
aspects of my prior history with the Centre and subsequent research endeavor.  Starting with 
positive angles, the staff that I had worked with in the past felt comfortable with me joining 
their team as the pharmacist since a rapport was already established between us. 
 
A)  I certainly looked forward to the experiment, whatever difficulties the person might 
have anticipated, I think were allayed, because we knew Lynette from before, and 
knew her abilities, her personality, so it was not at all difficult for her to feel part of the 
group and for us to accept her quickly, and trust her work…. We know from her 
performance in other roles that she did for us, that she’d perform anything you gave 
her at an extremely high level. 
 
The staff also saw an advantage to me being familiar with them, “She came in knowing the 
team, she knows what we do.”    
My prior connection to the Centre allowed the staff to feel more at ease during the initial 
stages of the study.  However, when they evaluated the role of the pharmacist at the end of 
the study, some felt it challenging to separate myself from the role.  One participant stated, 
“… to look at it as a position, and divorce it from who the person was, I find it somewhat 
difficult”.  This same participant commented that it was also hard to disconnect my 
previous role as an undergraduate student from their pharmacist, “… because of our 
experience with Lynette… I viewed her as a [undergraduate] student… she didn’t come to 
us as some unknown clinical pharmacist who was going to set feet in our place…”.  Other 
comments included:  
 
A)  … it’s hard to separate Lynette from the position. I’m sure not every person who 
was filling that role, we would experience the high quality we got from Lynette. 
 
D)  I do wonder though, if a different personality - Lynette was known to us and she 
has a certain ethic or work habit about it that is lovely and I’m wondering if somebody 
else came into that mix if it would be quite a different affect to a relationship on the 
team. 
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Another concern the team had was whether I felt limited with what I could do, due to my 
previous role with the team. 
 
A)  So maybe in a way having somebody like Lynette who we knew, who we liked, got 
along with, and she had worked with us and viewed us in some ways as her 
supervisors over the last couple of years, maybe in some ways she wasn’t the ideal 
person to come and explore… maybe she didn’t have the freedom to just say, here’s 
what I think I should be doing. We were telling her what we think she should be 
doing.  
 
B)  … I’m not sure we ever really got Lynette’s vision 100 percent. I think that there 
was a relationship that wasn’t where she could sit there and give her complete vision, I 
don’t think she felt maybe she could 100 percent do that.  
 
As previously introduced, the action research terms ‘outsider’ and ‘insider’ are used to 
describe the relationship a researcher may have with a health care team.    Outsiders can 
sometimes encounter difficulties with being accepted by the group.50  Insiders may feel 
limited in their potential to create change, as they are knowledgeable of the hierarchy within 
their setting.74  These power relations may have a greater influence on decision making than 
the action researcher’s project and findings.74  Again, our study is unique in the sense that I 
was an outsider who was previously an insider, but contributed to the team in a different 
role –i.e. health education. 
The obstacles I encountered did not involve joining the group, but instead revolved 
around my attempts at establishing a clinical role for a pharmacist on their team.  It was 
sometimes challenging to gain certain team member’s approval for specific direct patient 
care initiatives I wanted to initiate.  A prime example being the original antidepressant 
counselling format that I developed, but had to simplify based on a few team members’ 
concerns that I was stepping out of the traditional role for pharmacists.  During these times, 
I felt the frustration that insiders often do, as I was aware of the existing politics within the 
health care team, but felt that I lacked the power to change them.  
As the researcher and clinical pharmacist, I did have a strong vested interested and 
personal commitment to the project.  This is not uncommon in action research, even for 
those who act solely in one capacity – researcher or intervention.  When assessing the 
external validity of an action research project, it is recommended that the notion of 
transferability is used rather than generalizability.6  Transferability occurs when knowledge 
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is transferred from a sending context to a similar receiving context – i.e. another primary 
health care centre.6  Every action research project is unique, just as every health care team 
and health care professional is.  We presented some of our results as a list of 
recommendations in Chapter 5, which we hope will be beneficial for and applicable to other 
pharmacists and primary health care teams. 
 
4.4.1.3.2 Role Overlap 
Role overlap occurred between the pharmacist and physicians/nurse practitioner in the 
area of counselling patients on their medications.  Because of this, the debate of whether 
hearing the same message more than once, from multiple health care professionals, results 
in a duplication of services or reinforcement of valuable information was brought up.  One 
physician mentioned how a patient may hear similar information from three health care 
providers – a physician, clinical pharmacist and community pharmacist. 
 
H) … They’ll come into my office, I’ll provide them with a certain amount of 
information about the medication which we were probably are going to be prescribing 
for them, then potentially they would, if they were to be referred to the in-house 
pharmacist they would receive some reinforcement of the information. And then when 
they get the prescription filled at the pharmacy you never know what - either by 
handout or discussion they might have, so… is it all just sort of duplication or is it all 
just good reinforcement because, you know, it’s better to hear it more than once 
anyway. 
 
Another participant added that, as physicians, their role in providing standard drug 
information would likely not change.   
 
J) … explaining, you know, side effects of the medication or how they work or 
whatever else, probably shouldn’t change from the physician’s point. 
 
One explanation of their continued practice, of supplying patients with standard drug 
information, was to avoid feeling neglectful when providing patient care.  However, the 
following physician also acknowledged that roles would evolve over time.  
 
H) I’m just so used to explaining certain things just to patients about medications and 
effectiveness and side-effects potential and all that kind of thing. But it’s not that I 
wouldn’t trust the pharmacist to do it, but I’m so used to doing it that if I didn’t do it 
I’d feel like I’d somehow been neglectful.  I think that’s something that would just 
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gradually change as somebody became more established as part of the team as a 
pharmacist.  Those roles would become better defined… 
 
Role overlap in interdisciplinary teams is sometimes inevitable, however practitioners 
report less anxiety when a collaborative approach is used.5  Determining team 
accountability – i.e. what the team, not an individual, does for a patient, may remove any 
sense of neglect.  However, team accountability takes time to delineate and requires roles 
and responsibilities to be clearly defined.16 
In an optimal health care team, each member has the freedom to apply their own 
unique expertise.17, 73  Physicians, nurse practitioners and pharmacists are all capable of 
counselling patients on medications; however the approaches and perspectives of the 
professions may differ.  Task duplication can result in a waste of time and resources if health 
care professionals do not brief each other after patient interactions.25  In our study, the 
Student Health Centre staff members were pleased with the feedback I provided them after 
meeting with a patient – which will be further discussed under the communication theme.   
 
4.4.1.3.3 Role Evolution 
Expanding on the previous quote that team roles would become more defined over 
time, other participants also identified the likelihood of this – particularly with the role of 
the clinical pharmacist.  To deal with this anticipated change, they suggested that the team 
re-examine the role as it changes over time. 
 
J)  … I think that probably with time her role would probably change slightly,... Or 
how we would use her would change. 
 
E)  … And I think that if we had a pharmacist on our team that role definitely would 
evolve and - just like all of us would become a dynamic part of our team.  
 
G)  Well this was kind of an innovative thing, so I would think over time, after a 
certain number of months, it would be important to sort of meet and clarify the roles 
even further, based on experience as opposed to just what we think the roles should be, 
you know, how it’s worked out… 
 
M) ... expect the role to keep changing so to keep reviewing so that you can add to or 
fix or change or whatever you need to do at the time. 
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Along these lines, one participant used hospital pharmacists as an example of how 
pharmacists’ roles have became more defined over time. 
 
O) … the first person who decided you have to have a pharmacist in hospital, probably 
had the same debate … years of having a pharmacist in hospital-based patient care, 
everybody knows what is the role of a pharmacist, and it’s very much precise... so I 
guess that’s the same problem, we are at the beginning of something...  
 
Using action research as an integrative methodology provides a structure for reflecting on a 
change in practice and implementing any modifications.  As such, it would provide the 
team with opportunities to revisit and redefine the role as needed. 
 
4.4.1.3.4 Impact on the Team Members’ Roles 
Despite being satisfied with the drug information services, the staff did have concerns 
with what impact this could have on the team in the long run.  In a general sense, one staff 
member pointed out that their own roles may change when a new health care professional is 
added to the mix, and this may not be a desired effect. 
 
B) … but sometimes when you add a new person to the team with a different type of 
expertise… people might feel that part of their role changes and they’re not sure they 
want to change their role.  
 
More specifically, the physicians discussed their concerns with having a pharmacist provide 
drug information.  For example, one physician wondered if (s)he would become lax, over 
time, with retrieving drug information when answering patient’s questions. 
 
A) … I wonder if having somebody like Lynette on staff, a person - at least maybe as a 
physician I would get lax in doing a lot of digging myself on some of the stuff that now 
she would do…. What affect that would have in the long term I don’t know. 
 
Another physician acknowledged that this may be a concern, but added that the concern 
was attenuated with good communication between the pharmacist and physician.  In 
addition, this physician stated that (s)he learned a lot when I answered their drug 
information questions. 
 
O) … it could be like dependency, in fact, if there is no feedback.  But if there is a good 
feedback, I learned a lot… on every single patient I learned a lot. 
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Tension may result when health care professionals’ roles change due to a new team 
member taking on their responsibilities.  However, as clinical credibility of the new member 
becomes evident, the rest of the team starts to value this additional expertise.21  Having an 
increased understanding of what another health care profession brings to the team can 
heighten other team members’ awareness of their own clinical expertise.5 
 
4.4.1.4 Theme 4: Attributes  
Although the staff questioned whether all pharmacists share the same characteristics, 
there were several attributes identified by them as being important for a pharmacist to have.  
The following traits were valued by the team: 
• Knowledgeable: 
 
A)  ... I was very impressed with her knowledge. I mean she was pretty good on stuff 
that she didn’t have opportunity to go read up on all of a sudden.  
 
D)  I was surprised by the amount of knowledge that she did have on some of the 
questions. I had a question on weight-loss drugs and she provided me with this very in-
depth piece of information that I found very helpful…  
 
• Diligent/Thorough: 
 
A) … I think a lot of her success was that she got in there and sort of dug and did 
things, and so I think it was all in all a positive…  
 
D)  … she has a certain ethic or work habit about it that is lovely…  
 
G) … she got back to me very quickly and I could get back to the patient... and very 
detailed, you know, she sent me a very detailed e-mail as answer to my question.  
 
H)  Ya, I would agree, that her thoroughness in sort of accomplishing whatever task 
had been asked of her… 
 
J)  One thing I noticed with her is that, you know, like I said before, she was very 
keen…  I mean I found her very helpful, and even times when I hadn’t even asked for 
her help she would know that I would be seeing somebody who, you know, had a 
certain problem and she would, you know, spontaneously kind of give me information 
about, you know, the medications that the person should be on or the side-effects, that 
sort of thing. 
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• Professional courtesy: 
 
H) … it was just a positive experience in terms of the collegiality…. whenever we 
would have discussions about anything that was even the slightest bit contentious or 
subject to different opinions or whatever, there was never any kind of a defensiveness 
on her part, that she would hear me out and I would hear her out and we would come 
to some middle ground or agree right from the outset and it was - just always a very 
pleasant interchange in that way.  
 
G) … she was quite sensitive to, you know, not wanting to have anyone think that she 
was sort of stepping on their toes… 
 
• Communication skills:  
 
I)  Lynette was very thorough, very open to questions.  She was a really easy person to 
communicate with, and she put people at ease. I felt really comfortable with patients 
working with her…  
 
?) So she has really good writing skills as well, and like any research that she does, you 
know, she does a really good job with that, and also any patient visit documentations, 
very thorough, very legible, you know, just very clear. 
 
All of the aforementioned attributes allowed me to make a positive impact on the team, as 
they were “very impressed with the nature of the work” I had completed.   
Research into developing effective interdisciplinary teams acknowledges that an 
individual’s attributes, experience, and ability to establish competence cannot be controlled 
for.  However, identifying characteristics that have been linked with success can aid future 
health care professionals who are interested in joining an interdisciplinary health care 
team.16  The ability to challenge one’s self, willingness to work with others, good 
communication skills, responsiveness to requests, and clinical credibility are personality 
traits that have been associated with establishing effective teamwork.16, 17, 21  Exercising 
mutual respect for other health care professionals’ input, not trying to control situations or 
competing with the responsibilities of co-workers also facilitate integration of a new team 
member onto a health care team.21 
 
4.4.1.5 Theme 5: Process 
In terms of process, four sub-themes emerged from the data: providing co-located 
clinical pharmacy services, full-time versus part-time services, the patient referral process 
and using action research. 
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4.4.1.5.1 Co-located Clinical Pharmacy Services  
Over the past several years, the staff had developed relationships with community 
pharmacists in the surrounding area, but noted that having a co-located pharmacist afforded 
them increased access to and an enhanced level of clinical pharmacy services. 
 
I) … we did have some good relationships obviously with other pharmacists in the 
community and stuff but with having Lynette as part of the team it was just kind of on 
a whole other level, because I used her more in her role as the resource person… just to 
have that person at our fingertips to answer our questions and to work on requests that 
we had… 
 
M) … I think that the key of it being part of our health care team is that, I mean we 
have always had access to pharmacists around the area who students have interacted 
with or who the team has, but it was very nice to have her right there. And I think that 
the piece of it, of the flow, and the likelihood that more people that we encourage to 
go, went, because she was right there as opposed to, you know, having to go on 
another day or whatever because she’s in another building or three blocks away, or 
whatever. 
 
Integration into a health care team would take longer if the new team member worked 
primarily off-site.  Being present, even during lunch breaks, reminds the staff that a 
pharmacist is on-site and available to them.  In fact, my very first patient referral arose from 
a discussion on non-compliance between a physician, nurse and myself over lunch.  
Pharmacists who work in family practice clinics have noted that being co-located promotes 
greater interaction between them and the physicians, and allows for easier access to patient 
care areas and medical records.26, 42  This subsequently results in a more active pharmacy 
involvement with drug therapy decision-making and direct patient management.42   
Taking a closer look at the advantages for the patients, the on-site clinical pharmacist 
services offered the patients more time to discuss medications and active engagement than 
what community pharmacists can provide. 
 
E)  And there were times when I identified that the patients just really needed to sit 
down and talk about their drugs… they saw Lynette to talk in detail about, you know, 
birth control side effects, or you know pain medication and proper use of it, travel 
medications,… you would feel like you were being heard and that someone’s going to 
spend the time with you as well. I mean when you’re in a pharmacy you always see 
them scrambling around counting pills and doing the till and people waiting in line 
and you don’t feel valued, particularly.  
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I)  I think too that, you know, as far as myself dealing with pharmacists has always 
been just sort of a quick review of a patient’s medications, a quick question on side 
effects, and personally just, you know, being handed a piece of paper with a bazillion 
side effects and things I should know about a medication I’m taking but there’s never 
been, you know, a real dynamic communication with a pharmacist as there was with 
Lynette…   
 
Along those lines, a physician reflected on a patient (s)he had referred to me who was 
frustrated when unable to get the information she needed from a community pharmacist. 
 
O)… she was actually going to a different pharmacist in the city and like begging for 
information. They were busy, they couldn’t talk to her. So just referring her to Lynette 
she was very much happy... 
 
The benefits of a pharmacist-patient interaction in a primary care setting is that is occurs in 
an unhurried, private, accessible and credible environment.37  In addition, questions that 
arise during the interaction, which need to be addressed by the patients’ other primary 
health care providers, can be quickly dealt with when all are operating under the same roof.  
It is also a convenient means of receiving clinical pharmacy services, as we would often try 
to schedule patients in close proximity to any other medical appointments they had booked 
at the Centre. 
 
4.4.1.5.2 Full-time versus Part-time Clinical Pharmacy Services 
We asked the staff to what extent should clinical pharmacy services be accessible to the 
team (i.e. full-time versus part-time).  As the staff reflected on my two months with them, 
they noted I provided full-time services ‘which made it nice so everybody could access 
[me]’.   
 
H) … whether it was by sort of an official referral, because there was a referral form 
that was put together that we could use, or probably just as often by kind of casually 
popping into her office to ask a question or pick her brain about something, I think it 
was all quite positive in that sense… she had a very open-door policy… we had the 
luxury of being able to do it just on the fly. 
 
O) … it was great that she was available at any time, we just stepped into her office 
and ask her a question… 
 
Several of the participants agreed that ideally, a clinical pharmacist would be employed full-
time to increase accessibility and foster role development. 
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M)  And we may think that’s always the ideal, that everybody’s there full time because 
then you can interact and consults easiest , when you have access to everyone. 
 
E)  And they would… grow more dynamically if someone was there full time. 
 
A) … I mean sure in an ideal world each doctor would have a clinical pharmacist full 
time…  
 
One of the benefits of having a full-time clinical pharmacist is that urgent issues are 
addressed in a timely fashion.  Although there was some debate as to how often these 
pressing situations occur.   
 
H) … I mean it does raise the issue that if they’re not here full time, then there would 
be times in the week where even if you fairly urgently would like to have use out of the 
pharmacist, you can’t get it… if the total position is less than full time there might be 
some frustration in, you know, just at the times that you want the person to be 
available, and they’re not even on site. 
 
J)  … most of the questions don’t need to answered right away, and then if somebody 
was part time, that that could be easily worked around. 
 
O) … I could wait for a couple of days until I see her and ask her that question. Or my 
patients could wait like for one week to get an appointment with her. So I would say 
part time. 
 
The staff was also quick to point out the hiring a pharmacist for a full-time or part-time 
position would depend on several variables – such as the responsibilities assigned to the 
pharmacist, the team structure and volume of patients, resources and space. 
 
H)  … would generally depend very much on the size of the team and the range of 
services being provided… the number of physicians, the number of patients…  I’m not 
sure that we could justify a full-time position year round, for a pharmacist to be on 
staff, but then again I guess it would depend on how widely you describe the essential 
role…  
 
M)  And I think it would depend on their role, like when she was busy doing kind of 
research or putting together pamphlets or information for us, then you know maybe 
half time is good, depending on resources and space and all that stuff. And if her main 
role were client consultation and us wanting her to be available, you know, I’ve just 
seen a patient, can you see them now, well then you’d want her there full time so that 
you had more ability to do that. So it also I think would depend on how the role is 
broken down. 
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Within that same thread of discussion, a few participants drew attention to the fact that not 
all of the staff utilized my services to the same degree, and the significance of having a 
pharmacist on the team may only be appreciated by those who are scheduled on the same 
day – if the position was only part-time. 
 
I)  … I think some team members felt more of a need, or would use that service more 
than other team members would.  
 
L)  … if there were a pharmacist here probably like most of the rest of us she or he 
would be part-time, and it might just be those who actually work on the same day as 
that person who will find the value of that person, the others will not…  
 
I agree with the staff that full-time services would assist with the development of the 
pharmacist’s role.  This would be particularly important for clinics like the Student Health 
Centre who employ several part-time staff.  However, the reality of having the resources for 
a full-time clinical pharmacist would vary for each health care team. 
 
4.4.1.5.3 Patient Referral Process  
One important piece for integrating a pharmacist into a primary health care team, that 
needed to be further defined, was the referral process.  Looking specifically at the comments 
made by one of the nurses, the study did not provide her with enough time to feel 
comfortable with the process of referring patients to me.  Her concern was based on not 
knowing the impact a pharmacist may have with direct patient care interactions, as well as 
working part-time and therefore having less contact with me. 
 
B) … I don’t think it was always long enough for the nurses, anyway, to look at who 
we should refer and who we shouldn’t. …. Sometimes I wasn’t sure whether I was 
creating an extra step if I put the person in with the pharmacist, or straight with the 
doctor - because of the short period of time not 100% knowing the benefit.… I had 
some compunction, I think, a little bit about her role and I think she wasn’t there very 
long and because I don’t work full time, I think maybe I didn’t utilize her or get to 
understand totally her capabilities, that maybe some of the other people that worked 
there more days a week would have had. 
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One team member agreed that the referral process still needed to be fine tuned.  
However, when it came to mental health patients, (s)he felt more comfortable with a 
physician deciding whether or not a pharmacist should be involved. 
 
?)  … As far as patients coming out of depression, that’s something I still prefer for the 
physicians to see first and then decide whether that patient is best seen by the 
pharmacist, so as far as flow goes that still was sort of being established... 
 
Along those lines, one participant pointed out that (s)he viewed me as an adjunct, not a 
replacement, to a physician visit when referring patients to me. 
 
E)  … the people that I refer to Lynette I used her as an adjunct to also a physician 
visit. I didn’t utilize her separately under them for information on medication, as her 
role on the team.  
 
In contrast, one of the physicians felt that often the issue was resolved after a nurse had 
referred a patient to me, and a subsequent physician visit was not always necessary.  
 
O)  … lots of time I saw that the nursing staff they always turn to Lynette, and they ask 
a question and there is no need for me to see the patient and they get their answer and 
everything is done. 
 
These differing statements portray the uncertainties that surrounded the referral 
process.  A pharmacist referral form was developed prior to me joining the team to help 
identify which patients I could provide care to (see Appendix IX), however doubt still 
existed in some of the staff member’s minds.   In another study investigating the feasibility 
and content of clinical pharmacy medical consultations in a primary care setting, nurses did 
not refer any of the twenty-five recruited patients over a three month period.37  All primary 
health care professionals on the team were encouraged to refer patients to the pharmacist; 
however physicians were the only health care profession to do so.37 
The team members felt more comfortable with referring patients if they knew the 
patient would still be seen by their physician.  However, as the one physician pointed out, 
this approach was not always time efficient for the team.  A clearly defined direct patient 
care role and experience with what a clinical pharmacist can offer would alleviate their 
concerns regarding appropriate patient referrals.  The timing of integrated care must also be 
determined in order to develop effective interdisciplinary teams.16  
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4.4.1.5.4 Action Research Process 
Staff members were asked to comment on the approaches we used, as researchers, for 
integration a pharmacist into their team.  One team member recalled that I had consulted 
primary health and ambulatory care pharmacists at the beginning of the study, and (s)he 
considered it an appropriate step. 
 
H) … it made good sense that she would have consulted with whoever that description 
is available...   
 
Connecting with colleagues who hold a similar background plays a valuable part 
when developing new roles in multidisciplinary teams.  This link can provide professional 
identity, as well as a resource for support and guidance. 21 For me personally, seeking advice 
from established primary health and ambulatory care pharmacists was very important.    I 
realized that my role at the Student Health Centre would be tailored to meet the needs of 
the team and patient population.  However, involving other pharmacists allowed me to feel 
assured that the clinical pharmacist role I would take on would be supported by my 
colleagues and not jeopardize the direction our profession is taking to expand our presence 
in health care.   
This study investigated the integration of a primary health care pharmacist – a role for 
the profession which was new to the Student Health Centre staff.  Scheduled meetings with 
the team to define my role, prior to providing clinical services, were deemed a reasonable 
approach. 
 
H) … in terms of the discussion with staff,… that was certainly a logical starting point 
in terms of some consensus between her and us as to how we would define her role for 
the short time that she was here. 
 
When adding a new member to a health care team, the staff should collaborate to define the 
role and responsibilities, as well as the logistics, with this new professional before they 
officially join the team.16, 17  This philosophy aligns well with action research, which 
encourages key players to be involved in decision making.46 We can also learn from nurse 
practitioners and their experience of creating roles in primary care, as they discovered that if 
stakeholders are not involved in the planning stages for the new role, role conflicts and 
resistance from the stakeholders surfaced.18  In addition, a team approach can help identify 
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where the current treatment gaps exist - which in turn can help shape the role of the new 
member.21  I felt it was critical to have the staff assist with the development of my role, as I 
wanted them to feel ownership of the project as well.   
 Despite our efforts of defining my role, as the pharmacist prior to providing clinical 
services, one staff member admitted to being puzzled with how to incorporate a health care 
profession that had never been part of the team before. 
 
M) I think the biggest negative is just the confusion of startup process so I don’t think 
that that was specifically her, or specifically a pharmacist added to our team but just 
trying to figure out how we were going to do that, how we were going to use her, how 
she would fit in, all of that. 
 
Another team member highlighted that the study was ‘exploratory’ in nature and ‘you kind 
of almost expect to be a little bit unsure of what’s going to be’.  This same participant 
acknowledged that (s)he was unsure, like the others, as to how I would fit into the team, but 
also pointed out how much they did learn in terms of what a clinical pharmacist can offer. 
 
B) I wasn’t sure what she would do, and how she would fit into the team. I think that 
was part of the process anyway and I think we all perhaps learned a lot more about 
what a pharmacist did have to offer our team, … there was a lot more than perhaps I 
thought a pharmacist might have to offer. 
 
 Action research is a flexible process, which does not require a detailed outline at the 
onset of a research project.47  Those who are involved can improvise on the preliminary 
findings, and the study unfolds as the participants learn more about the project at hand.50  
Because the study was exploratory and action research was the selected methodology, some 
degree of uncertainty may be inevitable. 
 
4.4.1.6 Theme 6: Communication 
Defining, implementing and evaluating the role of the pharmacist required open 
communication between the pharmacist and primary health care team. 
 
4.4.1.6.1 Formal and Informal Discussions 
It took the staff some time to adapt to having a pharmacist on their team, and they 
therefore appreciated the opportunities to gather and reflect on my role.  They felt that they 
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were provided with a sufficient number of occasions to discuss my contribution to the team, 
through both organized meetings and casual conversations.  The two methods used to 
exchange ideas – the formal and informal gatherings, were considered ‘complementary’ to 
each other.  
 
M) … she did lots of discussion with us to define her role… I think it was good that 
she kept meeting with us along the way to kind of revamp and check in. 
 
H) … A medium midpoint, I think that was also useful… I think there was a lot of 
ongoing kind of discussion and that outside of sort of formal meetings, which was 
probably just as helpful as the formal meetings. 
 
In addition, since not all of the staff could attend the planned meetings – primarily due to 
scheduling and the large number of part-time staff employed at the Centre, the team 
regarded the impromptu discussions as a valuable part of the process. 
 
I) … the previous comments about her role, you know, we as the staff have some 
responsibility in that and we had ample opportunity to have discussion and come up 
with ideas and stuff and I think one of the negative things -- and it’s not anybody’s 
fault, it’s just there’s a number of part-time staff and to try and get everybody on the 
same page, everybody reading the same meaning… it never happens, that’s not any 
fault of Lynette’s or anybody’s, it’s just a reality of how our clinic is because we just 
are never all in one place at one time. It’s difficult to communicate I think…. 
 
D) ... conversations with Lynette, I think that informal piece was very helpful. I know 
that we weren’t all present at the formal meetings just because of when they were 
held…. Somehow those informal things were very important. 
 
 When reflecting on roles, it is important to work with the team to identify what needs 
to be modified versus imposing the researcher’s ideals onto them. Action research is a 
cyclical and dynamic process, and this collaboration should be maintained throughout the 
study.25  In our study, allowing the staff to share their views when it was convenient for 
them (i.e. scheduled meetings or informal discussions) helped convey the message that all 
feedback on my role was welcomed. 
 
4.4.1.6.2 Consultations for Medication-Related Projects 
 In an effort to involve vital players throughout the process, two approaches were 
applied and I believe were key to the integration of a pharmacist onto the team.  First, I 
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used a team approach with every task I undertook, and as such, I consulted several staff 
members throughout the process.  The second, was to know when to consult these team 
members.   
 A few staff members noted my efforts of consulting key players for initiatives I 
undertook. Not only did they appreciate being asked for their input, they also acknowledged 
my strategy of approaching only one staff member, when I had a first draft available, as a 
logical approach. 
 
H) … there were some little initiatives that she was trying to go forward with… and 
she was very good at consulting… to sort of wanting to run things by me first, rather 
than just sort of forging ahead with something which may or may not have been 
entirely a good idea or which may have had some weaknesses to the approach, and so 
I really appreciated the fact that she was consulting appropriately in terms of things 
that she was thinking of doing… a lot of that stuff, it just made more sense to happen 
informally one-on-one with her and me or whoever else she might have consulted, 
rather than sort of leaving it to a general meeting to go over those things. 
 
G) ... she checked with me too about an initiative she was looking at in my area… 
 
4.4.1.6.3 Debriefing after Direct Patient Care Interactions 
From the staff’s perspective, they appreciated the verbal debriefing I gave the referring 
team member after each patient encounter, as well as the documentation I left in the 
patient’s chart.  To them, these actions portrayed my efforts of being a team player and also 
helped establish credibility with the staff. 
 
I) … she always debriefed afterwards, after I sent her someone she would say okay, 
this is what we did, I think that we’ve covered this, like she was very thorough. So I 
also felt reassured that the issue had been tackled and I knew it had been 
documented…and certainly the confidence level of her counseling skills, you know, 
because it was really good.   
 
O) But that was the routine that she leaves a very good note on their chart, and before 
we had time to go take a look at her notes, she comes and gives us a very clear 
feedback about what she thinks or what she did. 
 
?) She always provided a team meeting after she saw clients, like there’d be certain 
clients and she would always get back to you and describe how it went. And after, you 
know, if she thought that patient needed follow-up or more education... she was a 
team member, and nothing was left open-ended. There was closure or follow-up.  
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?) … she has really good writing skills as well, and like any research that she does, you 
know, she does a really good job with that, and also any patient visit documentations, 
very thorough, very legible, you know, just very clear. 
 
Expanding on the communication piece, I believe it was a key element to the 
integration process.  After working in a hospital setting with a strong team focus, my 
framework for providing patient care always involved discussions with the patient’s other 
health care professionals to optimize the care they received. From a researcher’s point of 
view, I felt it was essential to continue in this fashion, as it would also assist with the 
Student Health Centre staff’s process of understanding how a clinical pharmacist 
approaches patient care. 
 
4.4.1.7 Theme 7: Limitations 
The limitations from the study included the duration, patient population, funding and 
space.  
 
4.4.1.7.1 Duration of the Study 
4.4.1.7.1.1 Limited the Impact and Exploration of the Role 
Despite demonstrating value as a support to the staff during the study timeframe, as 
discussed earlier, several of the team members cited the duration of the study as a limitation.  
One staff member pointed out that the impact on his/her practice would have been greater 
had I been at the Centre for a longer period of time. 
 
 G)  I think if she’d been there longer it would have affected my practice more, in terms 
of, you know, perhaps considering medications I’m not so familiar with or 
combinations I haven’t tried before…  
 
Another team member also highlighted that two months was not enough time for them to 
fully explore the role of a pharmacist for their team.   
 
B) … I think there is a lot more of a role for her, and I think that we haven’t explored it 
as much as we potentially could… I don’t think we’ve really got to know 100 percent 
all that the pharmacist could do in the team… I think what she did was invaluable, I 
think we learned lots, but I think that there’s still a long way to go. 
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At the end of the two month period, my role as a drug information resource for the 
staff was far more developed than my direct patient care role.  Therefore, the limitations 
with the study timeframe were more of a barrier for my role with the patients than the staff.   
 
A) … the piece dealing with individual patients, I really don’t think we had enough 
time to say did that help or didn’t it help… in the long term was it effective? Did it help 
the patient? Did it help me? Did it help efficiency in the clinic? Did it take more 
resources or fewer resources? I don’t see how we could tell at this point… 
 
It was difficult for the staff to evaluate my role with the patients as they did not know how 
the patients felt about seeing a pharmacist in this unique role.   One staff member 
highlighted the difference of patients agreeing to see me because their physician 
recommended it versus truly having an interest in meeting with a pharmacist to discuss their 
medications. 
 
H) … not that I asked for it, but I didn’t get that much feedback from students that had 
seen her, as to what their perception was of looking at the information that she had 
provided to them… where I made referrals… I wasn’t entirely sure in some cases 
whether it was something that they agreed to do because they figured well, this is just 
part of the process, or whether they were really quite keen to have had that opportunity 
to have spoken with a pharmacist about all those things.  
 
In addition, the team members were still unclear on exactly what my role with the patients, 
and degree of involvement, should be. 
 
A) …I found where she did good work, that to my mind the best work, at least the 
most helpful for me, was the research component… I still don’t understand how the 
clinical pharmacist would work with the care giver in evaluating side effects and giving 
advice. I think there would need to be a more a closer clinical relationship to prescribe 
or the patient and the pharmacist, than we developed, for that to work.  
 
Interestingly, the evolution of clinical pharmacy services – pioneered by hospital 
pharmacists, followed a similar path.75, 76  Historically, providing drug information to 
physicians and nurses was a fundamental step in the development of the clinical pharmacist 
role.75  The provision of drug information by clinical pharmacists was established prior to 
the inception of direct patient care services.76  As the role expanded, health care 
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professionals – including pharmacists, were not clear on what the direct patient care role 
would be, but did acknowledge that the role needed to be clearly defined.76  Today, the roles 
of clinical pharmacists continue to evolve and have migrated from hospital practice to 
ambulatory setting,75 as demonstrated in our study. 
 
4.4.1.7.1.2 Generation of Patient Referrals 
The number of patients I saw was dependent on the number of referrals the team 
made.  Of note, the opportunities to answer the staff’s drug information questions surfaced 
more easily and quickly compared to patient referrals. 
 
D)  Unfortunately I never got as far as referring that client to her, but just great 
resource for me as a professional in that way. 
 
G) … Especially their referring patients to meet with her, you know, like I had no 
difficulty, you know, using her as a resource, and I’d done that before, but I actually 
hadn’t had the opportunity to refer patients to sit down and talk to a pharmacist and 
that would have taken me longer to make good use of that.  
 
One of the challenges the staff experienced with referring patients to me was remembering 
that there was a pharmacist on the team.  They acknowledged that it ‘takes a while for 
everyone to change practice patterns’ and the referrals ‘required a conscious thought’.  Each 
participant who brought up this issue noted that had the study been longer, they would have 
become more accustomed to the idea of having access to a pharmacist. 
 
H) … it takes a long time to change your own habits... I even put a sticky on my 
computer saying, you know, with her name on it, just so that I would constantly 
remind myself… the longer she was here the more that would have become 
ingrained…. 
   
J) … perhaps if I had worked with a pharmacist longer I would - in that sort of 
situation that I would have had a better sense of when I should be, you know, talking 
with her or referring to her,… and you’d probably, you know, do that more quickly 
rather than, you know, kind of thinking about that as an after thought.  
 
One of the allied health care professionals added insight to establishing referrals by using 
her/his own experiences with the team.  (S)he commented that the number of patient 
referrals increased for her/him over time. 
 
 89 
D)  … when I first started as a [allied health care professional], there had been 
someone in place before but referrals weren’t quite as easy as they are now. You 
should see my list! I think that new added step in figuring out when to send them and 
when not to send them just takes time for the practitioners to get used to.  
 
Other researchers have also noted that patient referrals to primary health care 
pharmacists were slow to generate, initially.26, 37 However, an explanation for this delayed 
acceptance of clinical pharmacists providing direct patient care was not provided.  In my 
introduction, I discussed a survey involving randomly selected physicians from the state of 
California, which discovered that physicians do not know what to expect from 
pharmacists.20  One of their findings was that physicians believe that pharmacists are 
capable of providing non-patient specific drug information; however they were less 
confident in our ability to provide information tailored to individual patients’ clinical 
situations. They also concluded that the level of physician acceptance to pharmacy services 
is related to their degree of exposure.20  
The Seniors Medication Assessment Research Trial (SMART), which was also 
highlighted in my introduction, was a study evaluating a collaboration between six 
expanded role pharmacists and six family physicians.  The pharmacists were only brought 
in for medication consultations in an effort to optimize the patients’ therapy.  The 
researchers found that the physicians were reluctant to support the pharmacists in anything 
beyond a traditional pharmacy role.  The need for developing a trusting relationship was 
identified as an important piece to creating an effective collaboration between the two 
health care professions.  When the physicians were asked for suggestions to change or 
improve the program, they recommended that the pharmacists provide academic detailing, 
which would assist the physicians in making informed choices when selecting medical 
therapy for patients.19  In other words, the physicians offered ideas for enhancing the drug 
information they could receive from the pharmacists, as they were not comfortable with the 
pharmacists providing direct patient care.  
In our study, creating my drug information role was a comfortable and natural process 
for the team.  Whereas my direct patient care role was new to them, and required more than 
two months to develop.  Although the above reference to the evolution of clinical pharmacy 
in hospitals is an interesting link to our current study, the previous progression dealt with 
hospital pharmacists pioneering direct patient care activities versus our present practice in 
 90 
which direct patient care activities have been established and successfully implemented by 
clinical pharmacists in ambulatory settings.  If we draw on the findings from the above 
reported studies on pharmacists’ roles, establishing credibility by providing team members 
with drug information needs to occur before the health care professionals are prepared to 
refer patients to pharmacists in an expanded role. To facilitate the understanding of what a 
clinical pharmacist can offer, I feel that the drug information questions should include both 
general and patient specific inquiries.  The latter will increase the team’s confidence in our 
ability to tailor the information to best suit the scenario. Over time, as credibility is formed 
and the staff is more familiar with a pharmacist’s capabilities, the team should be more 
willing to foster a direct patient care role for the pharmacist – however additional research is 
needed to confirm this notion.   
It should be noted that other patient referral methods, not only those requested by the 
Student Health Centre health care professionals, were considered prior to Phase II.  During 
the on-line focus group with the established primary health and ambulatory care 
pharmacists, two options were proposed; a patient referral form and an automatic patient 
referral process.  With the latter, two approaches were used by one of the focus group 
pharmacists at different practice sites.  In one, patients completed a self-administered drug 
related problem risk assessment questionnaire.  In the other, all patients with coronary 
artery disease or diabetes were referred to the pharmacist for medication reviews. The 
receptionists at both practice sites were responsible for identifying and contacting the 
patients and making an appointment to see the pharmacist.   
Although this patient referral method would have been beneficial, we felt that the 
Ethics Board would have rejected our request to incorporate this selection process in our 
proposal.  The pharmacist incorporating the patient referral method in his/her practice was 
employed by the team to provide direct patient care.  In our study, the Ethics Board likely 
would have reviewed our proposal from a researcher’s perspective and not as a practitioner.  
In addition, one of the focus group participants currently conducting clinical research 
reported being able to access patient charts only after a referral was made by a physician, 
which was stipulated by the Ethics Board.   
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4.4.1.7.2 Patient Population 
4.4.1.7.2.1 Narrow Patient Demographic 
The type of patients who seek medical care at the Student Health Centre are ‘very 
specific’, and are comprised of a relatively ‘young, healthy population’.  In addition, ‘there 
isn’t as much chronic illness management’ compared to other primary health care centres in 
the city of Saskatoon.  Despite these limitations with the demographics, the team still saw 
benefit in working with a clinical pharmacist, as one participant added, “… but that doesn’t 
mean that there isn’t value in having a pharmacist on site”.  
Primary health care involves a proactive approach to preventing health problems, 
along with an appropriate management plan and follow-up once a disease or condition has 
been diagnosed.77   As I reflected on my patient interactions, as a primary health care 
pharmacist I focused on how medication compliance can have a favourable impact on a 
disease or condition.  For example, taking an antidepressant for an appropriate duration - 
even after the symptoms of depression resolves, to decrease the risk of suffering from 
another episode.  Education around the benefits of a medication and management of side 
effects, along with encouraging patients to take an active role in their health also align with 
the primary health care philosophy.  To my knowledge, there are no published papers 
assessing clinical pharmacy services with university students.  However, the Student Health 
Centre allowed me to specialize in this particular patient population while maintaining a 
primary care approach. 
The patient population should be taken into consideration when selecting a primary 
health care centre; however a narrow patient demographic does not preclude the ability to 
establish clinical pharmacy services.  The Seniors Medication Assessment Research Trial 
(SMART) focused solely on elderly patients.  Medication use and the number of medical 
conditions tend to increase with age, and the pharmacists who participated in the study had 
more of an opportunity to make several recommendations to optimize the patients’ therapy.  
However, they were unable to secure physician acceptance of expanding the role of a 
pharmacist.19  In contrast, pharmacists have been able to successfully develop roles on 
health care teams which provide care to a specialized group of patients when using action 
research as an integrative approach.50 Therefore, the process of establishing patient care is 
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more important than the patient population itself, when integrating a pharmacist into an 
already established team. 
 
4.4.1.7.2.2 Timing of the Study   
As for the timing of the study, the clinical services were provided at the end of the first 
school term – i.e. November and December.  One of the focus group participants noted that 
December was not an ideal month for recruiting patients. 
 
B)  … December is not a good month, because students start exams practically right off 
the bat, and that changes whether they’re going to turn up for appointments and 
results. 
 
The direct patient care interactions I was able to obtain decreased during the month of 
December.  University courses ended the first week of December.  Students were busy 
studying for exams, and then often left campus immediately after their last test to head 
home for the holidays.  The drop in patient visits not only declined for me, but the entire 
Centre. 
I feel that the duration of the study was more of a limitation than the months we 
selected, as the academic calendar is always busy for students.  Therefore, I would 
recommend a period greater than two months when trying to establish and evaluating a 
direct patient care role.  A longer timeframe could compensate for fluctuations in patient 
volumes. 
 
4.4.1.7.2.3 Lack of Patient Buy-in 
As mentioned earlier, patients who seek care at the Student Health Centre often want 
to know a lot about their medications.   A caveat to this is that they want to receive the 
information in a fashion that is quick and convenient for them.  Therefore, issues arose 
regarding a lack of patient buy-in, as booking an appointment with yet another health care 
professional did not always appeal to them. 
 
H)  … a lot of our student population is sort of rushing in and out looking for a quick 
easy fix kind of care…  there certainly would have been occasions where I did make an 
offer to a student in my office that they be seen by the pharmacist, where they basically 
would have said no. And for them it was just too much of a hassle, like it had been 
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enough of an inconvenience in their life to see me… how do I actually get the student 
to see her in a way that meets their needs and also meets my needs…   
 
The patients would need to perceive value in meeting with a primary health care 
pharmacist before they would agree to do so.  With the uncertainty the team had 
surrounding my direct patient care role, conveying the benefit of meeting with a clinical 
pharmacist to a patient would have been difficult for them.   To complicate the situation 
further, all patients who received a prescription from their physician/nurse practitioner 
would have an interaction with a pharmacist, albeit a community pharmacist, when the 
prescription was filled.  I admit that at certain points of the study, I feared that the staff 
would not allow my direct patient care role to evolve beyond the traditional boundaries of 
community pharmacy.  These concerns support the importance of having a clearly defined 
role when a new health care professional joins an already established health care team.   
 
4.4.1.7.3 Funding and Space   
Concerns surrounding funding and space emerged from the focus group discussions. 
The staff recognized that ‘funding is an issue’ and they may have to reallocate resources in 
order to add another health care profession to their mix. 
 
A) … I don’t know how the pharmacist would be funded, when you’re on a global 
budget of sorts… you’ve gotta balance this resource against an additional counselor… 
I mean you can’t just keep adding, adding, adding and getting bigger, bigger and 
bigger, you end up having to reallocate resources at some point. 
 
In terms of space, as with the majority of buildings on campus – space is a premium.  It was 
noted that the Centre was short one office while I provided clinical services, and the lack of 
space could be a large enough barrier to prevent the addition of a pharmacist onto their 
team. 
 
H)  … we were a little shorter on rooms, sometimes when she was here. But we knew 
that that was going to be an issue and we knew we could work our way around it … if 
we were to have someone in that position on a permanent basis as part of our team, I 
mean it would just accentuate our need for more appropriate space… but that honestly 
might be a deal breaker… we could all in principle think that this is a great idea and 
come to the conclusion that no, we can’t have a pharmacist because we don’t have 
adequate space, to house one. 
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The Student Health Centre did not have to pay for the clinical pharmacy services I 
provided over the two month period.  They were unable to dedicate one office solely for a 
pharmacist; however there was always a room for me to work out of.  Nurse practitioners 
found that a lack of office space and inattention to basic resources marginalized their 
purpose and legitimacy when they expanded their roles in primary health care.7 Therefore, 
funding and office space would need to be addressed by a health care centre prior to a 
pharmacist joining their team.   
 
4.4.2 Minor Theme 
4.4.2.1 Theme: Recommendations 
As mentioned earlier, the Student Health Centre staff members provided several 
recommendations to facilitate future integrations of pharmacists into primary health care 
teams.  The following section includes the suggestions that surfaced during the focus group 
discussions. 
 
Bring in established primary health care pharmacists to describe their role. 
The roles of health care professionals working in primary health care centres can vary 
from team to team – based on the needs of the patient population and existing treatment 
gaps, as discussed previously.  For these reasons, I did not provide much detail of what 
other primary health/ambulatory care pharmacists do.  Instead, I presented the Student 
Health Centre with the results of the on-line focus group with established primary 
health/ambulatory care pharmacists, during our initial planning phases.  These results – i.e. 
a list of clinical pharmacy activities tailored specifically to the Student Health Centre, is 
what we used as a base for creating my role.   
 Unfortunately, the staff appeared disconnected from this expert panel of pharmacists.  
As a future consideration, the team suggested they be provided with more detail of how 
clinical pharmacists, already established on other primary health care teams, function within 
their teams. 
         
A)  … we didn’t actually have another clinical pharmacist come in... I wonder if it 
would have helped if somebody would have actually come in and said here’s what we 
do, first hand…  
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H)  I guess it might have been… nice to have heard a little bit more… of an 
introductory synopsis of how this does play out in other settings where it has been 
established, and not necessarily even just in Saskatoon but you know, in other.. in 
other settings, because it is kind of a newer idea, because evidently Lynette has done 
some research on that. Maybe there just wasn’t time for her to sort of share that with 
us, and that wouldn’t necessarily have helped all that much in terms of the specific 
setting that we’re in but it would have been - to me it would have been interesting. 
 
Identify the pharmacist’s vision to assist with role creation. 
When selecting a pharmacist to join your team, ensure you ‘interview somebody and 
look at their vision’.   One participant recommended that a team should ask a pharmacist 
‘…what their vision is, what they think that they could ultimately achieve, what would be 
their idea.” This will help establish the role and direction of adding a pharmacist.    
IMPACT (Integrating family Medicine and Pharmacy to Advance primary Care 
Therapeutics), was an initiative to integrate seven pharmacists into primary health care 
centres in Ontario, Canada.  When reflecting on their hiring process, they acknowledged the 
importance of identifying the each pharmacist’s vision for the position.   By learning more 
about the candidates’ vision – along with their previous experience and practice settings, the 
IMPACT team felt they were better equipped to match the job applicant to the available 
positions.78 
 
As a profession, pharmacists need to market ourselves better to highlight the diverse roles we can 
take on. 
One staff member noted that the profession of pharmacy needs to promote the variety 
services we can provide.  
 
B)  … I also think that pharmacists maybe haven’t done a good job of telling us what 
they really can do, and maybe that’s why I think we kind of have problems thinking 
about it. Maybe they need to stand up and say, we can offer this so much more.  
 
Pharmacists should not assume that other health care professionals understand our 
background or capabilities.  To facilitate our role expansion in health care, we need to 
educate other health care providers on the various responsibilities we can take on. 
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The health care team needs to think big and outside the box when considering what a pharmacist 
can do for their team.  
When forming the role of a clinical pharmacist, one participant suggested the team 
members open their minds to the possible functions a pharmacist can take on and not to 
restrict the opportunities based on their traditional view of pharmacy services. 
 
B)  I think we have to think out of the box too about what pharmacists do do, and 
maybe not think about pharmacists who, you know, have their own business and sell 
drugs and make money… but what they have to offer as a team in doing that, and look 
at pharmacy in a different way,… I think you have to think about what they can do… I 
think if you could look at it outside of how these pharmacists function now, to how 
you think an ideal pharmacist should function… I think you’d have to think big. Think 
about all the things that pharmacists can do and more, and don’t just restrict what you 
know about pharmacists.  
 
The team’s recommendations of bringing in an established primary health care pharmacist 
to describe their role, along with having the pharmacist who will join the team promoting 
our diverse services, could assist the staff with this step. 
 
When shaping the role of clinical pharmacist for your team, it is important to identify the 
treatment gaps that exist in your current service.  
It was noted that a team should recognize the areas in their practice that could be 
improved upon or enhance the level of care patients receive. 
 
A)  ... I think you’d sit down ahead of time and figure out that here’s areas in our 
service that are weak, here’s the way we can help our patients, our clients, here’s needs 
we see that aren’t getting fulfilled. We need somebody to work on those things. 
 
The treatment gaps that also fall under the scope of practice for pharmacists can form the 
initial clinical activities that the pharmacist takes on.   
 
Create a job description and/or policies and procedures to ensure the role of the pharmacist is 
clearly defined.  
Once the role of a clinical pharmacist has been defined for a team, a few of the team 
members felt that a job description and/or policies and procedures would be beneficial to 
ensure the expectations and responsibilities are outlined.  
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A)  I think it would help if there had been some development of a protocol for how a 
clinical pharmacist works in a multidisciplinary team… the primary health care teams 
before going this direction had a clear idea -  clear statement of what they at least 
initially intended that the pharmacist to do… I’d think you’d want some more 
definition of the role rather than just hiring somebody sort of on principle it’s a good 
thing to do, and then let them sort out what they’re going to do…  
 
H)  … important process of having, you know, policies and procedures and very clear 
sort of job descriptions and what are the ranges of services that can be provided, what 
are services that require the input of a physician and those that don’t require the input 
of a physician, those kinds of things would need to be pretty clearly delineated…  
 
Because my role as the Student Health Centre’s clinical pharmacist was still being 
explored and defined, we would have been unable to create an official job description.  
However, as the responsibilities of the clinical pharmacist are solidified over time, I agree 
with the team that developing a job description – as a next step, would beneficial.  In 
addition, writing a job description may identify areas that need to be further discussed with 
the team in a proactive manner. 
 
The team members should be aware that their roles may change when a clinical pharmacist joins 
their team.  
As highlighted earlier, a team member noted that their own roles may change when a 
new team member is added to the mix of health care professionals.  Another participant 
recommended that the staff be aware of this possible change. 
 
I)  … I think all of us at first, you know, you think a little bit about your own role … 
and how that may or may not change with the pharmacist on the team, so I think just 
being aware of that and exploring that and thinking about that a bit would be useful as 
well. 
 
Ideally, if individual team member’s roles were altered, the team would be able to identify 
how the changes could benefit the team.  In other words, how can the services be 
restructured to increase the level of care the patients are offered. 
 
Consider sharing a pharmacist with another health care clinic or having access to a pharmacist via 
phone or email and who is available for patient consultations.  
 98 
The staff suggested that a pharmacist could be shared with another health care centre.   
To expand on this idea, some of the team members recommended that they should still have 
access to clinical pharmacy services even if the pharmacist was working off-site. 
 
A)  Would it work if a pharmacist was shared between two clinics? 
 
H)  … it would be nice to have someone who’s more specifically designated to answer 
my questions... just a phone call away. 
 
J)  Or if she wasn’t there all the day - all the time… e-mail her with questions if you 
wanted them answered more quickly. 
 
O)  … hospital-based work… consult pharmacy… Pharmacist come to the wards, 
spent one hour, sees your patient, reads the chart, and writes a note for you. If we 
could have such a thing in our little clinic, not hospital, that you can have pharmacist 
coming, I don’t know, one, two half-days, and seeing your patient, and the same 
pharmacist or a group of pharmacists, will be available to answer your phone calls… 
possible there’s a group of pharmacists somewhere that they’ll be willing to answer, to 
cover for call sitting, and answering physicians questions… 
 
Having a pharmacist work for a health region, providing both on and off-site services to 
more than one primary health care clinic could be a solution to the current health care 
budget constraints.    
 
Investigate options for a clinical and dispensing pharmacist.  
Other options funding issues would be to collaborate with community pharmacists 
who are located near your centre and expand their role to include clinical activities, or have 
your clinical pharmacist dispense a certain number of commonly prescribed medications. 
 
B)  … to have somebody that could dispense, that could be there for students to supply 
over-the-counter medications and, you know, morning-after pills and stuff, to actually 
expand their role a little bit so they had a dual role, I think might be as a pharmacist 
but who also worked clinically, I think would be on campus would be a useful 
improvement, and maybe utilize them better too. Because lots of our students actually 
just want over-the-counter medications. 
 
H) … I don’t know how this would work but in actually having certain medications 
that could be dispensed right on site, rather than just sort of the consultation at a 
pharmacist and then they have to go yet again to another place... It just to me that’s 
not a very good integration service... if we ever get our new Student Health Clinic, that 
it would be immediately adjacent to a pharmacist which might still be separate from 
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the primary care pharmacist’s role. You know, there are just different ways… to 
minimize duplication of service…  
 
D)  Would the idea of having a pharmacy adjacent to the clinic be another way to 
involve them? You would just get to know that person a lot better, they would be a 
resource to the doctors as you phone back and forth, or the nurses, and the patients…  
 
In my experience, when the responsibilities of both dispensing and clinical services are 
combined, there is a risk of dispensing functions taking priority over a clinical role.  
Therefore, if a community pharmacist was hired by the health care team to provide clinical 
services, I would recommend that a clearly defined job description be created to ensure that 
the team receives a certain percentage of hours dedicated solely to clinical services.  In 
addition, if an on-site clinical pharmacist was to dispense medications, the regulations set 
forth by the Saskatchewan College of Pharmacists would need to be honored to ensure that 
legal requirements are met. 
Interestingly, my role on the team did not include product distribution, yet the staff 
still associated a clinical pharmacist with the provision of drugs.   Despite our attempts as a 
profession to expand the role of pharmacists, I feel that these efforts are often overshadowed 
by our most prominent traditional role – dispensing medications.  Hopefully, in the future, 
other health care professionals will acknowledge clinical pharmacists as having a distinct 
and specialized role. 
 
Investigate research opportunities which would involve pharmacists.  
One team member recommended that a health care team could create and implement 
research projects as a means of involving the profession of pharmacy with the team. 
 
H)  I mentioned research, and that was a way to involve pharmacists if there was some 
kind of a research project that could use the involvement of a pharmacist. That would 
be one way to make it a door into the evolvement. 
 
Conducting clinical research in an existing health care team is a practical option and 
provides an opportunity to work with other health care professions.  However, research 
projects are only run over a certain timeframe, therefore it does not provide a long-term 
solution of the lack of funding. 
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Consider establishing clinical pharmacy services in a primary health care centre that serves a wide 
patient demographic with need for chronic disease management.   
A few of the team members felt that a pharmacist may have more opportunities in a 
primary health care centre the served an older patient population suffering from more 
chronic conditions. 
 
A)  … I’m sure a geriatric unit would make far more use of a pharmacist than a clinic 
serving well, intelligent, young people that are on any one or two drugs.  
 
H)  Well I think in a more general practice such as the West Winds Clinic, where 
you’ve got the full demographic including a good proportion of elderly and I think that 
that sort of opens up a lot more possibilities or the kind of role that the pharmacist can 
have. Just sort of a multi system or organ diseases and a lot of probably pharmacy 
issues and all that kind of thing. And just the availability of clients to be part of that 
kind of a process… there’s a lot of follow-up being provided by the pharmacist to 
people’s chronic illnesses that makes a lot of sense.… we can’t pretend that in our 
setting that we’re really in the same situation…  
 
O)  … But if she could have this study in a place with more elderly population, you 
could really have a good assessment of her role in community.  
 
The patient population should be reviewed when selecting a primary health care centre, 
however as already discussed, the process of establishing pharmacy services is more 
important then the patient demographics. 
For our study, we used the two available Student Health Centre needs assessment surveys to 
identify services required for this patient population.   It is suggested that primary health care teams 
include members of the community on their governing bodies and have processes in place for 
identifying their need.1, 79  Means for ascertaining patient population health care requirements, in 
addition to needs assessment surveys, include focus groups or interviews with community members.  
Working in conjunction with local community programs can also assist in the recognition of 
essential services.1 
 
Advertise to patients that a pharmacist is on the team and available for them to see.   
One focus group participant noted that my services were not advertised to the patients, 
which could have made a difference in the number and type of referrals I received. 
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I)  … it wasn’t advertised to students… it could have been a different experience had, 
you know, students known up front somehow that that service was available. It might 
have brought her a whole different type of referral.  
 
This is a valid point, which unfortunately we did not think of while I was providing clinical 
services over the two months.  The Student Health Centre does advertise some services – 
such as chiropractor and massage therapy, to their patients in the form of posters displayed 
in the patient waiting areas inside the clinic, as well as on bulletin boards located throughout 
campus.  As a future recommendation, any advertising should provide examples of what a 
clinical pharmacist can offer.  In addition, it should be clear that the on-site pharmacist does 
not dispense medications – unless a dual clinical and dispensing role was developed for a 
particular health care centre, to avoid any confusion with the patients.  The team would also 
have to be comfortable with the idea of patient self-referral, which may be an issue for 
individual team members who have reservations of inviting pharmacists to participate in the 
care of their patients. 
 
Gather patient input/feedback to help define and optimize the role of a clinical pharmacist.  
During the focus group discussions, one participant suggested that feedback should be 
obtained from the patients. 
 
H) … I think for future integrations of pharmacy into a primary health care team... 
getting more info or feedback from the actual patients themselves as to what they see 
as being important. So kind of like having focus groups of people that are receiving 
service rather than just all the professional staff talking about what’s good. 
 
As mentioned earlier, we did try to organize an on-line focus group and survey to obtain the 
patient’s feedback on his/her experience with a clinical pharmacist, but unfortunately, our 
efforts were unsuccessful.  Nonetheless, it would be valuable to collect this information. 
 
 
 
 
 
 
 
 
 
CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
5.1 Introduction 
In this final chapter, the research findings are summarized under the research 
questions.  The major research findings are then presented, followed by the implications of 
our study for health care professionals. Finally, limitations and areas for future research are 
addressed. 
 
5.2 Summary of Research Findings by Research Question 
The following section uses the results from the Student Health Centre focus group 
discussions to answer the research questions.  Again, the main research inquiry was how to 
integrate a pharmacist into an already established primary health care team, which was 
further broken down into three subsequent questions. 
 
1. Can action research be used to assist with this integration process? 
Using the integrative process action research, aided the integration of a pharmacist 
into an already established primary health care team.  This exploratory process was new to 
staff; at the beginning of the study they were unsure of how to incorporate a pharmacist into 
their team.  However, by providing the staff with opportunities, both formal and informal, 
to reflect on and evaluate the role of a pharmacist, they began to get a sense of what a 
pharmacist could offer them.  Defining my role with the Student Health Centre staff, prior 
to providing clinical pharmacy services, and consulting appropriate team members for 
projects I undertook, fostered the collaborative approach which is encouraged with action 
research.   
 
2. How did the primary health care team members feel about having a clinical 
pharmacist join their team?  
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The Student Health Centre staff members welcomed the idea of having a pharmacist 
join their team and overall were quite pleased with the experience.  They did, however, have 
some initial uncertainty with what the role of the pharmacist would be, along with the 
degree of utilization.  As the study progressed and opportunities arose for using a 
pharmacist, their concern shifted to whether or not they were utilizing the clinical pharmacy 
services appropriately.   
The primary role established for the pharmacist was as a drug information resource for 
the staff.  The team members were impressed with the quality of the drug information 
provided, in particular, that the information was detailed and objective, as well as 
conducted in an efficient manner.  This aided with building credibility for the new team 
member.  Staff also noted that having a drug expert carry out these responsibilities increased 
the efficiency of the team.  Being a support to the team members was another role that was 
established, and the staff felt this enhanced the level of care they provided to their patients.  
By the end of the two month timeframe, the team had a good understanding of what the 
role of the pharmacist was in the above listed areas.  It was suggested, had the study been 
longer, the role would have been explored in greater depth.   
 In contrast, the staff members were unsure with what should be the direct patient 
care role for the pharmacist.  They acknowledged the primary health care role with patients 
was to provide drug information – particularly with correcting patients’ inaccurate 
perceptions about medications, offering reassurance by reinforcing the recommendations of 
other health care providers, and empowering patients to make decisions around medication 
use.  Yet, the short study duration appeared to inhibit the development of a clearly defined 
role and there was some uncertainty surrounding the degree of involvement a pharmacist 
should have with patients.  Some staff members were also unable to identify patients to refer 
to the pharmacist within this timeframe. 
 There was also some uncertainty surrounding the roles of the researcher, the clinical 
pharmacist and team members.  Role ambiguity surfaced at times, as the researcher was also 
the clinical pharmacist, as well as a previous employee at the Student Health Centre in 
health education.  Role overlap between the pharmacist and the physicians/nurse 
practitioner was brought forward in the areas of drug information and medication 
counselling.  The staff members noted that their own roles may change when a new health 
 104 
care professional is added to their team.  However, they also highlighted that roles would 
evolve over time and the pharmacist’s role would become better defined.  The 
generalizability of the study was questioned by the staff, due to the researcher also 
functioning as the clinical pharmacist.  As well, the staff wondered if the attributes they 
valued in a pharmacist – i.e. knowledgeable, diligent, thorough, professional courtesy and 
communication skills, were generalizable to other pharmacists. 
The staff identified several process related issues during the focus group discussions.  
Offering co-located and full-time clinical pharmacy services increased the level of service for 
the patients, along with enhanced accessibility for the staff. The patient referral process, 
however, needed to be further defined to ensure that staff could identify patients to be 
referred to the pharmacist. 
 As eluded above, the duration of the study was a limitation.  Another limitation, 
identified by the staff members, was the patient population.  In particular, the narrow 
patient demographics, the timing of the study in relation to the patients’ academic 
schedules, and the lack of patient buy-in to see a clinical pharmacist were noted by the team.  
Funding and space were also brought forward as limitations. 
 
3. What recommendations can be provided to support the integration of pharmacists 
onto primary health care teams? 
The recommendations provided by the Student Health Centre team, for facilitating 
future integrations of pharmacists into primary health care teams, are used to answer the 
third research question.  Their comments, along with some of my own – based on my 
experience, form the following guide for integrating pharmacists into already established 
primary health care teams.  As highlighted earlier, our study involved a specific primary 
health care team and pharmacist; however, our recommendations are transferable to other 
pharmacists and primary health care settings. 
 
1. Choose a collaborative process to assist with the integration of a pharmacist into a 
health care team, such as action research.  Apply the framework throughout the 
integration process. 
2. Select a primary health care team. 
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a. Find a health care team that will welcome and support a clinical pharmacist 
as a new member of their team. 
b. Identify how resources – such as funding and space, will be generated for the 
expansion of the team.   
3. Define the role of a pharmacist with the primary health care team prior to joining the 
team. 
a. Analyze the health centre’s patient demographics to identify what pharmacy 
services are required. 
b. The pharmacist should share with the team their vision of how they see their 
role. 
c. Educate the health care team on the diverse functions a clinical pharmacist 
can be responsible for.  Bring in established primary health care pharmacists 
to discuss their role and how it compliments their team. 
d. Encourage the health care providers to think big and outside of the box when 
creating the role of the pharmacist – emphasizing the difference between 
dispensing and clinical roles. 
e. Have the team identify treatment gaps within their current services, and 
identify how a pharmacist could enhance the level of care patients receive. 
f. Create a list of projects for the pharmacist to work on when not occupied with 
patient consultations or drug information questions. 
g. Develop a job description or policies/procedures to ensure the expectations of 
both the pharmacist and health care team are clearly defined. 
4. Determine the logistics of the pharmacist providing direct patient care with the 
health care team.  Again, this should be accomplished before the pharmacist joins the 
team. 
a. Decide whether the pharmacy services will be available on a full-time or part-
time basis. 
b. Discuss how patients benefiting from a pharmacy consultation will be 
identified. 
c. Develop a process for referring patients to the pharmacist.  Ideally the 
pharmacist would be available to patients via appointment or walk-in basis. 
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d. Ensure the pharmacist has access to office space and administrative support. 
e. Construct a plan to advertise the clinical pharmacy services to the patients. 
5. Once the pharmacist officially joins the team, the first priority should be to establish 
credibility with the health care team.  Answering drug information questions and 
completing medication-related projects for the team will assist with this process. 
6. Conduct patient consultations as the referrals arise.  Be patient as the volume of 
referrals take time to gain momentum.  As you establish credibility with the team as 
a drug information resource, they will feel more comfortable with inviting you to 
participate in their patients’ care. 
7. Depending on the integrative approach you selected, follow the framework to revisit 
and redefine the role of the pharmacist, with the team, as it evolves.  In addition, the 
pharmacist’s original vision for their role (refer to step 3c) should be reviewed and 
evaluated to determine if alignment between the desired and created role exist.   
8. Gather patient feedback to identify areas that require improvement. 
 
5.3 Major Research Findings 
1. The primary health care team involved in the study welcomed and supported the 
idea of having a pharmacist join their team.  They were interested and curious as to 
what a pharmacist could offer them.  However, the team was also unsure what the 
exact role of the pharmacist would be, how well the pharmacist would be utilized 
and whether the utilization of this new team member was being conducted in an 
appropriate manner. 
 
2. Being a drug information resource for both the staff members and patients was 
one of the responsibilities for the pharmacist, and aided the pharmacist with 
establishing credibility with the staff members. The staff was impressed with the 
quality of the drug information services, as they felt it was conducted in a thorough, 
objective and efficient manner.  However, despite acknowledging the provision of 
drug information to patients was valuable – especially with the Student Health 
Centre patient population keen to learn about their medications, the staff was unsure 
to what extent the pharmacist should provide direct patient care. 
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3. Two months is an adequate timeframe for a clinical pharmacist to demonstrate 
added value, as a support to the staff, when added to a primary health care team.  
This support took the form of answering drug information questions, completing 
medication related projects requested by the staff, and being available for patient 
consults; however it was primarily based on non-direct patient care activities as two 
months was not enough time to develop a direct patient care role.  The amount 
accomplished by the clinical pharmacist, along with the staff becoming cognizant of 
what a clinical pharmacist can offer, assisted in this process.  However, the team also 
recognized that the impact and exploration of the pharmacist’s role was limited by 
the study duration.  This finding may be a useful benchmark for pharmacists when 
evaluating their impact on a team, as they can strive to establish a role as a support to 
the staff within an eight-week time frame.   
 
4. Concerns regarding role ambiguity for the pharmacist, as well as role overlap 
between and role evolution for the pharmacist and primary health care team, 
surfaced during the project.  The staff sometimes found it difficult to separate my 
roles as clinical pharmacist, researcher and previous Health Education Coordinator 
Assistant.  They acknowledged that the role of the pharmacist would evolve with 
time, and noted that individual team members’ roles may also change when a 
pharmacist is added to their staff. 
 
5. Having a pharmacist who is knowledgeable, diligent, and thorough; extends 
professional courtesy to co-workers; and displays good communication skills is 
valued by a primary health care team.  These attributes were identified by the staff 
as being important, however they did question whether all pharmacists have these 
character traits.   
 
6. Offering co-located clinical pharmacy services provided the staff and patients 
with greater accessibility to a pharmacist and an enhanced level of clinical 
pharmacy services.  As such, the pharmacist was available to answer questions and 
conduct patient consults as the need arose and in a timely fashion.  However, 
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resources such as funding and office space need to be addressed prior to hiring a 
clinical pharmacist.  
 
7. Using an integrative approach that fosters collaborative relationships and 
provides opportunities to establish credibility with the primary health care team – 
like action research, has a greater effect on expanding the role of pharmacists than 
the patient population.  The process used to integrate a pharmacist into an already 
established primary health care team is more important than the perceived 
opportunities or limitations with the patient population.  However, the patient 
population should be taken into consideration prior to defining the role of a clinical 
pharmacist and still has the ability to influence the initiative.   
 
8. Good communication between the pharmacist and primary health care team was 
essential for defining, implementing and evaluating the role of the pharmacist.  
Scheduled formal meetings, along with informal conversations, provided the staff 
with multiple opportunities to reflect and comment on the role that was created.   All 
project ideas were discussed between the pharmacist and key players during the 
initial stages, and feedback was obtained throughout the initiatives until a final copy 
was produced.  Having the pharmacist provide debriefing – both verbal and written, 
to the referring staff member after patient referrals was also appreciated by the team. 
 
9. Direct patient care opportunities take time to gain momentum.  Adding a new 
health care professional to a primary health care team requires a process change, and 
the staff needs time to adapt to this additional available service.  In addition, the 
team members were able to generate several drug information questions for the 
pharmacist, however not all could identify patients who would benefit from a 
pharmacist interaction within the two month study duration. 
 
10. A template outlining a series of steps to facilitate the integration a pharmacist 
into an already established primary health care team has been proposed.  These 
guidelines are based upon the experiences of and recommendations brought forward 
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by the primary health care team and clinical pharmacist involved in the study.  The 
suggested framework can be tailored to suit the needs and structure of any primary 
health care team.  Some of the recommendations were not tested during the project 
(e.g. bringing in established primary health care pharmacist to describe their role, 
advertising the clinical pharmacy services, etc.) but were based on practical 
considerations that the staff felt would aid with the integration process. 
 
5.4 Implications for Pharmacists and Primary Health care Teams 
The purpose of this study was to provide guidance on how to integrate a pharmacist 
into a primary health care team.  As mentioned in the introduction, pharmacists within the 
province of Saskatchewan see value in expanding the profession into primary health care.4  
However, limited experience with team establishment and no clear understanding of the 
role of pharmacists on primary health care teams were identified as barriers.4  Investigating 
team establishment is beyond our study, as current literature suggests that a minimum of 
four months is required for the development.25  Our results, on the other hand, allow us to 
propose a template to assist with defining the role of a pharmacist, as well as tailoring the 
role to suit individual primary health care teams.  In addition, the proposed template may 
also be beneficial to health care teams who are interested in expanding their 
multidisciplinary service to include clinical pharmacists.   
 
5.5 Limitations 
The principal limitation with our study was the timeframe for the pharmacist to 
provide clinical pharmacy services at the Student Health Centre.  The short study duration 
of two months constrained the possible impact the clinical pharmacist may have had on the 
primary health care team.  In addition, the staff members were unable to fully explore the 
potential opportunities and roles that could be taken on by a clinical pharmacist.  The time 
period had a definite impact on the direct patient care role for the pharmacist, as there was 
insufficient time to develop a clear role.  Some of the team members were unable to identify 
patients to refer to the pharmacist over the two month period.  As well, time is required for 
staff to implement a process change – such as referring patients to a health care professional 
who is new to the team and functioning in a role that is novel to them.  
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Another limitation was the patient population.  The Student Health Centre provides 
health care services to a fairly narrow patient demographic.  The majority of patients are 
relatively young healthy adults; suffering from few chronic conditions, and requiring 
minimal medications compared to other primary health care centres.   Because the study 
involved university students, academic schedules and the demands of post-secondary 
education also affected the number and level of participation by patients.  The study was 
conducted at the end of the first school term – a time when patients are occupied with 
completing their course work, writing final exams, and possibly heading home for the 
holidays.  In addition, the Student Health Centre patients often want health care to be 
provided in a quick and convenient manner.  Some patients were unwilling to meet with a 
pharmacist, as that required booking an appointment with yet another health care 
professional.  Despite our best attempts, we were unable to obtain patient feedback on 
meeting with a primary health care pharmacist. 
An important limitation of this study was my dual role as a researcher and a clinician. 
This may have introduced some bias in my decision making as a researcher.  For example, 
if these roles were carried out by two individuals, the researcher would have likely included 
the two patients suffering from a Borderline Personality Disorder in our on-line focus group.  
However as a pharmacist I likely let my biases dictate who would be included in the 
evaluation of the services I provided.  I also had previous working relationships with some 
of the Student Health Centre staff, and these members were familiar with my work ethic and 
personality.  Concerns regarding the generalizability of the study were identified by the team 
based on my dual roles and they questioned whether all pharmacists would perform at the 
same level. Due to this potential role conflict, it was essential to reduce any bias when 
analyzing the data collected from the focus group discussions.  This was achieved by having 
two researchers, Dr. Neubauer and I, code the transcripts independently and then discussing 
the results to ensure we agreed on the findings.  
There is a large number of part-time staff employed at the Student Health Centre.  This 
made it difficult for some staff to attend the meetings we held at the Centre for the purpose 
of discussing the project and defining, reflecting on and evaluating the role of the 
pharmacist.  In addition, the part-time staff had less contact time and opportunity to work 
with the clinical pharmacist.  Lastly, resources – such as funding and space, may exist as 
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barriers for integrating a pharmacist into an already established primary health care team.  
However, for our study, these issues were not addressed as the clinical pharmacy services 
were provided in exchange for participating in the project and office space was only required 
for a two month period. 
 
5.6 Future Research 
Our study offers direction on how to incorporate pharmacists into primary health care; 
however additional research into other areas would expand on our findings and further 
assist with the expansion of pharmacy into primary health care.  First - due to the study 
duration, we were unable to investigate or provide guidance on how to achieve team 
establishment which has been identified as a barrier for pharmacists who are interested in 
primary health care.4  Second, our initiative investigated the integration of a pharmacist into 
a primary health care team – not the sustainability.   It would be advantageous to identify 
how to maintain clinical pharmacy services once they are established.  Third, it would be 
valuable to explore in greater detail whether establishing credibility with a primary health 
care team via drug information services and support is required before a direct patient care 
role for a pharmacist can be developed.  Fourth, capturing patient feedback on how they felt 
when meeting with a pharmacist in this relatively novel role would be beneficial.  As 
discussed already, we attempting to gather this data, but unfortunately we were 
unsuccessful.  Insight into the above areas of research could contribute to and promote an 
expanded clinical role for pharmacists in primary health care, which would be beneficial to 
the profession of pharmacy as well as the evolution of primary health care. 
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Appendix II: Email Invitation to Primary Health care Pharmacists  
 
Dear Colleague,  
 
Dr. Fred Rémillard and I are co-supervising a graduate student, Lynette Kolodziejak, 
working toward her Master of Science (Primary Care). We are investigating how to 
integrate a pharmacist into an already established primary health care team and require your 
expertise. There are three phases to the study: 1) defining the role of the pharmacist, 2) 
implementing the purposed role, and 3) evaluating and prioritizing the implemented role.  
 
For the first phase of the study, we are seeking pharmacists who:  
1) Have established themselves on Canadian primary health care teams; 
2) Were the first pharmacist to join their primary health care team;  
3) Are willing to share their experiences with primary health care teams using an 
on-line focus group; and 
4) Are willing to complete a survey regarding the use of an on-line focus group. 
  
Would you be interested in participating in an on-line focus group to help create a 
prioritized list of possible clinical pharmacy activities tailored specifically for the Student 
Health Centre at the University of Saskatchewan (the primary health centre chosen for the 
project)?   
 
The on-line focus group will be accessible for three weeks this summer, likely during the 
months of August and/or September, 2006.  New discussion questions will be posted every 
week during the three week period.  Participants will be asked to log onto the website to 
read responses and post replies at least once a week.   
 
Pharmacists from across Canada are being asked to participate.  Due to different time 
zones, the on-line focus group will not be live, and therefore you can log onto the website 
whenever is convenient for you.  The total time required to participate is estimated at 3-4 
hours over the three weeks.  An activity log will be kept electronically to assess how often 
participants log on and the time spent during each visit.  At the end of the three week 
period, participants would also complete a survey regarding their experience with an on-line 
focus group.  For your participation, we would like to offer you a $50 honorarium to 
partially compensate you for your time.  
 
You will be receiving a follow-up letter in the mail regarding this opportunity.  If you are 
interested in learning more about this study, please contact me for additional details.  The 
project has been submitted to ethics for approval from the Behavioural Research Ethics 
Committee of the University of Saskatchewan. 
 
Thank you for your consideration, 
 
Shannan Neubauer, BSP, PharmD 
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Appendix III: Information Package for Primary Health and Ambulatory Care 
Pharmacists Participating in On-Line Focus Group 
 
 
 
College of Pharmacy & Nutrition 
 
 
 
Integration of a Pharmacist into a  
Primary Health care Site 
A Qualitative Approach 
 
 
 
Information for the Primary Health/Ambulatory Care 
Pharmacists Participating in Phase I of the Study 
August, 2006 
 
 
 
PRIMARY INVESTIGATORS: 
Lynette Kolodziejak, BSP, MSc (Candidate) 
Dr.Shannan Neubauer, BSP, ACPR, PharmD, FCSHP 
Dr. Alfred Rémillard, BSc (Pharm), PharmD, BCPS 
 
 
RESEARCH COLLABORATORS: 
Dr. Roy Dobson, PhD 
Dr. Shawna Berenbaum, PhD 
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Primary Health/Ambulatory Care Pharmacist 
Consent Form 
 
You are invited to participate in a study entitled:  Integration of a Pharmacist into a Primary 
Health care Centre 
 
Purpose of the Study: 
The purpose of this study is to identify how to integrate a clinical pharmacist into an already 
established primary health care team.  There are three phases to the study: 1) defining the 
role of the pharmacist, 2) implementing the proposed role, and 3) evaluating and prioritizing 
the implemented role.  You are being asked to participate in the first phase of this study 
because of your experience as a primary health/ambulatory care pharmacist.   
 
You have agreed to participate in an on-line focus group to help create a list of possible 
clinical pharmacy activities tailored specifically for the Student Health Centre at the 
University of Saskatchewan.  In addition, you can also fill out a survey regarding your 
experience with using an on-line focus group.  
 
Procedures:  
The on-line focus group will be accessible for three weeks during the month of September, 
2006.  New discussion questions will be posted every week during the three week period.  
You will be asked to log onto the website to read responses and post replies at least once a 
week.  Since pharmacists from across Canada are being asked to participate, resulting in 
different time zones, the on-line focus group will not be live.  You can log onto the website 
whenever is convenient for you.  The total time required to participate is estimated at 3-4 
hours over the three weeks.  An activity log will be kept electronically which will assess how 
many postings are read and the number of responses posted per each participant.  
Instructions for using the on-line website are providing in this information package (refer to 
pages 9 & 10). 
 
Potential Risks:  Due to the fact that the participants for this focus group have been selected 
from the same professional group, some of whom are known to each other; it is possible that 
you may be identifiable to other people on the basis of what you have posted. After the 
focus group discussion, and prior to the data being included in the final report, you will be 
given the opportunity to review the transcripts from the focus group, and to add, alter, or 
delete information from the transcripts as you see fit. 
 
Potential Benefits:  Although not guaranteed, the results of this study will provide guidance 
to other pharmacists who are interested in joining primary health care teams.  
 
Storage of Data:  The data, in both electronic/hardcopy formats, will be stored in a 
password protected computer/in a locked file cabinet in the office of one of the researchers 
(Shannan Neubauer), 219 Thorvaldson Building, University of Saskatchewan, for a period 
of five years. 
 
 122 
Confidentiality: The transcripts will be analyzed for themes and will be reported in 
aggregate form, so that it is not possible to identify individuals.  The researchers may use 
direct quotations in the publication; however, the speaker will not be identified by name or 
practice site.  The researchers will undertake to safeguard the confidentiality of the 
discussion, but cannot guarantee that other members of the group will do so.  Please respect 
the confidentiality of the other members of the group by not disclosing the contents of this 
discussion outside the group, and be aware that others may not respect your confidentiality.  
 
Right to Withdraw: You may withdraw from the study for any reason, at any time, 
without penalty of any sort.  If you withdraw from the study at any time, any data that you 
have contributed will be destroyed.  You have the right to refuse to answer any question(s) 
posed by the facilitator.  The $50.00 payment will be prorated if you choose to withdraw 
from the study. 
 
Questions: If you have any questions concerning the study, please feel free to ask at any 
point; you are also free to contact the researchers at the numbers provided below if you have 
questions at a later time.  This study has been approved on ethical grounds by the University 
of Saskatchewan Behavioural Sciences Research Ethics Board on July 28, 2006.  Any 
questions regarding your rights as a participant may be addressed to that committee through 
the Office of Research Services (966-2084).  Out of town participants may call collect.   The 
results of the study will be used to partially complete the requirements for a Masters of 
Science (Primary Care) degree through the College of Pharmacy and Nutrition.  
Furthermore, the results may be published and/or presented at in-
services/seminars/conferences.   
 
Consent to Participate:  Please note that logging on to the website and posting responses to 
the on-line focus group questions will be considered as providing consent, and as such, you 
are granting the researchers permission to use the data gathered in the manner described.  
Retain this document for your own records. 
 
Researchers: 
Shannan Neubauer, BSP, PharmD       Alfred Rémillard, BSc (Pharm), PharmD, BCPP 
Associate Professor of Pharmacy       Professor of Pharmacy 
College of Pharmacy & Nutrition       College of Pharmacy & Nutrition 
University of Saskatchewan        University of Saskatchewan  
Phone: 306-966-6332        Phone: 306-966-6345 
Email: Shannan.Neubauer@usask.ca       Email: AJ.Remillard@usask.ca 
 
Lynette Kolodziejak, BSP 
MSc Candidate 
College of Pharmacy & Nutrition 
University of Saskatchewan 
Phone: 306-966-6346 
Email: Lynette.Kolodziejak@usask.ca 
 
Please feel free to contact any of the listed researchers with questions or comments. 
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Background Information on the Student Health Centre 
 
CITY OF SASKATOON 
Saskatoon is centrally located in Saskatchewan and is the largest city in the province with a 
population of 206,900.  There are approximately 305 family physicians practicing in Saskatoon 
District, and of those, 25 family physicians are currently accepting new patients.  The University of 
Saskatchewan is situated in the city of Saskatoon. 
 
UNIVERSITY OF SASKATCHEWAN 
The University of Saskatchewan’s layout is unique in the sense that the entire campus is located in 
the same area of Saskatoon, versus dispersed throughout the city.  Therefore, students can easily 
access the numerous services which are available to them on campus.  In 2004-2005, the total 
student headcount was 19,763 (15,707 full-time and 4.056 part-time) and of those, 1,825 students 
self-declared Aboriginal ancestry.  Approximately 56% of students are female (n=11,160) and 46% 
are male (n=8,603).  Of the 16,915 undergraduate students, only 5,551 lived in Saskatoon prior to 
starting school.  
 
Table 1: Age Distribution based on U of S Registration Status for 2004-2005 
Registration 
Status 
N Mean Age Minimum Maximum 
Undergraduate 16,915 23 16 82 
Graduate 1,969 31 20 67 
Post-graduate 221 31 23 52 
Non-degree 658 36 17 69 
 
STUDENT HEALTH CENTRE 
The Student Health Centre at the University of Saskatchewan has been selected as the 
primary health care centre for this project.  The Centre received its primary care designation 
in March 2000 and is one of eight primary care sites within the Saskatoon Health Region.  
They provide comprehensive health care services to students registered at the university and 
their families.  The Centre does not offer services to university staff or faculty. 
 
Primary Health care Team 
The team includes a variety of health care professions including: 
• Manager – 0.6 position 
• Registered Nurses – two full-time positions (filled by four part-time nurses) 
• Nurse Practitioner – one full-time 
• Physicians – 3.2 positions (filled by two full-time, one part-time and two casual 
physicians) 
• Psychiatrists – 0.5 position (filled by three part-time psychiatrists) 
• Internal Specialist – one half day per week 
• Obstetrician/Gynecology – one half day per week 
• Orthopedic Surgeon – one half day clinic each month 
• Dietitian – one dietitian who works four half days per week 
• Social Worker – 0.5 position 
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• Massage Therapist – three half days per week from September to April 
• Chiropractor – two half days per week from September to April 
• Health Educator – 1.1 position (filled by two part-time Health Education Coordinators) 
 
To date, a pharmacist has not been incorporated onto the primary health care team. 
 
Needs Assessment Survey 
In 2003, the Student Health Centre conducted a Needs Assessment survey to update their data on 
student health behaviour and knowledge (original survey conducted in 1997), to obtain more 
demographic data and to evaluate their current services.  Students were surveyed on mental health, 
alcohol and drugs, sexual health, sexual assault, nutrition and physical fitness, and service 
utilization.  Please note that the following information is based on a survey of 1279 University of 
Saskatchewan students, not solely Student Health Centre patients.  However, the results help to 
identify the needs of the student population.  Relevant data are as follows: 
 
Mental Health: 
• 64.8% of females and 35.2% of males indicated that they were highly stressed or 
overwhelmed.   
• The top sources of stress were academic performance, class load and finances. 
• There was a statistical significance between the number of years spent in university and 
overall stress levels.  Those who had spent more years in university tended to have higher 
stress levels. 
• 20% of students stated that they had talked to a health care professional regarding a 
mental/emotional issue within the past year. 
• Approximately 5% had made previous suicide attempts. 
 
Sexual Health: 
• 72.4% had engaged in sexual intercourse within the past 12 months.  32% had more than one 
partner 
• 16% of students indicated they were not using any method of contraception.   
• Of the students using contraception, birth control pills were the most common (38%) and 
male or female condoms were the second most common (30%) 
• 11.3% had used the morning after pill once, and 3.4% more than once. 
• 31% stated that they always use condoms. 
• 9.5% females & 6.5% males had one unplanned pregnancy.  2.6% females & 2.7% males had 
more than one unplanned pregnancy.  54.1% of pregnant females either aborted or 
miscarried. 
 
The Student Health Centre offers several services geared towards the Needs Assessment findings, 
such as employing three psychiatrists to fill a half-time position, a Contraception Counselling 
program, and a volunteer group of peer health educators to educate and motivate students towards 
optimal health.   
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Summary of Services Based on Billing Codes 
Table 2: Summary of the Number of Physician Visit Services by Diagnosis at the 
Student Health Centre 2005-2006 
Most Frequent Individual Diagnoses 
Diagnosis Number of Visits  
Depressive Disorder 1056 
Contraception Management 585 
Neurotic Disorders 490 
General Medical Examination 449 
Seeking Consultation without Complaint 
or Sickness 
345 
Affective Psychoses 341 
Acute Pharyngitis 239 
Normal Pregnancy 222 
Disorders of skin & subcutaneous tissue 203 
Acute Nasopharyngitis (common cold) 203 
Most Frequent Blocks of Diagnoses 
Neurotic, Personality and other 
Nonpsychotic Mental Disorders 
1956 
Health Services related to Reproduction 
& Development 
843 
Acute Respiratory Infections 824 
Diseases of the Skin & Subcutaneous 
Tissue 
738 
Symptoms of Ill-Defined Conditions 570 
Injury & Poisoning 536 
Diseases of the Genitourinary System 515 
Persons without reported diagnosis 
encountered during examination & 
investigation of individuals & 
populations 
462 
Note: In-province beneficiaries only.  Physicians and insured fee-for-service billing codes only. 
Table 3: Discrete Patient & Number of Services for 2005-2006 
 In-province Out-of-province 
Discrete Patients 2,891 793 
Number of Services 13,680 2,559 
Note: Does not include massage therapy, obstetrician/gynecology or orthopedic clinic patients. 
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Hours of Operation 
From September to April, the Centre is open Monday to Friday from 8:30am-4:30pm, with 
the exception of starting at 9:30am on Thursday (staff meeting held between 8:30-9:30am 
that morning).  During the months of May to August, the Centre closes over lunch, between 
12:00-1:00pm. 
 
Health & Dental Plan 
All full-time University of Saskatchewan students are automatically covered by a Health & Dental 
Plan through either the undergraduate or graduate student society.  Part-time students have the 
option of enrolling.  Spouses and dependants (under 21 years of age or 25 if still attending school) 
may be enrolled in the program by paying an additional family coverage fee.  The plan includes a list 
of comprehensive services.  Two very relevant services are: 
Prescription Drugs:  The Health plan covers 80% of prescription drugs costs, listed in the 
Saskatchewan Formulary. 
Health Practitioners:  The Plan will cover the cost of a physiotherapist, chiropractor, 
psychologist, naturopath, osteopath, registered dietitian, podiatrist/chiropodist, athletic 
therapist, speech therapist and massage therapist for a maximum of $20 per visit, $400 per 
category of practitioner per policy year.  A referral by a physician or nurse practitioner is 
required for registered dietitians and a massage therapist. 
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WebCT® On-Line Focus Group for Pharmacists 
 
Thank you for agreeing to participate in our on-line focus group.  Below are some key points to 
review before starting.  On the reverse side are instructions for using WebCT®. 
 
• The website will be available starting Sunday, September 3rd at 6:00am and will close Saturday, 
September 23rd at midnight (central time). 
• You will need your NSID and password to log in to the website. 
• Please log onto the website at least once a week to respond to the questions and other postings.  
The moderator will check the website on a daily basis to facilitate the discussion.  New questions 
will be posted on a weekly basis. 
• The focus group discussion is not live, therefore you can log onto the website whenever it is 
convenient for you, and as often as needed. 
• Avoid using the ? Back  button when using WebCT®.  Instead, use the breadcrumb trail, 
Course Menu or Select Topic menu to navigate through the website (see next page for more 
information).  
• You will not be able to change any of your responses; however, you may clarify a statement by 
posting another response during the one week period. 
• To ensure the discussion remains focused, please do not compose your own messages.  Instead, 
only post replies to the questions posted by the moderator and/or other participants’ comments. 
 
Problems or Concerns with WebCT® 
• If you experience any technical problems with the website, please contact the University of 
Saskatchewan’s Information Technology Services Help Desk. You will need to provide them 
with your NSID. 
o On campus: Room 70 Arts Building, Monday-Friday 8am-5pm (central time). 
o Phone: 966-4817 (toll free 1-800-966-4817), Monday-Friday 8am-5pm (central time). 
o Email: help.desk@usask.ca 
• If you have any questions regarding using WebCT®, you can try searching for an answer using 
the Help menu. 
• If you have any questions, comments or concerns regarding the on-line focus group, please feel 
free to contact Lynette via email: Lynette.Kolodziejak@usask.ca  
 
WebCT® Icons and Definitions 
 Focus group question      Read the previous reply 
 A message you have not read yet     Read the next reply 
 A message you have read       Show all postings for a question 
 A posted reply to a question or comment       Hide all postings for a question 
     
 Display: All  Unread    Threaded  Unthreaded    Select topic:  
All   Displays all of the messages that have been posted.  If it appears as though some 
messages are missing from your list, ensure that Display All has been selected so that 
all postings are displays. 
Unread   Only displays messages that you have not read yet. 
Threaded   Displays postings by question. 
Unthreaded   Displays postings by date.  
Select topic Move to another focus group question. 
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Instructions for Using WebCT® 
 
1. Open your internet browser (Internet Explorer preferred). 
 
2. Proceed to http://webct.usask.ca. 
 
3. Click ‘Log In to MyWebCT’. 
• If you are unable to log in, click on Having Trouble? below the log in link. 
 
4. Enter your WebCT identification number and password (use your NSID username and 
password).  Click Log In  
 
5. Select On-Line Focus Group for Pharmacists. 
 
6. Read through the information.  When you are ready to view the focus group questions, 
select the ‘Discussions’ icon: 
  
 
 
         Discussions 
 
7. Click on Question #1.  To read the question posted by the moderator and all the responses 
posted by other participants to date, click on .   
• You can also view individual postings by clicking onto them directly. 
 
8. To post a reply, click the Reply button.  Type your response in the box, and then click Post. 
You can post a reply to the focus group question, or to another participant’s response.  
 
9. After you have posted a reply, click the Update Listing button.  If you forget this step, your 
posting will not be visible during your current visit. 
 
10. To return to the other questions, you may use any of the three options: 
a) Use the breadcrumb trial, along the top of the screen, and click Discussions: 
Homepage > Discussions > Question #1 
 
b) Use the Course Menu, along the left-side of the browser, and click Discussions. 
 
c) Use the Select topic pull down menu.   
 
Select topic:  ? GO 
                             
     Click the l?l to access the pull down menu options.  Select the question you would like 
to view and click GO    
 
11. Continue to read all of the questions posted for the week and the other participants’ 
responses, and post your own comments. 
 
12. Once you are ready to leave the website, please remember to log off (located along top of 
webpage).   
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Focus Group Questions  
 
     WEEK #1 
 
Opening Question 
1. Tell us what type of primary health/ambulatory care team you work on (for 
example: family medicine, women’s health, etc) and how long you have been on the 
team. 
 
Introductory Question 
2. Tell us about your role on the health care team.  Think about what you do with or 
for patients, for the practice or for the team. 
 
Transition Statement 
During the second week, you will be asked to identify clinical pharmacy activities that could 
be implemented at the Student Health Centre.  Once you have created a list of clinical 
pharmacy activities, you will then be asked to prioritize that same list.  Please refer to the 
Background Information on the Student Health Centre section in your information package to 
help tailor your suggestions for the primary health care team and needs of the patients.   
 
WEEK #2 
 
Key Questions 
3. Based on the Student Health Centre demographics and needs of their patient 
population, what clinical pharmacy activities do you think should be offered? 
4. In what order would you prioritize the suggestions you gave for Question #3. 
 
Transition Statement 
During the third and final week, a list of the recommended prioritized clinical activities, 
based on the focus group discussion, will be posted by the moderator.  You will asked be to 
review the list and ensure it is an accurate representation of what was discussed.  Once you 
have answered the last focus group question, you will then be asked to complete a short on-
line survey based on your experience with using an on-line focus group. 
 
WEEK #3 
 
A list of the recommended prioritized clinical activities, based on the focus group discussion 
will be posted. 
 
Ending Question 
5. Do the identified clinical activities capture what was discussed in the focus group? 
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-----------------------FOR YOUR INTEREST ONLY------------------------ 
 
Background Information on the Research Study 
 
INTRODUCTION 
Over the past five years, several government officials – such as Commissioner Fyke and 
Commissioner Romanow, along with the Saskatchewan’s Pharmacy Coalition on Primary 
Care, have released documents regarding the underutilization of pharmacists on primary 
health care teams.1, 2, 4  However, to date, there are no published articles discussing the 
actual implementation process of a pharmacist into a primary health care site.  Until 
literature is available highlighting solutions to these concerns, as well as guidance on how to 
successfully integrate a pharmacist into a primary health care site, the profession of 
pharmacy may be unable to advance towards this opportunity. 
 
There are numerous quantitative studies in the literature which have portrayed the positive 
impact pharmacists have on patient care,26, 27, 31-33, 35, 44, 61 the favourable impressions that 
physicians and nurses have towards clinical pharmacist’s interventions,26, 31, 35, 36, 62 and the 
satisfaction patients have expressed regarding their interactions with clinical pharmacists.26, 
63  However, no studies have tried to capture the social aspect of how this positive impact on 
patient care is created or relationships are formed.  Therefore, a qualitative approach was 
selected as the research methodology for this project. 
 
Primary Health care Centre 
The Student Health Centre at the University of Saskatchewan has been selected as the 
primary health care centre for this project.  The manager of the Centre informally presented 
the project to the team during a staff meeting.  The team welcomed the idea, however 
because they had never worked with a clinical pharmacist, they were unable to envision 
how a pharmacist could be incorporated into their team.   
 
Since the Student Health Centre staff is uncertain as to what the role of a pharmacist could 
be, pharmacists who have already established themselves on primary health/ambulatory 
care teams will be consulted to help tailor the clinical pharmacy activities for the Centre.  
Bringing experts together, in this manner, has also been used by nurse practitioners for 
establishing their role in primary health care.23, 24  To establish consensus amongst these 
specialists, focus groups can be used.53 
 
PHASE I: DEFINING THE ROLE OF A PHARMACIST 
To aid with successful integration onto a health care team, the new team member’s role, 
responsibilities, and timing of the care need to be clearly defined prior to joining the team.  
This process should be a collaborative effort put forth by all members of the team.16, 17  Role 
conflict, role overload, and variable acceptance for the new team member can result when 
there is a lack of role clarity and inconsistent expectations.  In addition, dissatisfaction 
within the team can occur when uncertainty with a job description – i.e. role ambiguity, 
exists.18   
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To provide optimal care, primary health care teams should assess and evaluate the health 
needs of their patient population, and subsequently customize their services based on these 
needs.3  To tailor the clinical pharmacy activities based on these patient needs, it would 
seem logical to initiate discussion with those who know the population best - that is, the 
primary health care team. However, this can be very difficult and frustrating when the team 
has no clear understanding of the spectrum of activities that a clinical pharmacist can offer.   
 
The Seniors Medication Assessment Research Trial (SMART) is an excellent example of 
the above.  The study evaluated the collaboration between specially trained expanded role 
pharmacists and family physicians.  A major drawback for the pharmacists involved was 
that physicians did not recognize their full potential.  The physicians expected the 
pharmacists to stick specifically with investigations involving over-the-counter medications.  
In addition, the pharmacists could not discuss possible alternatives with patients as the 
physicians felt this would be a criticism on their performance.  This inhibited the 
pharmacists from having significant impact on patients’ drug therapy.  In addition, the 
pharmacists were not aware of occasions when physicians had unsuccessfully tried a 
particular therapy or plan because they were restricted from discussing therapeutic 
alternatives with patients.19  
 
Another study, conducted in California, investigated physician expectations of pharmacists.  
A questionnaire was used to capture physicians’ – office and hospital based, and medical 
residents’ current and future expectations, as well as their current experiences with 
pharmacists.  A total of 463 physicians (19.3% response rate) participated in the study.  The 
authors concluded that physicians do not know what to expect of pharmacists.  In addition, 
there was no correlation between the responses and practice setting.20 
 
If health care professionals do not realize the range of clinical activities that can be 
implemented or know what to expect from pharmacists, integration is jeopardized. 
Interdisciplinary teams report a increased awareness of each member’s role, however 
difficulties in defining the roles of professional groups may still exist.5 Another approach for 
defining the role of a pharmacist involves discussion with those who hold a similar role 
within another organization.  These colleagues can offer their expertise on how to establish 
activities based on the needs of the patient population.  In addition, establishing 
relationships with these key players can lead to further peer support in the future.21 
 
METHODOLOGY – PHASE I: DEFINING THE ROLE OF A PHARMACIST 
On-line focus groups have been used as a data collection tool in qualitative health services 
research.53, 55, 56  Like in-person focus groups, on-line focus groups have the advantages of 
obtaining a broader range of responses and elicitation of details that are not captured during 
individual interviews.57  Despite not having the participants physically in the same location, 
on-line focus groups are still able to create active engagement and group interaction.    
 
Both provincial and national pharmacists have been invited to participate in this stage of the 
study.  On-line focus groups will be the method used to extract information and formulate 
ideas from the geographically dispersed panel of pharmacists.  Focus groups will allow the 
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pharmacists to draw on their own experiences and discuss with colleagues a range of 
possible clinical activities that can be implemented at the Student Health Centre. 
 
RESEARCH QUESTION 
How can a pharmacist be integrated into an already established primary health care team?  
 
OBJECTIVES 
The study objective has been divided into three phases: 
 
Phase I: Define the role of the pharmacist. 
As discussed in the preceding pages. 
 
Phase II: Implementing the purposed role. 
Once the role of the pharmacist is clearly defined, one of the researchers (LK) will be 
providing two months of clinical pharmacy services for the Student Health Centre at the 
University of Saskatchewan.  All clinical activities and interactions will be documented.  
After one month, a team meeting will be held to discuss how the role of the pharmacist has 
been received by the staff to date.  The pharmacist’s role will be modified based on the 
recommendations that surface from the meeting. 
 
Phase III: Evaluate and prioritize the role of a clinical pharmacist.  
At the end of the two months of clinical services, focus groups will be organized with 
Student Health Centre staff, as well as with patients who had direct interaction with the 
clinical pharmacist.  Participants will be asked to reflect on their experience with having a 
clinical pharmacist on the primary health care team.  The purpose of the focus groups is to 
identify what went well, what did not and areas for improvement from all stakeholders’ 
perspectives.  The Student Health Centre staff focus groups will be face-to-face and 
moderated by an external facilitator.  The patient focus group will be conducted on-line. 
 
SIGNIFICANCE 
The role of the pharmacist that will be defined, implemented, evaluated and prioritized will 
be tailored to meet the specific needs of the primary health care centre chosen for this 
project.  However, the process could be generically applied to any other primary health care 
team.  Therefore, this study should provide guidance on how to integrate a pharmacist into 
a primary health care team or serve as a stepping stone towards other investigations. 
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Appendix IV: On-line Focus Group Questions for the Primary Health and Ambulatory 
Care Pharmacists 
 
     WEEK #1 
 
Opening Question 
1. Tell us what type of primary health/ambulatory care team you work on (for 
example: family medicine, women’s health, etc) and how long you have been on the 
team. 
 
Introductory Question 
2. Tell us about your role on the health care team.  Think about what you do with or 
for patients, for the practice or for the team. 
 
Transition Statement 
During the second week, you will be asked to identify clinical pharmacy activities that could 
be implemented at the Student Health Centre.  Once you have created a list of clinical 
pharmacy activities, you will then be asked to prioritize that same list.  Please refer to the 
Background Information on the Student Health Centre section in your information package to 
help tailor your suggestions for the primary health care team and needs of the patients.   
 
WEEK #2 
 
Key Questions 
3. Based on the Student Health Centre demographics and needs of their patient 
population, what clinical pharmacy activities do you think should be offered? 
4. In what order would you prioritize the suggestions you gave for Question #3. 
 
Transition Statement 
During the third and final week, a list of the recommended prioritized clinical activities, 
based on the focus group discussion, will be posted by the moderator.  You will asked be to 
review the list and ensure it is an accurate representation of what was discussed.  Once you 
have answered the last focus group question, you will then be asked to complete a short on-
line survey based on your experience with using an on-line focus group. 
 
WEEK #3 
 
A list of the recommended prioritized clinical activities, based on the focus group discussion 
will be posted. 
 
Ending Question 
5. Do the identified clinical activities capture what was discussed in the focus group? 
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Appendix V: Project Plan for the Student Health Centre 
 
Integration a Pharmacist into a Primary Health care Centre 
Project Plan for the Student Health Centre Staff 
 
Staff Meeting: Introduction of Study & Obtaining Consent 
All staff members are encouraged to attend an initial meeting with the researchers.  During 
this meeting, the researchers will introduce themselves to the staff, present the study, outline 
how the staff can contribute to the research and provide consent forms to those who are 
interested in participating in the study.   
• Meeting scheduled for: Monday, September 11th 12:00-1:00pm 
 
Staff Meeting: Defining the Role of the Pharmacist 
The staff members who are interested in the study will be invited to attend the second 
meeting.  During this time, the researchers will present data collected from a focus group 
involving primary health/ambulatory care pharmacists, which will highlight a list of 
possible clinical pharmacy activities that could be offered at the Student Health Centre.  A 
discussion between the researchers and staff members will then occur to identify which 
clinical pharmacy activities would compliment the existing services the best.  As a team, the 
role of the pharmacist will be discussed and defined, as well as the logistics of providing the 
services. 
• Meeting scheduled for: Thursday, September 28th 8:30-9:30am. 
 
Staff Meeting: Midpoint Meeting 
One of the researchers, Lynette Kolodziejak, will provide two months of full-time clinical 
pharmacy activities during the months of November and December, 2006.   At the end of 
the first month, another staff meeting will be held.  During this time, the pharmacist will 
present a summary of the clinical pharmacy activities that have been implemented thus far.  
Staff members will be encouraged to provide feedback on the pharmacy services that have 
been provided.   As a team, the role of the pharmacist will be discussed and modified to suit 
the needs of the primary health care team.   
• Meeting scheduled for: Thursday, November 23rd 8:30-9:30am. 
 
Focus Groups with the Staff 
During the month of January, 2007, focus groups will be organized with staff members to 
evaluate the integration of a pharmacist into an already established primary health care 
team.  The objective of the focus groups is to identify what went well, what did not and 
areas for improvement.  An external moderator will be contracted to facilitate the focus 
groups. 
• Focus groups will be scheduled closer to the date. 
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Appendix VI: Cover Letter to Student Health Centre Staff Who Could Not Attend the 
Initial Meeting 
 
 
 
Monday, September 11th, 2006 
 
 
Dear (name),  
 
 
Sorry that we missed you on Monday, September 11th, 2006, during a meeting we held with 
your coworkers at the Student Health Centre.  The purpose of the meeting was to introduce 
our study - investigating how to integrate a pharmacist into an already established primary 
health care team, as well as to obtain consent from those staff members who are interested 
in participating in the study.  Please find attached a copy of the PowerPoint presentation 
slides, program plan and the consent form.  All highlight what your role would be if you 
agree to participate. 
  
Another meeting, to define what my role on the team would be as a clinical pharmacist, will 
be held on Thursday, September 28th from 8:30-9:30am.  If you are interested in 
participating in our study, you are welcome to join us that morning.  Please bring your 
signed consent form to the meeting. 
 
If you require any additional information or have questions regarding the study, please 
contact either of my supervisors - Shannan Neubauer (email: 
Shannan.Neubauer@usask.ca), Fred Rémillard (email: AJ.Remillard@usask.ca), or myself. 
 
Thank you for your consideration. 
 
 
 
 
Lynette Kolodziejak 
MSc Candidate 
College of Pharmacy & Nutrition 
Email: Lynette.Kolodziejak@usask.ca 
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Appendix VII: Possible Clinical Pharmacy Activities Generated from On-Line Focus 
Group with Primary Health & Ambulatory Care Pharmacists 
 
How to Integrate a Pharmacist into a Primary Health care Centre 
Phase I: Defining the Role of the Pharmacist 
 
POSSIBLE CLINICAL PHARMACY ACTIVITIES 
 
1) Direct Patient Care: 
a) Mental Health - Psychiatric Medication Counselling & Monitoring 
• In-depth initial counselling sessions for a new medication or change in therapy. 
• Assist with continuity of care/developing guidelines for follow-up. 
• Follow-up to ensure/encourage compliance, efficacy of the medication, monitor for side 
effects, review lab data to prevent toxicity, identify & solve drug related problems, assess 
possible substance abuse issues and address lifestyle issues (proper nutrition, sleep). 
• Make drug therapy recommendations and provide drug information to 
physicians/psychiatrists. 
 
b) Management of Acute Illness  
• Over-the-counter medications for cough/cold/flu management. 
• Optimizing antibiotic use:  
o Ensuring appropriate choice of antibiotic - follow culture & sensitivity and provide 
suggestions if resistance to empiric therapy. 
o Provide follow-up - phone call to assess how patient is doing and encourage them 
to complete the full course of antibiotics. 
o Develop an antibiograms specifically for the Centre. 
 
2) Drug Information 
a) Team members 
• Literature searches on request and answering drug information questions. 
• Drug use in pregnancy & lactation. 
• Therapeutic updates. 
• Forum: presentations at rounds/meetings, email updates, bulletin boards. 
 
b) Individual Patient Education Sessions 
• To help them understand how their medications are linked with the condition(s). 
• Assist with compliance by identifying how medications administration times fit best with 
their lifestyle. 
 
3) Health Education/Promotion 
a)  Group Patient Education Sessions 
• Offer regularly, be consistent with time & place, select convenient times for students (e.g. 
evenings) and match topics with time of year when applicable (e.g. flu vaccination). 
• Collaborate with other team members and university groups. 
• Topics: sexual health options/contraception, depression & its treatment, weight control 
issues & agents, herbals, drugs of abuse, smoking cessation, travel information 
(vaccinations, travelers diarrhea, malaria), flu vaccinations, health/stress management. 
• Develop information materials on common illnesses & medications. 
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Appendix VIII: Student Health Centre Staff Memo Summarizing the Meetings 
 
Thursday, October 26, 2006 
 
Dear Student Health Centre staff: 
 
I will be starting at the Student Health Centre, as a clinical pharmacist for my Masters project, on 
Wednesday, November 1st.  Through the staff meetings we have had, my role will consist of a 
mixture of direct patient care and drug information for the staff.  For direct patient care, the 
following main areas have been identified for patient referral: 
• Psychiatric Medication Counselling and Monitoring 
o Examples: Counsel on new medication/change in therapy; follow-up to assess 
compliance, efficacy of medication, presence of side effects 
• Asthma 
o Examples: Counsel on device use; follow-up to assess compliance, efficacy of 
medication, presence of side effects. 
• Contraception 
o Examples: Provide supplemental care; discuss risks vs benefits of continuous vs 
cyclical oral contraception. 
• Patient Medication History 
o Examples: Medications that require therapeutic drug monitoring (lithium, 
carbamazepine, etc), frequent medication changes (>3 changes in past 12 months), 
herbal/complementary medications. 
 
Please note the above are examples and other referrals would also be accepted.  I have created a 
Patient Referral form to assist with the referral process.  When referring patients, please fill out the 
form and ask the student to take the form up to the front desk to book an appointment.  Walk-ins are 
also an option, in which case a verbal reason as to why would you like me to see the patient would 
suffice.   You can start referring patients as of today. 
 
Even though this is a study, the patients will not have to a sign consent form or be notified that this 
is a study prior to seeing me.  The relationship I develop with the patients is under investigation, 
which will be evaluated using focus groups at the end of the project.  If the patient agrees to 
participate in the focus group, they would then be provided with the consent form.  This process has 
been approved by the University of Saskatchewan Behavioural Sciences Research Ethics Board. 
 
As for drug information, the projects will include expanding information for the Contraception 
Counselling program, last minute travel concerns, medication use in athletes, herbals, and 
medications and alcohol consumption. 
 
Any comments you have regarding the above and the Patient Referral form are welcome.  I look 
forward to working with all of you. 
 
Thank you, 
 
 
Lynette Kolodziejak, BSP, MSc Candidate 
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Appendix IX: Pharmacist Referral Form 
 
PHARMACIST REFERRAL FORM 
Student Health Centre      
 
PATIENT INFORMATION 
Please place patient identification sticker here. Date of referral:  _____________________ 
      Date of appointment _________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OTHER RELEVANT INFORMATION:  (Please use back of page if necessary) 
 
? Mental Health Medication Counselling and Monitoring 
o Counsel on new medication. 
o Counsel on change in therapy. 
o Follow-up to assess compliance, efficacy of medication, presence of side effects 
o Other: 
 
? Asthma 
o Counsel on device use. 
o Follow-up to assess compliance, efficacy of medication, presence of side effects. 
o Other: 
 
? Contraception 
o Provide supplemental care. 
o Discuss risks vs benefits of continuous vs cyclical oral contraception. 
o Other: 
 
? Patient Medication History 
o Medications that require therapeutic drug monitoring (lithium, carbamazepine, etc) 
o Frequent medication changes (>3 changes in past 12 months). 
o Herbal/complementary medications. 
o Other: 
 
? Other: 
 
 
 
REASON FOR REFERRAL   
 
 
Referring Health care Professional Name: ___________________________________ 
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Appendix X: Patient Documentation Form 
 
PATIENT DOCUMENTATION FORM 
Student Health Centre 
 
Patient Information 
Name: _______________________________________    Date of Birth: _____________ 
College & Year: __________________________           HSN: ___________________ 
Preferred method of contact: 
□ Phone Number: 
□ Address: 
□ Email: 
 
Allergies/Intolerances: 
 
 
 
 
Medications (prescription, OTC, herbals) 
Medication Use Duration 
   
   
   
   
   
   
   
 
Additional Medical/Surgical History: 
 
 
Referral  
Date: ________________ 
Reason for Referral: _______________________________________________________ 
Patient’s Primary Concern: _________________________________________________ 
 
 
 
 
 
 
 
 
 
 
Follow-up:  
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Appendix XI: Pharmacist Depression Counselling Form – Initial Draft 
 
PHARMACIST COUNSELLING FORMAT - DEPRESSION 
 
Student Health Centre Staff: 
 
Please review the following proposed pharmacist counselling format for patients suffering from 
depression.  Although it may seem very structured, please note that it is also intended to be flexible 
and each visit could be tailored to a patient’s specific needs – based on your recommendations and 
patient’s response during the counselling.  All comments and suggestions are greatly appreciated. 
 
Objectives:  
• To provide supplemental care to patients suffering from depression, as they often have 
difficulty with concentration and a poor memory due to their depression. 
• To help increase patient compliance by providing education on the illness, how 
antidepressants work, when to expect an effect, anticipate duration of therapy, the benefits of 
therapy and an overview of the side-effects, including a proactive approach to manage side 
effects. 
• To develop a collaborative process with other health care professionals at the Student Health 
Centre via developing the counselling structure and aid future patient referrals. 
• To create a clinical pharmacy opportunity for direct patient care. 
 
Proposed Process: 
• Work with Student Health Centre staff to develop the counselling format. 
• Any health care provider at the SHC could refer patients to the pharmacist.  Patients could 
be antidepressant naïve, previous or chronic antidepressant users. 
• Initial Visit: the pharmacist would cover as much information that the patient is comfortable 
with, following the predetermined format.  Depending on the patient, an additional visit may 
need to be scheduled with the pharmacist to conclude the counselling intended for the initial 
visit. 
• Follow-up visits: the patient would book another appointment with the pharmacist in close 
proximity to the follow-up appointment with the physician.  Logistics of whether the 
pharmacist would see the patient before the physician or vise versa would depend on staff 
input.  The pharmacist would counsel the patient following the predetermined format. 
• Additional follow-up would be at the discretion of the patient, referring health care 
professional and pharmacist. 
• The forms would consist of a series of counselling topics, each with a tick-box to be checked 
once the topic has been discussed with the patient.  At the end of the visit, the pharmacist 
would sign the bottom of the form indicating that each of the checked topics was reviewed.  
The form would be placed in the patient’s chart to inform the prescriber of what has been 
discussed. 
• The patient would be given the pharmacist’s contact information, for any future questions or 
concerns.  If a patient contacts the pharmacist, the issue will either be addressed by the 
pharmacist (providing within scope of practice) or redirected to the physician.  All 
interactions will be documented in the chart. 
 
 
 
 
 143 
 144 
PHARMACIST PATIENT COUNSELING FOR DEPRESSION – INITIAL VISIT 
Date: ________________________ 
 
Patient Information 
Name: ___________________________________   Date of Birth: _________________ 
College & Year: __________________________          HSN: ____________________ 
Preferred method of contact: 
□ Phone Number: ________________________ (best time to call____________) 
□ Address:  ___________________________________________ 
□ Email: _____________________________________________ 
 
Allergies/Intolerances: (drug, reaction, date of reaction) 
 
 
 
Medications (prescription, OTC, herbals, recreational, nutritional) 
Medication Use Duration 
   
   
   
   
   
   
   
 
Other medical conditions:  
 
 
Medications possibly linked to depression: (? if patient has used the following) 
□ Interferon 
□ Systemic corticosteroids 
(chronic use) 
□ Benzodiazepines 
□ Narcotics 
 
□ Barbiturates 
□ Contraceptives/HRT 
□ Antihypertensives (BB, 
methyldopa, diuretics) 
 
 
□ Alcohol (chronic abuse) 
□ Anabolic steroids 
□ Hallucinogens 
□ Other:  
If the patient is on any of the above, does a temporal relationship with their depression exist? 
 
 
Pregnant/breast feeding: □ Yes □ No □ NA 
Positive family history for mood disorder: □ Yes □ No  
If yes, who, when & what were they treated with: 
 
 
 
Previous antidepressant use: □ Yes □ No  
If yes: indicate the antidepressant, dose, duration, when, reason for discontinued 
 
 
 
Current antidepressant: ______________________________________ 
Any contraindication, precaution or drug interaction present                ? Yes    ? No 
If yes, discuss with prescriber. 
 
Patient’s primary concern: 
 
PHARMACIST PATIENT COUNSELING FOR DEPRESSION – INITIAL VISIT 
 
? How common is depression 
o One of the most common mental health disorders; 1 in 5 Canadians will be diagnosed with a 
mood disorder; in North American ~18% of the population has at least one episode of 
depression (vs 5% affected by diabetes) 
  
? What causes depression 
o Exact cause unknown; possible causes: psychological, biological and genetic factors 
 
? Why take your antidepressant (goals of therapy) 
o Prevent harm to self, relieve symptoms, restore function, & prevent recurrence. 
o BENEFIT: Taking your antidepressant as prescribed increases your ability to achieve these 
goals. 
 
? How do antidepressants work 
o Antidepressants work to restore the correct balance of important chemicals (called 
neurotransmitters) in the brain that affect a person’s mood. 
o Explain how their specific antidepressant works. 
 
? How long will it take before the antidepressant starts to work 
o Usually within 1 week: insomnia, anxiety, & decreased appetite improve; 3-4 weeks: 
increased libido/energy and depressive symptoms improve. 
o Minimum trial of 6 weeks at an adequate dose is needed to fully assess efficacy. 
 
? What type of side effects may occur 
o Discuss possible side effects and how to manage.   
o Serotonin syndrome if SSRI prescribed (signs to watch for, medications to avoid). 
 
? How to take your antidepressant 
o Taking your antidepressant as prescribed increases your chances of recovering from 
depression. Create a system to help you remember to take your medication. 
o Do not skip doses or stop treatment abruptly.  Discontinuation syndrome: “FINISH” - Flu-
like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbance, Hyperarousal.   
 
? Should alcohol be avoided while taking antidepressants 
o Alcohol may worsen your mood, increase antidepressant side effects and can make you feel 
‘off’.  If necessary, have the first few drinks at home with people you trust.  Do not stop 
taking your antidepressant just so you can drink. 
 
? Follow-up appointment: 
o Includes: assessment of side effects, response to therapy, and duration of treatment. 
 
 
A pharmacist has discussed the above information with the patient. 
 
_____________________________ 
BSP Signature 
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PHARMACIST PATIENT COUNSELING FOR DEPRESSION – FOLLOW-UP VISIT 
Date: _____________________ 
 
Patient Information: 
Name: ___________________________________                HSN: _________________ 
 
 
Assessment of Antidepressant Therapy 
Side Effects 
? Blurred vision, dry eyes 
? Dry mouth/thirst 
? Constipation 
? Urinary retention 
? Headache 
? Insomnia/agitation 
? Nausea 
? Orthostatic 
hypotension/dizziness 
? Sedation 
? Sexual dysfunction 
? Weight gain 
? Other: ___________ 
 
Indicate the severity, course (tolerance vs worsening), how disturbing to the patient and 
management for all side effects. 
 
 
 
 
 
Response to Therapy – has there been any improvement in the following: 
? Sleep 
? Interest in activities 
? Appetite 
? Motivation 
? Concentration 
? Energy 
? Feelings of 
guilt/worthlessness 
? Mood 
 
Additional Information: 
 
 
 
 
 
 
Compliance 
o Is the patient taking their medication properly  ? Yes  ? No 
o How often does the patient forget to take their medication __________________ 
o What does the patient do when they miss a dose? ________________________ 
o What does the patient do to remind themselves to take their medication 
________________________________________________________________ 
 
Comments:  
 
 
 
 
 
 
Medication Changes (additions, discontinuation, dose changes for other medications) 
 
PHARMACIST PATIENT COUNSELING FOR DEPRESSION – FOLLOW-UP VISIT 
 
Patient Education 
 
? Patient’s primary concern: 
_________________________________________________________________________________
_________________________________________________________________________________
_______________________________________________________________ 
 
? Review Goals of Treatment 
o Prevent harm to self, relieve symptoms, restore function, & prevent recurrence. 
o BENEFIT: Taking your antidepressant as prescribed increases your ability to achieve these 
goals. 
o An increase in antidepressant dose or change to another antidepressant may be required to 
reach goals. 
 
? Course of Depression 
o Remission: absence of depressive symptoms.  Goal of treatment. 
? ~½ of people suffering from depression will only have one episode. 
o Response: ~50% reduction in baseline symptoms.  Suboptimal. 
? ~¾ of people will have a response to therapy.  
o Relapse: return of significant depressive symptoms. 
? Relapse rates at one year are ~50% for people who discontinue their therapy. 
o Recurrence: another major depressive episode. 
? See your prescriber as soon as possible.  The longer you are symptomatic, the lower the 
likelihood of recovery. 
 
? Response to Therapy 
o Response may take 2-4 weeks and the dose may have to be adjusted before treatment is 
successful. 
o If there is no improvement in your mood after ~6 weeks, there is an excellent chance you 
will respond more favorably to a different antidepressant. 
o The most common cause of not responding to therapy is failure to take the antidepressant 
properly, or even at all. 
 
? Duration of therapy 
o Depends on the severity & duration of the current depressive episode, and the number of 
previous episodes. 
o First episode - minimum of 6-9 months of treatment after symptoms have cleared.  Severe 
first episode or prior previous episodes - 1 year to a lifetime. 
o Your prescriber will determine the exact duration and never discontinue your antidepressant 
on your own. 
 
? Follow-up appointment: 
o To complete counselling or at the patient’s or other health care provider’s request. 
 
A pharmacist has discussed the above information with the patient. 
 
_____________________________ 
BSP Signature 
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Appendix XII: Final Version of the Pharmacist Antidepressant Counselling Form 
 
PHARMACIST ANTIDEPRESSANT COUNSELLING 
 
Date: ___________________ 
 
Patient Information: 
Name: ___________________________________                HSN: _________________ 
Current antidepressant & regimen: _________________________________ 
 
Patient’s primary concern: 
 
 
 
 
Possible Anti-depressant Side Effects: 
? Blurred vision, dry eyes 
? Dry mouth/thirst 
? Constipation 
? Urinary retention 
? Headache 
? Insomnia/agitation 
? Nausea 
? Orthostatic 
hypotension/dizziness 
? Sedation 
? Sexual dysfunction 
? Weight gain 
? Other: ___________ 
 
 
Indicate the severity, course (tolerance vs worsening), disturbance to the patient and management of 
side effects. 
 
 
 
 
 
 
 
 
Assessment of Compliance: 
o Is the patient taking medication properly   ? Yes  ? No 
o How often does the patient forget to take medication ______________________ 
o What does the patient do when they miss a dose? ________________________ 
o What does the patient do to remind themselves to take their medication? 
________________________________________________________________ 
 
 
 
Comments:  
ANTIDEPRESSANT COUNSELLING 
 
 
? Why take your antidepressant (goals of therapy) 
o Prevent harm to self, relieve symptoms, restore function, prevent recurrence. 
o BENEFIT: Taking your antidepressant as prescribed increases your ability to achieve these 
goals. 
 
 
? How do antidepressants work 
o Exact cause of depression is unknown; possible causes: psychological, biological and genetic 
factors. 
o Antidepressants work to restore the correct balance of important chemicals (called 
neurotransmitters) in the brain that affect a person’s mood. 
o Explain how their specific antidepressant works. 
 
 
? How long will it take before the antidepressant starts to work 
o Insomnia, anxiety, and decreased appetite typically improve within 1 week. 
o Libido, energy and depressive symptoms typically improve within 3-4 weeks. 
o Minimum trial of 6 weeks at an adequate dose is needed to fully assess efficacy. 
 
 
? What type of side effects may occur 
o Discuss side effects (current and possible) and how to manage them.   
o Serotonin syndrome if SSRI prescribed (signs to watch for, medications to avoid). 
 
 
? How to take your antidepressant 
o Taking your antidepressant as prescribed increases your chances of recovering from 
depression. Create a system to help you remember to take your medication. 
o Do not skip doses or stop treatment abruptly.   
 
 
 
 
 
 
 
 
 
A pharmacist has discussed the above information with the patient. 
 
___________________________________ 
BSP Signature 
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Appendix XIII: Patient Information Handout on Managing Antidepressant Side Effects 
 
Antidepressant Side Effects 
 
All drugs, whether prescription, over-the-counter, herbals, nutritional and/or recreational, can cause side 
effects.  Some people are more sensitive to medications and may experience side effects, where side effects 
may never occur in others.  The key is to know what side effects may occur with the medications you are 
taking, how to manage them if they occur and when to report them to your doctor.   
 
Side effects caused by antidepressants, if they do occur, are often mild and typically go away with continued 
treatment.  The following side effects may occur when you start your antidepressant or the dose is increased, 
and is usually temporary.  If a side effect continues for more than a week or worsens, let your doctor know.  
Remember - taking your antidepressant is very important and increases your chances of recovering from 
depression. 
 
Possible antidepressant side effects: How to manage the side effects if they occur: 
Blurred vision Reading under a bright light, at a distance or with a 
magnifying glass may help.   
Dry eyes Try using eye drops that contain methylcellulose (e.g. 
Artificial Tears®).   
Dry mouth Sugarless lemon drops, sugarless gum and ice chips may 
help.  Drink more water and try to avoid sweet, high-calorie 
drinks.  Brush your teeth regularly. 
Constipation Increase the amount of fiber in your diet (e.g. fruits, 
vegetables, bran) and drink more water.  If that does not help 
to regulate your bowels, try a laxative (e.g. Metamucil®) or 
stool softener (e.g. Colace®).  
Headache Use acetaminophen (e.g. Tylenol®) or ibuprofen (e.g. 
Advil®, Motrin®). 
Problems sleeping/agitation Decrease caffeine intake (coffee, tea, pop) & alcohol. 
Practice good sleep hygiene. 
Upset stomach/nausea Take your antidepressant with a meal or snack. 
Dizziness Get up from lying or sitting slowly.  If you feel really dizzy 
or faint, sit or lie down until the feeling passes. 
Drowsiness Avoid other medications and alcohol that can also make you 
drowsy. 
Changes in sex drive or sexual  
performance 
Depression itself can decrease someone’s desire to have sex.  
Talk to your doctor if your mood improves, yet you still have 
concerns regarding your sex drive or sexual performance.  
Sweating If you sweat more than usual, shower frequently and use 
deodorants. 
Weight gain Some people lose their appetite when depressed.  Gaining 
weight when on antidepressants may be a sign that you are 
getting better and your appetite is improving.  Eat healthy 
and exercise.  Talk to your doctor or dietitian if you are 
concerned about weight gain.  
 
If you have any questions or concerns regarding antidepressant side effects, talk to your doctor or pharmacist.  
Please refer to the antidepressant information you received when you filled your prescription for further 
information. 
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Appendix XIV: Email Sent to Student Health Centre Staff Regarding the Shortage of 
Alesse® and Triphasil® Oral Contraceptives 
 
Shortage of Alesse® and Triphasil® 
 
Alesse® and Triphasil® are both manufactured by the same pharmaceutical company – 
Wyeth.  Recently, due to problems with their manufacturing plant, there has been a 
shortage of supply throughout Canada for both of these oral contraceptives.   
 
I talked to the drug company today and they have recently distributed a supply of Alesse to 
Canadian pharmacies.  However, I also called a few community pharmacies in Saskatoon 
and not all have received a new shipment of Alesse®.   As for Triphasil®, Wyeth does not 
have an expected date for when new stock will be available. 
 
In the meantime, here are a few options for patients who are unable to fill their Alesse® or 
Triphasil® prescriptions: 
 
Alesse® (ethinyl estradiol 20mcg & levonorgestrel 0.1mg) 
If used for acne management only 
Alternative Oral 
Contraceptive 
Estrogen Progestin Comment 
Tri-cyclen® ethinyl estradiol 35mcg norgestimate 
0.18-0.215- 0.25mg 
Tri-cyclen-Lo® is not on the 
SK formulary.  
 
Diane-35® ethinyl estradiol 35mcg - Contains an antiandrogen -
cyproterone 2mg.  Does not 
have an indication for 
contraception and is not on 
the SK formulary. 
 
If used for contraception 
Min-Ovral® ethinyl estradiol 30mcg levonorgestrel 0.15mg - 
 
 
Triphasil® (ethinyl estradiol 30-40-30mcg & levonorgestrel 0.05-0.075-0.125mg) 
Other available triphasic oral contraceptives 
Alternative Oral 
Contraceptive 
Estrogen Progestin Comment 
Triquilar® ethinyl estradiol  
30-40-30mcg 
levonorgestrel  
0.05-0.075-0.125mg 
Exact same estrogen and 
progestin formulation as 
Triphasil®. 
Tri-cyclen® ethinyl estradiol 35mcg norgestimate 
0.18-0.215-0.25mg 
Tri-cyclen-Lo® is not on the 
SK formulary.  
 
Ortho 7/7/7® ethinyl estradiol 35mcg norethindrone 
0.5-0.75-1mg 
- 
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Appendix XV: Email Sent to Student Health Centre Staff Regarding the New Safety 
Information with Evra® 
 
New Safety Information on Evra® - Risk of Thromboembolism 
 
Over the past few months, Health Canada has been reviewing the safety of the contraceptive 
patch, Evra®.  An update was released today, informing the public that the product 
monograph has been revised based on preliminary, but conflicting, data concerning a 
possible increased risk of blood clots.   This data comes from two post-marketing studies 
which compared the patch (releases 20 mcg of estradiol and 150mcg of norelgestromin per 
day) to low-dose estrogen & norgestimate combination oral contraceptives).  One study 
found no increased risk, while the other on-going and unpublished trial found a 2-fold 
increased risk for developing venous thromboembolism (VTE). 
 
Keeping Things in Perspective 
Back in September, the FDA had updated the product labelling in the States to acknowledge 
this possible increased risk of blood clots with the use of Evra®.  Subsequently, the Star 
Phoenix featured an article on the topic and will likely highlight Health Canada’s decision 
in the near future.  If any of your patients are on Evra® and are concerned with the recent 
news in the media, the following can be brought to their attention: 
• Even if the new & conflicting information is correct, and the Evra® patch has a 2x ↑ 
risk of VTE, this risk is still extremely low (would ↑ from 1-1.5 per 10,000/year to 2-
3 per 10,000/year).  
• Reiterate that they should watch for any early signs of VTE (DVT, PE)  
• The warning that contraceptives may increase the risk of VTE is not new and is 
relevant with either the oral or transdermal formulations.   
 
To view Health Canada’s warning on this issue, visit http://www.hc-sc.gc.ca/dhp-
mps/medeff/advisories-avis/prof/2006/evra_hpc-cps_e.html. 
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Appendix XVI: Literature Review for Suppressive Therapy for Genital Herpes  
Simplex Virus  
 
LONG-TERM SAFETY OF ANTIVIRAL AGENTS FOR GENITAL HERPES SIMPLEX 
VIRUS SUPPRESSIVE THERAPY 
 
Introduction 
A review of the current literature was conducted to assess the safety of antiviral agents for genital 
herpes simplex virus (HSV) therapy.  The recent guideline recommendations are noted, however 
further investigation into the side effects reported with continuous therapy was carried out to aid in 
the decision-making process of initiating and maintaining patients on suppressive therapy.  In 
addition, information from the longest trials was sought to provide a sense of where the evidence lies 
for length of therapy. 
 
Canadian Guidelines on Sexually Transmitted Infections 
The 2006 Canadian Guidelines on Sexually Transmitted Infections recommends the following for 
Suppressive therapy: 
• Suppressive therapy is intended for patients with frequently recurring genital herpes, 
generally for those with recurrences at least every 2 months or 6 times per year.  In such 
patients, suppressive therapy is preferred to episode therapy and improves quality of life. 
• For individuals with fewer than 6 recurrences per year or one every 2 months, episode 
therapy is recommended.  However, suppressive therapy will probably be efficacious and 
may be considered on a case-by-case basis. 
Notes: 
• Acyclovir, famciclovir and valacyclovir are approved for suppressive therapy in Canada. 
• Safety and efficacy data suggest that acyclovir and valacyclovir can be administered for up to 
1 year based on controlled trials, whereas famciclovir has been evaluated only for up to 4 
months* administration.  
 
* Erratum on duration of famciclovir trials - Public Health Agency of Canada website 
(http://www.phac-aspc.gc.ca/std-mts/sti_2006/updates_e.html)  (see attached) 
Page 151, Table 3 - footnote 2. The new bullet should read: Safety and efficacy data 
suggest that acyclovir and valacyclovir can be administered for up to 1 year [A-I] 
based on controlled trials, 47-59, 62 famciclovir has also been evaluated for up to 1 year 
of administration [A-I].60, 61 
 
Suppressive Therapy for Non-pregnant Patients (all A-1 recommendations) 
• Acyclovir 200mg po three to five times daily OR 400mg po bid 
• Famciclovir 250mg po bid 
• Valacyclovir 500mg po OD (for patients with ≤9 recurrences per year) OR 1000mg po OD 
(>9 recurrences per year) 
 
2006 American Sexually Transmitted Diseases Treatment Guidelines 
Of note, the current American guidelines state the safety and efficacy of once daily suppressive 
therapy has been documented for as long as 6 years for acyclovir and 1 year for valacyclovir or 
famciclovir.  The document also suggests that patients be periodically reassessed (e.g. once yearly) to 
determine whether therapy should continue, since recurrent genital herpes outbreaks decrease over 
time. 
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Disclaimer 
The recommendations in the Canadian Guidelines on Sexually Transmitted Infections should be 
applied to daily practice.  The trials referenced by the expert panel were included in this review, 
when possible.  Several of the studies were not published in English or in very reputable journals; 
therefore it was not always possible to obtain the referenced literature.  In addition, due to a lack of 
well designed trails, the Guidelines have limited their evidence based recommendation to one year 
for safety and efficacy.  The following information that is beyond these recommendations is only to 
supply you with the data that is available – albeit, not always the most sound evidence. 
 
Overall Safety 
Suppressive therapy with antiviral agents appears to be well tolerated.  With each medication, the 
nature and incidence of side effects were similar to placebo.  In addition, the events that did occur 
were mild, transient and infrequent.  No cumulative toxicity has been reported and resistance rates 
are very rare.  Please refer to the following pages for details.   
 
Safety Monitoring with Suppressive Therapy 
There are no guidelines available outlining the type of parameters that should be monitored, or 
frequency of follow-up, in patients who are on suppressive therapy.  It should be noted that the 
antivirals have been suspected in case reports of hematological changes (i.e. anemia, leucopenia, 
neutropenia, thrombotic thrombocytopenia purpura) and hepatotoxicity.  It has been suggested that 
urinalysis, BUN, serum creatinine, liver enzymes and CBC be measured at baseline and periodically 
with continued therapy. 
 
References: 
1. Public Health Agency of Canada.  Canadian Guidelines on Sexually Transmitted Infections.  2006 
edition.   
2. Centers for Disease Prevention and Control.  Sexually Transmitted Disease Treatment Guidelines 2006. 
Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm.  Accessed December 4th, 
2006. 
3. Micromedex 2006. 
4. Tyring SK, Baker D and Snowden W.  Valacyclovir for Herpes Simplex Virus Infection: Long-Term 
Safety and Sustained Efficacy after 20 Years’ Experience with Acyclovir.  Journal of Infectious Disease 
2002; 186(Supp 1): S40-6. 
5. Diaz-Mitoma et al. Oral Famciclovir for the Suppression of Recurrent Genital Herpes. JAMA.1998; 280: 
887-92. 
6. Valtrex® and Zovirax® data on file.  GlaxoSmithKline. December 12th, 2006. 
7. Famvir® data on file.  Novartis. December 13th, 2006. 
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Acyclovir (Zovirax®) 
 
• Longest trial: 10 years 
• Source: 
o Data on file (GlaxoSmithKline). 
o Summary of data: Tyring SK, Baker D and Snowden W.  Valacyclovir for Herpes 
Simplex Virus Infection: Long-Term Safety and Sustained Efficacy after 20 Years’ 
Experience with Acyclovir.  Journal of Infectious Disease 2002; 186(Supp 1): S40-6. 
• Design: 
o First year: Randomized, double-blind, placebo-controlled 
? Intervention: acyclovir 400mg po bid or placebo 
? Recurrences: episodic acyclovir 200mg po 5 times a day for 5 days 
o Second-Sixth Year: open-label 
? Intervention: Patients selected either suppressive or episodic therapy, or 
discontinued from the study. 
o Seventh Year: open-label 
? Intervention: episodic therapy with acyclovir 200mg po 5 times a day for 5 
days only 
? ≥2 recurrences: continuous suppressive therapy with acyclovir 400mg po bid 
x 3 years 
• Population: N=1175 otherwise healthy patients with frequently recurring genital HSV 
infection 
 
Table 1: Frequency of most common adverse events (%) among patients receiving continuous acyclovir 
suppressive therapy for ≤10 years 
Year Therapy 
(n) 
Nausea Diarrhea Headache Rash Asthenia Dizziness Abdominal 
Pain 
Vaginitis 
1 S (586) 4.8 2.4 1.9 1.7 1.2 1.2 0.9 1.1 
 E (589) 2.4 2.7 2.2 1.5 1.2 1.2 1.7 0 
2 S (698) 0.7 0.1 1.9 1.1 0.2 1.1 1.1 0.3 
 E (85) 1.1 1.1 2.4 0 0 2.4 0 2.3 
5 S (430) 0.2 0.2 1.2 0 0.2 0 0.2 1.7 
9 S (152) 0 0 1.3 0 0 0 0.7 0 
E=episodic therapy (+placebo suppression for year 1); S=suppressive therapy. 
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Valacyclovir (Valtrex®) 
• Longest trial: 1 year 
• Source: 
o Below summary comparing valacyclovir to acyclovir and/or placebo: Tyring SK, 
Baker D and Snowden W.  Valacyclovir for Herpes Simplex Virus Infection: Long-
Term Safety and Sustained Efficacy after 20 Years’ Experience with Acyclovir.  
Journal of Infectious Disease 2002; 186(Supp 1): S40-6. 
o Study 1: Patel R, Bodsworth N, Woolley P, et al. Valaciclovir for the suppression of 
recurrent genital HSV infection: a placebo controlled study of once-daily therapy. 
Genitourin Med 1997; 73:105–9. 
o Study 2: Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of 
recurrent genital herpes simplex virus infection: a large-scale dose range-finding 
study. J Infect Dis 1998;178:603–10. 
o Study 3: Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for 
suppression of recurrent genital herpes. Obstet Gynecol 1999; 94:103–6. 
o Study 4: Conant MA, Schacker T, Murphy RL, et al. Valaciclovir versus aciclovir for 
herpes simplex virus infection in HIV-infected individuals—two randomized trials. 
Int J STD AIDS 2002; 13:12–21. 
• Design: 3 randomized controlled trials and one open-label study 
 
Table 2: Trials assessing valacyclovir for suppression of recurrent HSV infections. 
Study Population Total 
subjects 
# of 
valacyclovir 
recipients 
Total daily 
valacyclovir 
dose 
Variable compared  
(total daily dose) 
Trial 
duration 
1 382 288 500mg Placebo 16 weeks* 
269 250mg Acyclovir (800mg) 1 year 
540 500mg 
2 1479 
269 1000mg 
Placebo  
3 
Immunocompetent 
127 127 500mg - 1 year 
4 HIV infected 1062 713 1000mg Acyclovir (800mg) 1year 
Total 3050 2206  
* 313 patients continued with open-label valacyclovir to complete 1 year of therapy. 
 
Table 3: Adverse events reported in patients receiving valacyclovir (250-1000mg/day), acyclovir (800mg/day) 
or placebo for up to 1 year. 
Immunocompetent HIV Infected  
Event Valacyclovir 
(n=1493) 
Acyclovir 
(n=267) 
Placebo 
(n=228) 
Valacyclovir 
(n=713) 
Acyclovir 
(n=349) 
Headache 32 37 25 18 17 
Rhinitis 20 25 15 12 12 
Infection* 15 21 11 18 13 
Nausea 10 12 8 12 14 
Pharyngitis 9 11 10 11 13 
Diarrhea 8 12 10 20 19 
Abdominal pain 8 7 4 11 7 
Rash 6 6 7 15 14 
Depression 4 4 3 10 11 
Fever 2 <1 1 10 11 
Any event 82 85 67 77 77 
*Infectious illness included influenza, common cold, rhinitis, sinusitis. 
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Famciclovir (Famvir®) 
 
• Longest trial: 1 year 
• Source:  
o Diaz-Mitoma et al. Oral Famciclovir for the Suppression of Recurrent Genital 
Herpes. JAMA.1998; 280: 887-92. 
• Design:  
o Randomized, double-blind, placebo-controlled, multicentre (Europe and Canada), 
parallel-group study 
• Population:  
o N=455, ~48% male, mean age 37 (19-76 years old), mean duration of genital herpes 
was ~7 years, 85% had experienced at least 10 recurrences in the 2 years prior to 
study entry, 15% had previously tried suppressive therapy with acyclovir in the 12 
months prior to the study, and 40% had received episodic acyclovir treatment. 
• Intervention: 
o famciclovir 125mg po TID, famciclovir 250mg po BID, famciclovir 250mg po TID 
or placebo 
o Patients with either 2 virologically confirmed or 3 clinically confirmed recurrences 
were given the option of open-label famciclovir 250mg po TID for the remainder of 
the study. 
 
Table 4: Adverse events in patients (%) who received at least 10 months of double-blind study medication. 
Famciclovir   
Adverse Event 
125mg tid 
(n=69) 
250mg po bid 
(n=81) 
250mg po tid 
(n=76) 
Placebo 
(n=30) 
Patients with ≥1 event 67 (97.1) 75 (92.6) 70 (92.1) 27 (90) 
Headache 36 (52.2) 34 (42) 32 (41.2) 14 (46.7) 
Viral Infection* 16 (23.2) 29 (35.8) 25 (32.9) 10 (33.3) 
Upper respiratory tract infection 26 (37.7) 25 (30.9) 25 (32.9) 10 (33.3) 
Injury 15 (21.7) 10 (12.3) 19 (25.5) 7 (23.3) 
Back pain 7 (10.1) 9 (11.1) 15 (19.7) 4 (13.3) 
Pharyngitis 12 (17.4) 13 (16) 11 (14.5) 6 (20) 
Dyspepsia 4 (5.8) 3 (3.7) 7 (9.2) 5 (16.7) 
*Viral infection included influenza, flulike symptoms, and symptoms of a cold. 
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Appendix XVII – Last-Minute Travel Health Information Package Project 
 
LAST-MINUTE TRAVEL HEALTH INFORMATION PACKAGE 
 
Disclaimer: all patients should be encouraged to visit the International Travel Health Clinic through 
Public Health: 
  Location: #108-407 Ludlow Street 
  Hours: 8:00am-12:00 noon, 12:30pm-4:15pm M-F 
  For appointments call: 655-4780 
  Website: http://www.saskatoonhealthregion.ca/your_health/ps_itc_about_us.htm 
 
This information package is intended to provide you with travel health advice for patients who cannot 
attend the Travel Clinic. 
 
Recommendations for traveling change often and vary according to destination.  Once a patient’s 
current health status, travel itinerary (dates of departure and return, stopovers, plans after arrival, 
type & style of travel) and immunization history is assessed, visit the Centers for Disease Prevention 
& Control’s website (http://www.cdc.gov/travel/) for the latest recommendations. 
 
Table of Contents              Page # 
Malaria Prophylaxis         2 
• RxFiles newsletter & drug comparison chart  
 
Last-minute Hepatitis Vaccinations       4 
• Hepatitis A & B (TWINRIX®)      5 
• Hepatitis A (VAQTA®)       6  
• Hepatitis B (Recombivax HB®)      7 
 
Traveller’s Diarrhea: Prevention & Treatment      8 
• Patient Information sheet        12 
 
Economy Class Syndrome: Travel-induced Thrombosis    13 
• Patient Information sheet        15 
 
Recommended Over-the-Counter Medications (patient information sheet)  16 
 
Traveling with Medication        17 
 
Drug-induced Photosensitivity        19 
• Pharmacist’s Letter chart & newsletter 
 
High-altitude Sickness         23 
 
Additional Resources: 
• Immunization Action Coalition (http://www.immunize.org/index.htm) 
• World Health Organization (http://www.who.int/ith/en/) 
• International Society of Travel Medicine (http://www.istm.org/) 
• Public Health Agency of Canada – Travel Health (http://www.phac-aspc.gc.ca/tmp-
pmv/index.html) 
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Vaccinations for Travel 
 
Vaccinations for travelling can be divided into three categories: routine, required and recommended. 
 
Routine Vaccinations 
Travellers should ensure they are up to date on their routine immunization, which will help prevent 
the acquisition of diseases prevalent in other countries. In Canada, the routine immunizations are as 
follows: 
• Influenza 
• Tetanus, Diphtheria, Polio 
• Pertussis 
• Measles, mumps, rubella 
If patients are uncertain of their immunization history, ask them to contact their home town Public 
Health office to obtain their immunization record. 
 
Required Vaccinations 
Currently, there are only two vaccinations that are required for certain destinations: 
• Yellow fever (certain areas for sub-Saharan Africa and tropical South America) 
• Meningococcus (Saudi Arabia for travel during Hajj) 
Documentation of vaccination may be needed. 
 
Recommended Vaccinations 
These vaccinations depend on the destination, expected time in rural areas, time of year, age, health 
status and previous immunizations. 
 
To determine which vaccinations should be administered prior to travel, visit the Centres for Disease 
and Prevention (http://www.cdc.gov/travel/vaccinat.htm) for current recommendations 
categorized by region. 
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Hepatitis A & B 
TWINRIX® (purified, inactivated hepatitis A and purified hepatitis B surface antigen) 
 
Transmission:  
• Hepatitis A: ingestion of food and water that has been contaminated with human feces and/or oral-
fecal contact with an infected person.  
• Hepatitis B: blood, saliva, semen and vaginal fluids.  Patients should be encouraged to practice safe 
sex while traveling.  Risk of transmission is higher for those providing or receiving medical care in 
areas with intermediate or high rates of hepatitis B. 
 
Contraindications: patients with hypersensitivity to any constituent of the vaccine. Note: 
• TWINRIX® does not contain egg, but does have traces of neomycin in the formulation. 
• There is not enough data to establish the safety of TWINRIX® in patients who are <1 year old, 
pregnant or breast feeding. 
 
Administration: 
• Intramuscular – Deltoid muscle preferred in adults.  Anterolateral thigh preferred in infants.  Avoid 
the gluteal region due to suboptimal seroconversion.  
• May be given simultaneously with other inactivated vaccines, but administration should be at separate 
syringes and anatomical sites.  
 
Dose & Dosing Schedule 
TWINRIX Junior®: 0.5ml prefilled syringe contains hepatitis A 360 ELISA units & hepatitis B 10μg. 
• Standard Schedule: 0, 1, 6 months using TWINRIX Junior® (ages 1- 18 years old) 
• Alternate Schedule: primary dose plus a booster (either at 6 or 12 months) using TWINRIX® (ages 1-
15 year old) 
 
TWINRIX®: 1ml prefilled syringe contains hepatitis A 720 ELISA units & hepatitis B 20μg. 
• Ages ≥ 19 years old. 
• Standard Schedule: 0, 1, 6 months 
• Rapid Schedule: 0, 7, 21 days and a booster at 12 months 
 
Development of Immunity (based on studies involving people 18-50 years old) 
TWINRIX® Standard Dosing Schedule (0, 1, 6 months) 
% of people who 
developed antibodies 
Day 15 
(2 weeks after 1st 
dose) 
Month 1 
(1 month after the 1st 
dose) 
Month 7 
(1 month after the 3rd 
dose) 
Hepatitis A 88% 94% 100% 
Hepatitis B NA 70% 99% 
If the dosing schedule is interrupted, give the next dose as soon as possible.  If the second dose is delayed, 
ensure the third dose is administered 5 months after. 
 
Rapid/Accelerated Dosing (0, 7, 21 days & a booster at 12 months) 
% of people who 
developed antibodies 
Week 4 
(1 week after the 3rd 
dose) 
Week 8 
(5 weeks after the 3rd 
dose) 
Week 56 
(1 month after the 4th 
dose) 
Hepatitis A 100% 99.5% 100% 
Hepatitis B 82% 85% 100% 
The schedule for rapid dosing CANNOT be interrupted. 
 
Protection will likely last for approximately 20 years against hepatitis A and 15 years for hepatitis B. 
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Hepatitis A 
VAQTA® (purified, inactivated, whole virus) 
 
Transmission: ingestion of food and water that has been contaminated with human feces and/or 
oral-fecal contact with an infected person.  
 
Contraindications: patients with hypersensitivity to the drug or any of its components.  For those 
with contraindications, refer them to Public Health InternationalTravel Health Clinic to receive 
immune globulin, which will offer protection for up to 3 months.   Note: 
• VAQTA does not contain egg, but does have traces of neomycin in the formulation. 
• There is not enough data to establish the safety in patients who are <2 years of age, pregnant 
or breast feeding. 
 
Administration: 
• Intramuscular (deltoid muscle preferred). 
• May be given simultaneously with other inactivated vaccines, but administration should be 
at separate syringes and anatomical sites. 
 
Dose & Dosing Schedule 
Age Dose  (Primary & Booster) Dosing Schedule 
Pediatric & 
Adolescents 
(ages 2-17 years old) 
0.5ml (~25U) Primary dose & a booster 6-
18 months later  
Adults  
(≥18 years old) 
1ml (~50U) Primary dose & a booster 6-
18 months later 
If the dosing schedule is interrupted, administer the booster as soon as possible but restarting the 
series is unnecessary.  The booster dose is interchangeable; therefore if the patient’s first vaccine was 
another inactivated hepatitis A vaccine (e.g. Harvix®) they could receive VAQTA® as their booster 
dose. 
 
Development of Immunity 
% of patients with immunity 2 weeks after Primary Dose 4 weeks after Primary Dose 
Hepatits A (VAQTA®) ~70% ~94-100% 
* A booster shot is necessary to promote long-term protection.  
 
• The incubation period of hepatitis is long (20 to 50 days).  Therefore, it may still be beneficial 
to vaccinate a patient just prior to departure. 
• a person may develop immunity if they are vaccinated just prior to departure.  
• If travel is within 4 weeks of vaccination, a dose of immune globulin may be given alone or 
with the hepatitis A vaccine for optimal protection (administered at the International Travel 
Health Clinic). 
• Protection will likely last for approximately 20 years.  Additional booster doses or serologic 
testing, after the primary series has been completed, is not recommended at this time. 
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Hepatitis B 
Recombivax HB® (recombinant surface antigen) 
 
Transmission: via blood, saliva, semen and vaginal fluids.  Patients should be encouraged to 
practice safe sex while traveling.  Risk of transmission is higher for those providing or receiving 
medical care in areas with intermediate or high rates of hepatitis B. 
 
Contraindications: hypersensitivity to any component of the vaccine. 
• Does not contain egg, but harvested in yeast. 
• Available in two formulations:1) preservative-containing (thimerosal) (10mcg/ml) 
       2) preservative-free (thimerosal-free) (10mcg/ml & 40mcg/ml) 
• There is not enough data available to determine the safety of Recombivax HB® in patients 
who are pregnant or breastfeeding. 
 
Administration:  
• Intramuscular - Deltoid muscle preferred in adults.  Anterolateral thigh preferred in infants.  
Avoid the gluteal region due to suboptimal seroconversion.  
• Can be given concomitantly with DTP (Diphtheria, Tetanus and whole cell Pertussis), oral 
Poliomyelitis vaccine, M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live), Liquid 
PedvaxHIB, Conjugate vaccine (Meningococcal Protein Conjugate) or a booster dose of 
DTaP (Diphtheria, Tetanus, acellular Pertussis) using separate sites and syringes for 
injectable vaccines.  
 
Dose & Dosing Schedule 
Age Dose Dosing Schedule 
Birth – 10 years of age 2.5mcg 
11 – 19 years of age 5mcg 
≥ 20 years of age 10mcg 
Dialysis or immunocompromised 40mcg 
 
0, 1, and 6 months 
Two-dose regimen: 11-15 years of age 10mcg Primary dose and then a 
booster 4-6 months later 
If the dosing schedule is interrupted, do not restart the series.  Instead, give the next dose as soon as 
possible.  If a patient started their series with Engerix-B®, they may continue with the Recombivax-
HB® vaccine and schedule. 
 
If the dosing schedule is accelerated, a minimum of one month must pass between injections (e.g. 0, 
1, 2 months). 
 
Development of Immunity 
Age % Of Subjects with Immunity 
20-29 98 
30-39 94 
≥40 89 
Note: seroconversion rates and 
geometric mean antibody titers 
were only measured 1-2 months 
after the third dose. 
 
Protection will likely last for approximately 15 years.   
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Traveler’s Diarrhea 
 
What is traveler’s diarrhea? 
Traveler’s diarrhea (TD) is defined as the passage of 3 or more unformed stools over 24 hours and at least one 
of the following symptoms – fever, abdominal cramps, nausea, fecal urgency or dysentery.  It is self-limiting 
and can last for about 3-4 days. 
 
What causes traveler’s diarrhea? 
TD can be caused by bacteria, viruses or parasites.   Approximately 85% are bacterial in origin and the 
causative pathogens can vary based on geography. 
 
Table 1: Etiological Pathogens based on Geographic Area 
Geographic Area Important Etiology Pathogens 
All regions of the developing world Escherichia coli (~50% of cases) 
Shigella, Salmonella and Campylobacter spp. (~15% 
of cases) 
Mountain areas and recreational waters of North 
America 
Giardia spp. 
Southern Asia Shigella, Salmonella and Campylobacter spp. 
(~30%) 
Note: ciprofloxacin-resistant Campylobacter 
Russia (especially St.Petersburg) Giardia and Cryptosporidium spp. 
Nepal, Haiti, and Peru Cyclospora spp. 
India, Ecuador, Bali & Indonesia Vibrio cholerae 
Cruise ships Norovirus (e.g. Norwalk virus) 
 
Destination 
TD can affect ~30-60% of travelers from industrialized countries who visit developing countries of the tropical 
and semitropical world.  The rate of traveler’s diarrhea between regions is as follows: 
• One low-risk area to another: ~5% 
• Low-risk area to an intermediate-risk area: ~15% 
• Low-risk area to a high-risk area: ~40%  
 
Table 2: Risk of Traveler’s Diarrhea base on Destination 
Degree of Risk Geographic Region 
Low-Risk New Zealand, Australia, Northern/Western/Central Europe, US, Canada, 
Japan 
Intermediate-Risk Caribbean Islands, Southern and Eastern Europe, Northern Mediterranean, 
China, Russia, South Africa, Israel 
High-Risk South & Central America, Middle East, Africa, and Southern & Southeast Asia 
All travelers to high-risk areas should be provided with medication for self-treatment. 
 
Who is at increased risk of acquiring traveler’s diarrhea? 
There is a large variance in individual susceptibility; however the following people may be at greater risk of 
developing TD: 
• Children and adolescents due to a lack of gut immunity 
• Immunocompromised patients (HIV or AIDS, chronic corticosteroid and immunosuppressive 
therapy, common IgA deficiency) 
• Those with gastric hypochlorhydria due to H2-antagonists & proton-pump inhibitors use, or 
gastrectomy/vagotomy surgery 
• Lack of previous travel to high-risk regions in the past 6 months 
• Lack of careful food & beverage selection in hotels, restaurants & homes  
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How can traveler’s diarrhea be prevented? 
• Refer to the patient information sheet. 
 
Should medication be used as prophylaxis for traveler’s diarrhea? 
Prophylaxis with antibacterial agents is not recommended, due to the concerns with systemic adverse events 
and the increasing rates drug resistance with these agents. Loperamide is not recommended for prophylaxis 
either.  Bismuth subsalicylate offers ~65% protection rate, but requires frequent dosing: 2 x 263mg tablets with 
meals and at bedtime (8 tablets/day) [2 tablets=2 oz of liquid formulations].   
 
How should traveler’s diarrhea be treated? 
TD is self-limiting; however empirical self-therapy is a valid approach because: 
• Travelers may have a restricted schedule (pre-planned tour itineraries or business demands) and the 
loss of even one day due to illness may be very disruptive. 
• Seeking medical treatment may have its challenges, such as inaccessibility, unfamiliarity with foreign 
health care systems, language barriers, remoteness and time constraints. 
Travelers should be reminded that stress, menstruation, changes in diet, and excessive alcohol intake may also 
cause changes in stool consistency and frequency. 
 
Goals for Treating Traveler’s Diarrhea 
Prevent dehydration, reduce symptoms and duration of diarrheal illness, and prevent cancellation of planned 
activities. 
 
Maintaining Hydration Status 
• Recommend for all patients, regardless of age and severity of diarrhea.  Note: young infants should be 
given breast milk or lactose-free formula. 
• Maintain or increase fluid intake.   
• Oral Rehydration: drink soup and sugar-flavoured mineral water with salty crackers, or use oral 
rehydration solution (e.g. Gastrolyte®, Gatorade®). 
• Diuretics may need to be discontinued temporarily if substantial diarrhea. 
 
Table 3: Self-Treatment for Traveler’s Diarrhea 
Severity of Diarrhea  Symptoms Treatment 
Mild: 
1-2 stools/24hrs 
Mild or none • Oral rehydration (e.g. Gastrolyte®, Gatorade®) 
• May use loperamide or bismuth subsalicylate 
No distressing 
symptoms 
• Oral rehydration (e.g. Gastrolyte®, Gatorade®) 
• Use loperamide or bismuth subsalicylate 
• Add single dose antibiotic if worsening. 
Moderate: >2stools/24hrs 
Distressing 
symptoms 
• Oral rehydration (e.g. Gastrolyte®, Gatorade®) 
• Loperamide and antibiotic. 
• Reassess in 12-24hrs: 
o If resolved, stop antibiotic 
o If not resolved, continue antibiotic for up to 3 days. 
Severe: 
>6 stools/24hrs with fever 
or bloody stools 
Fever or bloody 
stools 
• Oral rehydration (e.g. Gastrolyte®) 
• Antibiotic for 1-3 days.  Seek medical if unable to keep 
down fluids or food, abdominal pain, persistent or 
worsening diarrhea. 
• Avoid antimotility agents. 
Refer to chart on next page for additional drug information. 
 
The above chart is based on the fact that ~85% of TD is caused by bacteria.  If chronic diarrhea 
occurs, consider the following pathogens and treatment options (also refer back to Table 1): 
• Giardia lamblia, giardiasis: metronidazole 250-500mg po tid x 5 days 
• Cryptosporidium spp: self-limiting, no established therapy 
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• Cyclosporia caytanensis: TMP/SMX i DS tab po bid x 7 days 
 
Dukoral® Vaccine 
An oral inactivated vaccine against enterotoxigenic E.coli and Vibrio cholerae is available in Canada, however it 
only prevents 1 out of every 8 cases of TD.   
 
Concern with Antibiotic Resistance 
One of the reasons why antibiotics are not recommended for prophylaxis is the concern regarding antibiotic 
resistance.  Resistance has already developed for the following agents: 
• Co-trimoxazole, sulfonamide agents, ampicillin and doxycycline, therefore the use of these agents are 
limited. 
• ~77% resistance rates for ciprofloxacin and levofloxacin with Campylobacter spp., especially in Spain 
and Thailand. 
• Azithromycin-resistant strains have also been identified in US troops stationed in Thailand. 
 
References: 
1) Al-Abri SS., Beeching NJ., and Nye FJ.  Traveler’s Diarrhea.  Lancet Infectious Disease 2005; 5:349-60. 
2) DuPont HL.Travelers’ Diarrhea: Contemporary Approaches to Therapy & Prevention. Drugs 2006;66(3):303-14. 
3) Canadian Pharmacists Association.  Patient Self-Care: Helping patients make therapeutic choices.  1st ed. Ottawa, ON. 
Canadian Pharmacists Association 2002. 
4) Do Bugs Needs Drugs. Antimicrobial Reference. Available at: http://www.dobugsneeddrugs.org/health 
care/antimicrobial/Antimicrobial_ref.pdf.  Accessed December 1st, 2006.  
5) Gilbert DN,.et al.  Sanford Guide to Antimicrobial Therapy. 36th ed.  Sperryville, VA.  Antimicrobial Therapy Inc 2006. 
6) Taylor Robert B.  Family Medicine – Principles and Practice.  6th ed. 2003 Springer New York.  Chapter 9: Health care of the 
International Traveler p77-84. 
Medications for Prevention & Empiric Antibiotic Treatment for Traveler’s Diarrhea 
Dosing Regimen Drug Mechanism of 
Action/ 
Efficacy 
Comments/Contraindications/Side Effects/ 
Drug Interactions/Pregnancy 
Prevention Treatment 
Antisecretory and Antimotility Agents: reduce the number of stools passed by 30-65%   
Bismuth 
subsalicylate 
(Pepto-
Bismol®) 
Antisecretory 
Antibacterial 
Anti-inflammatory 
 
Protection rate of ~65% 
Limit prophylaxis to 3 weeks. 
CI: ASA allergy, <2 years of age, renal insufficiency or gout 
SE: black tongue/stools, tinnitus 
DI: anticoagulants or salicylates, probenecid, methotrexate.  
Can interfere with doxycycline & fluroquinolones (space by 2 
hours) 
Pregnancy: B (salicylate component may inhibit platelet 
function & ↑ risk of premature closure of the fetal ductus 
arteriosus) 
2x262mg tabs (or 2 
oz.) QID (with meals 
and hs) x 3 weeks 
 
 
2x262mg tabs (or 2 oz.) q30min x 8 
doses, may repeat on day 2 
Loperamide 
(Imodium®) 
Antisecretory  
Antimotility 
 
↓ number of stools 
passed by 65% 
Antimotility DOC. Combined with an antibiotic is superior 
to treatment with either agent alone. 
Avoid if high fever, chills or bloody diarrhea (may worsen 
clinical course) 
May cause post-diarrhea constipation 
CI: <2 years of age (caution: <12 years of age) 
SE: abdominal pain/discomfort, drowsiness or dizziness, dry 
mouth, skin rash 
DI: St.John’s Wort, Valerian 
Pregnancy: B 
Not recommended for 
prophylaxis 
4mg stat then 2mg after every loose 
BM.  Max 16mg/day 
Antibacterials: shorten the duration of diarrhea by 1-2.5 days versus placebo  
Fluoroquinolones Antibacterial.  
 
Reduce duration of 
diarrhea by ~50% with 
relief of symptoms.  
Three days of therapy as 
effective as 5 days.  
Single dose treatment 
often sufficient. 
DOC for empiric therapy for moderate to severe diarrhea.   
CI: pregnancy, <8 years of age 
SE: GI complaints, headache, dizziness, rashes, 
photosensitivity (ensure adequate sunscreen protection) 
DI: warfarin, phenytoin, cyclosporine, theophylline 
Pregnancy: C 
 
Not covered by the SK Drug Plan for this indication. 
Not recommended 
due to ↑ rates of 
antibiotic resistance 
Options: 
1) Ciprofloxacin 750mg po OD  
2) Ciprofloxacin 500mg po BID  
3) Levofloxacin 500mg po OD  
4) Norfloxacin 800mg po OD  
5) Norfloxacin 400mg po BID 
 
*All regimens for 1-3 days. 
Azithromycin Antibacterial.   
 
As effective as 
ciprofloxacin and 
levofloxacin, but may 
have a slower response. 
An alternative to fluoroquinolones in areas of high incidence 
of campylobacter infection.  Can be used in children. 
CI: allergy to macrolides 
SE: diarrhea, abdominal pain, nausea, vomiting, rash 
DI: aluminum & magnesium containing antacids (space by 2 
hours), carbamazepine, phenytoin, theophylline, warfarin, 
cyclosporine, ergots 
Pregnancy: B 
Not covered by the SK Drug Plan for this indication. 
Not recommended 
(no evidence) 
Options: 
Adults 
1) 1g po as a single dose 
2) 500mg po OD for 1-3 days. 
 
Children 
10mg/kg po od for 1-3 days. 
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Possible effective: Probiotic Lactobacillus GG (10 billion bacteria/capsule) had protection rates of 12-45%.  Dose: i cap bid beginning 2-3 days before travel & for duration of trip.  Saccharomyces 
boulardii 250mg (5 billion bacteria) per capsule or packet.  Dose: 1-2 capsules daily beginning 5 days before travel and for duration of trip.  Ineffective: Probiotics Lactobacillus acidophilus and 
L.bulgaricus, kaolin-pectin preparations, activated charcoal, and anticholinergics 
Patient Information Sheet on Traveler’s Diarrhea 
All patients are encouraged to visit the International Travel Health Clinic through Public Health. 
 
Traveler’s diarrhea is the passage of 3 or more unformed stools over a 24 hour period with at least 
one of the following symptoms – fever, abdominal cramps, nausea, a sense of urgency to pass stools 
or the presence of blood/mucus in the stool.  These symptoms can last between 1 to 4 days.  It is 
important to note that stress, menstruation, changes in diet, and excessive alcohol intake may also 
cause changes in stool consistency and frequency. 
 
Preventing Traveler’s Diarrhea 
Traveler’s diarrhea is caused by ingesting food or beverages which are contaminated with bacteria, 
viruses or parasites.   Careful selection of what you consume will reduce your risk of getting 
traveler’s diarrhea.  Below are some tips to follow while traveling:  
 
Avoid 
• Tap water, bottled water where the seal is not intact, and ice. 
• Salads (unless washed in water known to be clean), unpasteurised fruit juices and dairy 
products, and cold sauces. 
• Fruit that you cannot peel and raw seafood. 
• Previously cooked foods that have been sitting at room temperature for several hours after 
initial cooking. 
• Items served in buffet tins without effective heating flame below. 
• Food from a street vendor. 
• Swallowing water while swimming. 
 
Do 
• Drink boiled water or carbonated beverages. 
• Eat freshly cooked, piping hot food. 
• Use a portable water filter. 
 
Medication for Traveler’s Diarrhea 
It is a good idea to plan ahead and pack medications in case you experience traveler’s diarrhea.  
Medications should be purchased in Canada prior to the trip.  Items to consider include: 
• Oral rehydration solution (e.g. Gastrolyte®, Gatorade®) 
• Non-prescription products like loperamide (e.g. Imodium®) or bismuth subsalicylate (e.g. 
Pepto-Bismol®). 
Check with your physician, nurse practitioner or pharmacist to ensure you can safely take the above 
medications, as well as to provide you with instructions for using these medications. 
 
If you do develop Traveler’s Diarrhea, seek medical treatment if you experience any of the 
following: 
• signs of dehydration, blood in the stools, vomiting, severe abdominal pain, or fever; 
• persistent diarrhea lasting longer than 3-4 days; 
• unable to keep down fluids because of vomiting; or 
• extreme exhaustion. 
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Economy Class Syndrome 
The Risk of Venous Thromboembolism While Traveling 
 
Venous thromboembolism (VTE) can result in pulmonary embolism (PE) and/or deep vein 
thrombosis (DVT).  PE and DVT can occur in travelers who are seated for a long period of time on a 
plane, train, car or bus.  The event can occur during, immediately after or even weeks after travel.  
Over the past several years, these thromboembolic events have received a lot of attention in the 
press, particularly when associated with flying.  The term Economy Class Syndrome has since been 
created, referring to the cramped space of an economy section of an airplane which can lead to 
venous pooling. 
 
What is the Risk 
The evidence for the link between VTE and long distance travel is controversial. It is estimated that 
PE occurs in: 
• 1/100million passengers who are traveling <6 hours 
• 1/700,000 passengers who are traveling >6 hours 
 
As for DVT, eight prospective trials (flights >4 hours), estimated the rate of asymptomatic DVT to 
be: 
• 1.2% for low-risk passengers (i.e. no risk factors)  
• 4% for those at high-risk (i.e. one or more risk factors) 
  
A case-control study (n=420) concluded that: 
• Air travel itself has a 2-fold increase risk of VTE compared to those who do not travel by air.  
The risk increased to 3-fold for long-distance flights. 
• Women who fly and are on oral contraceptives are 14 times more likely to develop a VTE 
than those who do not fly and are on oral contraceptives. 
Although not investigated yet, it can be assumed that other forms of estrogen therapy (e.g. 
contraceptive patch, hormone replacement therapy) would carry a similar risk. 
 
 
Assessing Risk of Venous Thromboembolism 
The risk factors for VTE can be divided into two categories: 
 
Cabin-related risk factors: Patient-related risk factors include: 
• Cramped seating 
• High-altitude cabin 
pressure 
• Low cabin humidity 
 
• Estrogen therapy 
• Obesity 
• Age > 50 years 
• History of VTE and/or risk factors for VTE 
• Family history for VTE 
• Dehydration 
• Recent surgery/trauma (abdomen, pelvis or legs) 
• Prolonged immobilization 
• Pregnancy 
• Cancer 
• Smoking 
• Blood clotting abnormalities (e.g. thrombophilia) 
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VTE Prophylaxis for Long Distance Travel 
The CHEST Guidelines reviewed seven randomized controlled trials assessing active thromboprophylaxis.  
The flight duration and presence of risk factors varied across all studies, but each used Doppler ultrasound to 
identify asymptomatic DVT.  The pooled analysis revealed the following: 
 
  Intervention Rate of Doppler-screened DVT 
No prophylaxis 3.7% 
Below-knee graded compression stockings 0.2% 
Single dose enoxaparin (100U/kg or 4,000IU) 2-4 hours 
before flying 
0% 
ASA 400mg po 12 hours before flying & once daily for 
total of 3 days 
3.6% 
 
Based on this evidence, the CHEST Guidelines recommend the following: 
1) For passengers traveling for longer than six hours: 
• Avoid constrictive clothing around the waist and lower extremities. 
• Avoid dehydration by drinking plenty of water and limiting alcohol/caffeine. 
• Do stretch calf muscles frequently (www.continental.com/travel/specialneeds/health.asp) 
 
2) For patients at high risk for VTE: 
• Above preventative measures. 
• Use properly fitted, below-knee graduated compression stockings providing 15 to 30 mmHg of 
pressure at the ankle(~$15-30), or 
• A single prophylactic dose of low-molecular weight heparin (e.g. enoxaparin 100U/kg or 4,000IU) 
injected 2-4 hours prior to departure  
(Note: pre-filled syringes range from ~$15-50 & are not covered by the SK Drug Plan for this indication) 
 
3) ASA prophylaxis is NOT recommended. 
 
Note: ASA therapy to reduce the risk of vascular events associated with arterial disease is well established.  
The difference in venous versus arterial protection is thought to be due to the degree of platelet aggregation in 
clot development.  In VTE, clot development is typically linked to venous status, which involves less 
platelet aggregation than arterial thrombosis due to vascular wall injury. 
 
Patient Education 
Patients at risk should be instructed to report swelling in one lower leg, swelling or bruising behind the knee, 
shortness of breath, chest pain and fainting.  It is also important for patients to realize that these symptoms can 
occur weeks after travel.  An information sheet, Practical Tips for Avoiding “Economy Class Syndrome”, can also 
be provided to patients. 
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rmtc/06vol32/dr3201ea.html (Accessed November 23rd, 2006). 
 
 
 
 
 
 
 170 
 171 
 
TRAVELING MEDICINE CABINET 
Patient Information Sheet 
All patients are encouraged to visit the International Travel Health Clinic through Public Health. 
 
Don’t let minor ailments ruin your vacation.  Plan ahead by packing the following items to treat 
conditions from abrasions to the zombie-like state caused by jet lag.  All are available without a 
prescription, but check with your doctor, nurse practitioner or pharmacist to ensure there are no 
concerns with a medical condition or your current medications. 
 
? Pain Relievers: Acetaminophen (e.g. Tylenol®) or ibuprofen (e.g. Advil®, Motrin®) for 
mild to moderate pain, fever or headache.   
? Antacids: several products available (e.g. Pepto-Bismol®, Diovol®, Zantac®) for relief of 
indigestion and heartburn.   
? Antihistamines: for minor allergic conditions.  There are two kinds of antihistamines – 
those that can cause drowsiness and those that are non-drowsy.  Sedating antihistamines – 
like diphenhydramine (e.g. Benadryl®) and dimenhydrinate (e.g.Gravol®) can be used as a 
sleep aid to help travelers adjust to jet lag.  Dimenhydrinate can also be useful for controlling 
motion sickness and nausea. 
? Antidiarrheals: loperamide (e.g. Imodium®) or bismuth subsalicylate (e.g. Pepto-Bismol®) 
for the management of mild-moderate traveler’s diarrhea.  
? Decongestant: Look for a tablet containing pseudoephedrine, ephedrine or phenylephrine.  
A decongestant is useful for preventing ‘ear popping’ during air travel descent or underwater 
diving.  If you have previously experienced ear discomfort while flying, take a decongestant 
30-60 minutes prior to arriving at the destination to help reduce the pain, blockage and 
hearing loss.  You can also chew gum or suck on candy. 
? Hydrocortisone 0.5% cream: useful for skin conditions such as mild inflammation and/or 
itching. 
? Insect Repellent: insect repellent containing DEET (30%) is effective against mosquitoes, 
ticks, fleas, chiggers and flies.  Protecting yourself from insect bites will reduce your risk of 
acquiring diseases such as malaria, dengue and Japanese encephalitis.    
? Laxatives: a stool softener (e.g. Colace®) or laxative (e.g. Senokot®, Metamucil®) can treat 
constipation, which may result from dietary changes while traveling. 
? Oral Rehydration Solution: packages (e.g. Gastrolyte®) are added to water to help prevent 
dehydration due to traveler’s diarrhea. Gatorade® may also be used (available in powder 
form as well). 
? Sunscreen: broad-spectrum (i.e. both UVA and UVB) sunscreen with at least SPF 15 to help 
prevent sunburn.  If using both sunscreen and insect repellent, avoid applying them at the 
same time – if possible.   Apply the sunscreen approximately 30 minutes before sun exposure 
and the insect repellent before heading outdoors. 
? Topical antibiotic cream/ointment: polymyxin B-gramicidin-bacitracin (e.g. Polysporin) 
for superficial wounds to treat minor irritation or infection. 
 
Make items more accessible by placing them in a self-sealing  
plastic bag or a plastic box. 
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TRAVELING WITH MEDICATIONS 
 
When preparing for a trip, medications deserve more attention then just ensuring they are packed.  
Purchasing medications from another country can be a gamble and there is tighter airport security, 
resulting in special precautions.  Patients should be educated on the following: 
 
PREPARING FOR THE TRIP 
Unfortunately, there is no international body that oversees brand name selection by pharmaceutical 
companies.  Therefore, different medications may have the same brand name in another country.  
For example, Dilacor is diltiazem in the US but is digoxin in Serbia.  This is also a concern with 
over-the-counter medications, different dosage formulations (e.g. XR, LA, XL, etc) and foreign look-
alike or sound-alike drug names. 
 
Patients should be instructed to: 
1) Pack an adequate supply of medications for the entire trip, with a bit extra in case of 
unexpected delays.   
2) Carry a complete list of current medications.  The list should include both the brand and 
generic names, dosage, how often the medication is taken and reason for use.   
3) Keep an update list of medical problems, along with the phone numbers of health care 
providers. 
4) Medications should be kept in their original prescription container.  Do not put medications 
in pill boxes. 
5) Recommended medications for traveling (e.g. over-the-counter, self-treatment of traveller’s 
diarrhea) and prescription medications should be purchased in Canada prior to leaving. 
 
PACKING FOR THE TRIP 
Canadian Air Transport Security Authority recommends the following: 
 
Prescription Drugs 
• Medication should be placed in carry-on baggage, in case it is needed while traveling. 
• Each prescription needs to be properly labeled (professionally printed label identifying the 
medication or a manufacturers name or pharmaceutical label);  
 
Syringes, Hypodermic Needles and Biojectors for personal medical use can be packed in either 
carry-on or checked luggage providing: 
• Needle guard is in place; and 
• The person possesses medication that is to be administered by means of the syringe or needle 
and biojectors; and 
• The medication is in a container that bears the name of the medication and the name of 
either the pharmacy that dispended the medication or the manufacturer of the medication 
 
Liquids, Gels or Aerosol 
Passengers will be permitted to bring liquids, gels and aerosols through security screening at 
Canadian airports provided that the items are packaged in containers with a capacity of 90 ml / 90 
grams (3 oz.) or less, and that the containers fit comfortably in one clear, closed and resealable 
plastic bag with a capacity of no more than 1 litre (1 quart). One bag per passenger will be permitted. 
Liquid prescription medicine labeled with a name that matches the passenger’s ticket or 
boarding pass, and other essential non-prescription liquid medicines continue to be 
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permitted and are exempt from the container size restrictions. In addition, they are not 
required to be placed in a plastic bag. 
To speed up the screening process, passengers should place all liquids, gels, and aerosols 
from their carry-on bags into the trays provided at the beginning of the screening process. 
When possible, passengers should have documentation supporting a medical condition. 
Patients should be encouraged to check with the airline they are traveling on for any 
additional requirements. 
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3) Canadian Airport Transport Security Authority.  Permitted and Non-Permitted 
Items.  Available at:http://www.catsa-acsta.gc.ca/english/travel_voyage/list.shtml. 
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HIGH-ALTITUDE SICKNESS 
 
Types of High-Altitude Sickness 
High-altitude sickness is a collective term for the following syndromes: 
1. Cerebral syndromes:  
a) Acute mountain sickness (AMS) 
• Clinical presentation: non-specific symptoms – headache (cardinal symptom – but 
indistinguishable from other causes of headaches), anorexia, nausea, vomiting, fatigue, 
dizziness, and sleep disturbance.  Note: not all need to be present. 
• Typically appear 6-12 hours after arrival at high-altitude. 
• Can be confused with exhaustion, dehydration, hypothermia, alcohol hangover, or 
migraine. 
 
b) High-altitude cerebral edema (HACE) 
• Clinical presentation: end stage of AMS and is preceded by AMS symptoms.  
Characterized by ataxia and altered consciousness, which may progress to coma or death 
due to brain herniation. 
 
2. Pulmonary syndrome:  
a) High-altitude pulmonary edema (HAPE) 
• Clinical presentation: dyspnea, cough, cyanosis, sleep disturbances, irritability, and 
clinical signs of right heart failure. 
• Typically occurs in the first 2-4 days after arrival at altitudes higher than 2500m. 
 
If HACE and HAPE present concomitantly, papilloedema, ataxia, retinal hemorrhage, and 
occasionally focal neurological deficits may be present. 
 
Table 1: Incidence of High-Altitude Sickness 
Type of High-altitude Sickness Incidence 
25% at moderate altitudes (1920-2957m) 
50% if walking to altitudes >4000m  
Acute mountain sickness 
84% if flying directly to 3860m  
High-altitude cerebral edema 
High-altitude pulmonary edema 
0.1-4% 
 
Risk Factors 
Most Important Others Potential 
• Rate of ascent 
• Altitude reached 
(especially sleeping 
altitude) 
• Individual susceptibility 
 
• History of high-altitude 
illness 
• Permanent residence lower 
than 900m*  
• Exertion (but not physical 
fitness) 
 
• Age: ≥50 years ↓ risk  
• Gender: women ↑ risk 
• Neck irradiation or surgery 
• Respiratory infections 
• Dehydration 
 
*The altitude of Saskatoon is 481.5m above sea level. 
 
 
 
 
Prevention & Treatment of High-altitude Sickness 
Prevention 
Gradual ascent, allowing time for acclimatization.  Rule of thumb: at higher than 3000m, each night should average not more than 300m above the 
previous, with a rest day every 2-3 days (or every 1000m).   
Treatment 
Avoid further ascent until symptoms resolve, to descend if there is no improvement or if symptoms worsen, and to descend immediately at the first signs 
of cerebral or pulmonary edema 
AMS: 
• Mild AMS: rest alone may be sufficient. Analgesics and antiemetics for symptom relief. Headaches responds to NSAIDS and steroids; inconsistent 
results with sumatriptan  
• Moderate to Severe AMS: descent (even 400-500m may relieve symptoms), oxygen & acetazolamide and/or dexamethasone 
HACE: Immediate descent, oxygen & dexamethasone 
HAPE: Immediate descent, oxygen & nifedipine 
Drug Mechanism/ 
Effect 
Comments/Contraindications/ 
Side Effects/Drug Interactions 
Dose 
Acetazolamide 
(Diamox®) 
M: ↑ ventilation during sleep & O2 
saturation, with a ↓ in erythropoietin 
& hematocrit. 
 
E: Normalize sleep-disordered 
breathing; ↓ incidence & severity of 
AMS.   
Drug of choice for prophylaxis. 
CI: adrenal gland failure, angle-closure glaucoma, cirrhosis, 
low Na+/K+/Cl- acidosis, hypersensitivity to 
acetazolamide, severe hepatic or renal disease 
SE: tinnitus, metabolic acidosis, sulfonamide reaction, 
paresthesias 
DI: ASA, lithium, cyclosporine, amphetamines, 
topiramate, phenytoin, certain cardiac glycosides & 
hypertensive agents 
250mg po bid  
 
Start 12-24 hours before 
ascent & continue for 48 
hours or longer at high 
altitudes 
 
Dexamethasone 
 
M: thought to ↓ intracranial pressure 
 
E: ↓ symptoms of AMS 
Alternative for prophylaxis in travelers with sulfa allergy  
CI: hypersensitivity to dexamethasone, systemic fungal 
infection 
SE: ↑appetite, nausea, heartburn, nervousness, edema 
DI: live vaccines, NSAIDs, potassium-depleting diuretics, 
anticoagulants, estrogens, cyclosporine 
4mg po q6 hours  
 
Start 48 hours prior to 
altitude exposure 
Nifedipine 
(Adalat®) 
M: reduces pulmonary artery 
pressure 
 
E: ↓ risk of pulmonary edema 
 
 
For the treatment of HAPE. May be used as prophylaxis if 
history of HAPE (lack of evidence). 
CI: hypersensitivity to nifedipine, immediate release in 
patients with CVD 
SE: headache, peripheral edema, dizziness 
DI: digoxin, grapefruit, ranitidine 
Prophylaxis: nifedipine XL 
20mg po OD 2-3 days 
before ascent 
Treatment: 
Nifedipine 10mg IR, then 
20-30mg XL OD-BID 
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Gingko biloba has also been studied due to its antioxidant effect; however there is not enough evidence to recommend using it at this time. 
References:Micromedex 2006.  Basnyat B and Murdoch D. High-altitude Illness.  Lancet 2003; 361:1967-74.  Valarde L et al.  Consensus Statement on Chronic and Subacute High Altitude 
Diseases. High Altitude Medicine & Biology 2005; 6(2) 147-57.  Spira AM. Preparing the Traveller.  Lancet 2003; 361:1368-81.  Levien T and Baker D. Travel Medicine.  Pharmacist’s Letter 
1997; 13(7):130713 
Appendix XVIII: Cross-reactivity to Antibiotics Project 
 
CROSS-REACTIVITY TO ANTIBIOTICS 
 
Patients often report allergies to antibiotics, however the actual incidence of allergic 
reactions to these medications are much lower than perceived – for a few reasons.  First, 
there are four different types of allergic reactions, and not all reaction types preclude the use 
of related drugs.  Second, patients often mistake antibiotic side effects or intolerances as an 
allergic reaction.  Therefore, a through investigation of the reaction is needed to ensure 
optimal use of medications. 
 
Information for Allergic Reaction History 
• Age when the reaction occurred 
o Penicillin-specific IgE decreases over time.  After ten years, 70% will not have 
detectable levels. 
• Description of the reaction  
o symptoms, severity, duration 
• Timing of the reaction  
o after first dose, after the tenth dose 
• Route of administration (oral, IV) and duration of therapy  
o anaphylaxis is more common with parenteral administration 
• Use of any other medications at the same time 
• What occurred when antibiotic was stopped?  Was treatment required? 
• History of other antibiotics taken since and tolerability 
o If patient is not sure what they have taken, check the Pharmaceutical 
Information Program (PIP). 
• Does the patient wear a medical alert bracelet because of the allergy 
• Has penicillin skin testing been performed (only indicates Type I reactions) 
 
It is also important to note that patients with allergies are typically at higher risk for being 
allergic to other, even structurally unrelated drugs.  Therefore, an allergic reaction may be 
due to this increase risk versus cross-reactivity between medications. 
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CROSS-REACTIVITY BETWEEN BETA-LACTAMS 
 
Approximately 5-20% of the population will report a penicillin allergy.  Of those, only 10-20% will have an 
actual IgE antibody mediated reaction to penicillins.  Anaphylactic reactions to beta-lactams are very rare 
(penicillins: 0.01-0.05%, cephalosporins: 0.0001-0.1%).   
 
Types of Allergic Reactions with Beta-Lactams 
Reaction 
Type 
Immunologic 
Mechanism 
Time to Onset Clinical Syndrome 
<1 hour Immediate: anaphylaxis, hypotension, 
laryngeal edema, angioedema, urticaria, 
bronchoconstriction, hyperperistalsis 
I IgE antibody mediated 
1-72 hours Accelerated: laryngeal edema, angioedema, 
wheezing, urticaria 
II Cytotoxic reactions 
(IgG, IgM) 
>72 hours Hemolytic anemia, thrombocytopenia, 
neutropenia 
III Immune complex 
reactions (IgG, IgM) 
>7 days, may 
occur after drug 
discontinued 
Serum sickness, nephritis 
IV T cell mediated >72 hours Contact dermatitis*, exfoliative dermatitis, 
maculoapapular or morbilliform rash, 
Stevens-Johnsons syndrome 
*Contact dermatitis most common reaction (penicillin: 1-4%, amoxicillin/ampicillin: 5-10%, Epstein-Bar 
virus: 70-100%).  Penicillins can be safely administered in patients with a history of contact dermatitis. 
 
Penicillins and Cephalosporins 
The true incidence of allergic cross-reactivity between penicillins and cephalosporins is <10%.  In general, the 
rate is highest with the first-generation cephalosporins, and the risk decreases with each subsequent generation. 
 
Recommendations Based on Reaction Type 
Type of Reaction Penicillins Cephalosporins 
Allergy to Penicillin 
Type I  Avoid Avoid until additional information 
is available.  If unavoidable, 
administer under close 
supervision. 
Type II, III or IV  May rechallenge under supervision, 
unless severe reaction – then avoid. 
Considered safe. 
Allergy to Cephalosporin 
All types Recommend a penicillin skin test 
first. 
Skin test to desired cephalosporin 
first. 
 
 
Carbapenems 
Cross-reactivity between penicillin and the carbapenems (imipenem, meropenem, ertapenem) has occurred, 
with an estimated incidence of 9.5%.  Until further information available, avoid using carbapenems in patients 
with allergies to penicillin or cephalosporins. 
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CROSS-REACTIVITY OF SULFONAMIDE DRUGS 
 
Approximately 3% of the population has a sulfonamide antibiotic allergy.  Reactions can occur when the 
medication is administered via oral, ophthalmic, topical or vaginal routes.   Several drugs and additives 
contain sulfur, which can cause confusion when determining the safety of these agents in patients with a 
sulfonamide allergy. 
 
Classification of Sulfa Drugs 
Sulfonamide-like agents are divided into three categories based on chemical structure: 
1) sulfonylarylamines (includes sulfonamide-type antibiotics) 
2) non-sulfonylarylamines 
3) sulfonamide-moiety 
In general, cross-reactivity between these classes is very unlikely, but it is important to note that the non-
sulfonylarylamines and sulfonamide-moiety drugs can cause their own allergic reactions. 
 
Types of Allergic Reactions with Sulfonamides 
Reaction 
Type 
Immunologic 
Mechanism 
Time to Onset Clinical Syndrome 
Type I IgE mediated 
 
1-3 days Common: maculopapular eruption, urticaria  
Serious: angioedema, hypotension, 
anaphylaxis (↑ with repeated exposure) 
Type II Hypersensitivity 7-14 days Common: fever, maculopapular rash – may 
progress to erythema multiforme & multi-
organ toxicity 
Serious: anaphylaxis, Stevens-Johnson 
syndrome, toxic epidermal necrosis 
 
Sulfa-Containing Agents that are Safe 
The following agents contain sulfur, but are chemically unrelated to the sulfonamides.  Thus, these agents may 
be safely administered to patients with sulfonamide-allergies without fear of cross-reactivity. 
 
Sulfa-Containing Agents 
Class of Agent Examples 
Sulfur-containing medications amoxicillin, captopril, omeprazole, ranitidine, 
spironolactone, sulindac 
Sulfates zinc sulfate, morphine sulfate 
Sulfites 
• used in drugs & foods as antioxidants 
• may cause dyspnea, wheeziness and chest 
tightness in asthmatics (not related to 
sulfonamide allergies) 
sulfur dioxide, sodium sulfite, sodium bisulfite, 
potassium bisulfite, sodium metabisulfite, and 
potassium metabisulfite 
 
Please refer to the attached Sulfa Dugs and the Sulfa-allergic Patient chart for a list of sulfonamide-containing 
agents and a summary of cross-reactivity information. 
  
References: 
1. Lesher BA. Allergic Cross-Reactivity Among Beta-lactam Antibiotics.  Pharmacist’s Letter 2005; 21(12): 
211206. 
2. Zvonar RK.  Cross-Allergy Among the β-lactam Antibiotic Agents: A Review of the Risks.  Canadian 
Journal of Hospital Pharmacists 2005; 58(2):90-6. 
3. Boehringer SK. Cross-Reactivity of Sulfonamide Drugs.  Pharmacist’s Letter 2005; 21(11): 211113. 
4. Sulfa Drugs and the Sulfa-allergic Patient.  Pharmacist’s Letter 2005; 21(11): 211113.   
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Appendix XIX: Focus Group Questions for the Student Health Centre Staff 
 
Opening Question: 
1.  What is your position at the Student Health Centre? How many years have you 
worked at this centre? 
 
Transition Question: 
1.  How did you feel about having a pharmacist join your multidisciplinary team? 
 
Key Questions: 
Interaction with a Pharmacist 
1. What type of effect did having a pharmacist on your team have? 
2. Please describe any positive experiences you had with having a pharmacist as a 
member of your primary health care team. 
a. What made these experiences positive? 
3. Please describe any negative experiences you had with having a pharmacist as a 
member of your primary health care team. 
a. What made these experiences negative? 
4. In what ways, if any, does having a pharmacist add value to your multidisciplinary 
team?   
a. How did this effect the patients?  Your practice?   
5. In what ways, if any, does having a pharmacist detract value from your 
multidisciplinary team?  
a. How did this effect the patients?  Your practice? 
6. Based on your experience, what suggestions for improvement would you give for 
having a pharmacist on your team? 
 
Integration of a Pharmacist into a Primary Health care Team 
1. The researchers used several approaches for integrating a pharmacist into your team 
(consulting established primary health care pharmacists, discussion with the staff to 
define the role prior to the pharmacist providing care, meeting at midpoint to discuss 
the study to-date, etc).  Please comment on the approaches that were used. 
2. What would you recommend for future integrations of pharmacists onto a primary 
health care teams? 
a. To what extent should pharmacy services be accessible to the team?  (i.e. 
should a pharmacist be available on a full-time or part-time basis).   Please 
provide an explanation for your answer. 
3. What approaches might be used by primary health care teams to involve pharmacists 
on their team?  
 
Ending Question: (moderator to give a quick summary) 
1. Does this summary capture what was discussed during the focus group? 
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Appendix XX: Transcript Verification Letter to the Student Health Centre Staff 
 
 
Date, 2007 
 
Name 
Student Health Centre 
University of Saskatchewan 
91 Campus Drive 
Saskatoon SK  S7N 5E8 
 
Dear (name), 
 
Thank you again for participating in the focus groups for my Masters of Science (Primary 
Care) project.  I really appreciate your input regarding the integration of a pharmacist into 
an already established primary health care team.  I have received the transcripts and will be 
analyzing the data shortly. 
 
Enclosed you will find the transcript(s) from the focus group(s) that you participated in.  I 
would like to give you the opportunity to add, alter or delete any of the information that you 
provided during the focus group discussions.  Please note that the transcripts were 
transcribed verbatim – but we are interested in your approval of the content rather than 
grammar. 
 
In order to maintain your confidentiality, names were removed from the transcripts, and 
each participant is represented by a number. The transcriber did her best to match the 
statements to the participants, however at times when she was uncertain, she placed a 
question mark beside the number. You are only responsible for verifying your own 
responses, and may have a different participant number for each focus group that you were 
involved with.  In your package, you will find an envelope attached to the transcripts.  To 
help facilitate this process, yet preserve your confidentiality, we had someone, who is not 
involved with the study, write down your participant number for each focus group you 
participated in and place it in a sealed envelope. 
 
I would like to provide you 4 weeks to review the transcripts.  Therefore, if I don’t hear from 
you by April 19th, 2007, I will assume that you are content with the transcripts as is.  If you 
would like to make any changes, please write the changes on the transcripts and return, 
anonymously, to the above address, by April 19th, 2007.   
 
Sincerely, 
 
 
 
Lynette Kolodziejak, BSP, MSc Candidate 
College of Pharmacy and Nutrition 
 
 185 
Appendix XXI: On-Line Focus Group Questions & Schedule for the Patients 
 
You have been invited to participate in an on-line focus group to discuss your experience 
with a pharmacist at the Student Health Centre.  Despite each of you having spent time with 
the pharmacist, please note that the interaction(s) were unique to your needs and would 
have varied in nature and depth.  
 
Week #1: 
This week’s questions focus on the interpersonal aspects of your interaction with the 
Student Health Centre pharmacist.  
 
Transition question: 
1. Describe your experience, both positive and negative, with the pharmacist.  
Subsidiary questions:  
a. What made these experiences positive? Negative? 
b. Was the pharmacist able to meet your needs/expectations? 
c. What was your comfort level like during your interaction with the 
pharmacist? 
2. What suggestions for improvement would you give for having a pharmacist at the 
Student Health Centre? 
 
Week #2: 
This week’s questions focus on the pharmacist’s work activities (what she did) and on the 
impact of having a pharmacist at the Student Health Centre. 
Key questions:  
1. How did you feel about seeing an additional health care professional (i.e. the 
pharmacist) at the Student Heath Centre?  
Subsidiary questions: 
a. How accessible was the pharmacist? 
b. How convenient was it for you to see the pharmacist? 
 
2. In your view, would the addition of a pharmacist to the Student Health Centre 
valuable?  Please elaborate.   
a. If the participants feel the addition of a pharmacist would be valuable, then ask: In 
addition to the services you received from the pharmacist, in what other ways 
do you see a Student Health Centre pharmacist helping you in the future?   
 
Week #3: 
A summary of the discussion will be posted for the group.  
 
Ending question:  
1. Does this summary capture what was discussed during the focus group? 
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Appendix XXII: Email Invitation to the Patients to Participate in the Study 
 
I am the pharmacist at the Student Health Centre, who recently worked with you regarding 
your medication.  The two months I spent at the Centre was part of a study that is looking 
at how a pharmacist can be incorporated into a primary health care centre.  Part of the study 
is evaluating the services I provided during the two months.  As a patient, you can offer 
valuable information on how you felt about having a pharmacist working at the Student 
Health Centre. 
 
I am inviting you to participate in an on-line focus group.  The focus group will allow you, 
and other patients, to discuss your experiences with seeing a pharmacist in a health centre.  
Your input will help me create recommendations for other pharmacists who are interested 
in working in similar health centres. 
 
The on-line focus group will run for three weeks during the month of January, 2007. New 
discussion questions will be posted every week during the three week period.  Participants 
will be asked to log onto the website to read responses and post replies at least once a week.  
The on-line focus group will not be live, and is set up similar to a discussion board.  
Therefore, you will be able to log onto the website whenever is convenient for you.  The 
total time required to participate is estimated at 2-3 hours over the three weeks.  An activity 
log will be kept electronically to assess how often participants log on and the time spent 
during each visit.  If you agree to participate, but change your mind later on, you can end 
your involvement with the study at any time without any penalty.   
 
If you are interested in learning more about this study, please contact me and more details 
will be provided.  The project received ethics approval from the Behavioural Research 
Ethics Committee of the University of Saskatchewan on (date).   
 
Thank you for your consideration, 
 
 
 
 
Lynette Kolodziejak, BSP 
College of Pharmacy & Nutrition 
University of Saskatchewan 
Office phone number: 306-966-6346 
Email: Lynette.Kolodziejak@mail.usask.ca 
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Appendix XXIII: Email Invitation to Students for the On-Line Survey 
 
We understand that not everyone was able to participate in our on-line focus group 
evaluating the addition of a pharmacist to the Student Health Centre.  However, we would 
still like to give you the opportunity to provide us with your feedback.  If you are interested, 
we have developed an on-line survey consisting of eleven questions and which should take 
approximately 10-15 minutes to complete. 
 
If you are willing to assist us with our research, please click on the below link (or paste the 
link into your internet address bar): 
 
https://survey.usask.ca/survey.php?sid=4204 
 
To ensure confidentiality, every participant will be assigned the same username and 
password.  When you reach the survey homepage, enter the following: 
Username: SHC 
Password: student 
 
The website includes instructions to complete the survey. 
 
We thank you in advance for taking time out of your busy schedules to fill out our survey. 
 
Lynette 
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Appendix XXIV: On-Line Survey Questions for the Patients 
 
Thank you for participating in our survey to evaluate the impact of having a clinical 
pharmacist at the Student Health Centre.  A clinical pharmacist helps to improve patient 
care by educating patients, optimizing medication use and monitoring goals of therapy.  
Please take 5-10 minutes to complete this short survey based on your interaction with the 
pharmacist.  Your input will be valuable in assessing the role of a pharmacist in a medical 
clinic, like the Student Health Centre.  Thank you in advance for your time. 
 
Demographic Information 
1. Age: 
2. Gender:  ? Male  ? Female 
3. College and year of study: 
 
Experience with the Pharmacist 
4. How would you rate your experience with the pharmacist 
? Positive   ?  Negative 
 
a) What made your experience with the pharmacist positive or negative? 
 
5. Did you feel that the pharmacist was able to meet your needs/expectations? 
? Yes    ?  No 
 
a) Describe how the pharmacist was able/unable to meet your needs/expectations? 
 
6. How did you feel about meeting with an additional health care professional (i.e. the 
pharmacist) at the Student Health Centre? Please consider accessibility and 
convenience. 
 
7. In addition to the services you received from the pharmacist, what other ways would 
you like to see a Student Health Centre pharmacist helping patients in the future? 
 
8. What suggestions for improvement would you give for having a pharmacist at the 
Student Health Centre? 
 
9. In your opinion, would the addition of a pharmacist to the Student Health Centre be 
valuable? 
? Yes    ?  No 
 
a) Please elaborate why/why not a pharmacist is valuable at the Student Health 
Centre. 
 
Thank you again for your participation.  We really appreciate your feedback. 
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Appendix XXV: On-Line Survey Results 
 
PATIENT ON-LINE SURVEY RESULTS 
Survey Time Stats  
Average Completion Time: 8min 57sec (Min: 8min 57sec, Max: 8min 57sec)  
 
Demographic Information 
1. Age: 25     
Total answers: 1 
 
2. Gender 
Female  0.00% 
Male  100.00% 
Total answers: 1 
 
3. College and year of study: Arts & Science – 4th year 
Total answers: 1 
 
Experience with the Pharmacist 
4. How would you rate your experience with the pharmacist? 
Positive  100.00% 
Negative  0.00% 
Total answers: 1 
 
5. What made your experience with the pharmacist positive or negative? 
She provided a very clear understanding of a prescribed drug; which I found very insightful. 
Total answers: 1 
 
6.  Did you feel that the pharmacist was able to meet your needs/expectations?  
Yes  100.00% 
No  0.00% 
Total answers: 1 
 
7. Describe how the pharmacist was able/unable to meet your needs/expectations? 
Making me understand every detail about the prescribed drug; side effects, do's, don'ts etc, 
which I wouldn't have known without talking to her.  
Total answers: 1 
 
8.  How did you feel about meeting with an additional health care professional (i.e. the 
pharmacist) at the Student Health Centre? Please consider accessibility and convenience.  
Very easy to talk to, very convenient.  
Total answers: 1 
 
9.  In addition to the services you received from the pharmacist, what other ways would 
you like to see a Student Health Centre pharmacist helping patients in the future?  
Total answers: 0 
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10.  What suggestions for improvement would you give for having a pharmacist at the 
Student Health Centre?  
Total answers: 0 
 
11.  In your opinion, would the addition of a pharmacist to the Student Health Centre be 
valuable?  
Yes  100.00% 
No  0.00% 
Total answers: 1 
 
12.  Please elaborate why/why not a pharmacist is valuable at the Student Health 
Centre. 
There are some details of particular prescribed drugs which a doctor might not have time or 
enough specific knowledge of the drugs, to advice specific patients on. Pharmacists come in 
very helpful with that. 
Total answers: 1 
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